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The circadian clock
To anticipate the recurring environmental changes resulting from the Earth’s 
rotation, most organisms have developed a circadian clock with periodicity of 
approximately (circa) one day (diem). Circadian rhythms can be found in behavior, 
physiology and metabolism. Well known examples are the sleep-wake cycle or 
rhythm in locomotor activity (Hurd et al., 1998, Cahill et al., 1998), daily variations 
in body temperature (Refinetti and Menaker, 1992) and blood pressure (Pickering, 
1990) and melatonin levels that rise at sunset and decrease at sunrise (Hardeland 
et al., 2006). In mammals, this internal timekeeping system is composed of a master 
or central clock, the suprachiasmatic nucleus (SCN) located in the brain, and 
peripheral clock in all other tissues in the body. The SCN consists of two bilateral 
nuclei in the ventral hypothalamus, just above the optic chiasm and is required to 
synchronize the peripheral clocks (Moore and Eichler, 1972, Moore, 1983, Van den 
Pol, 1980).
To keep these approximately 24 hour rhythms synchronized with the environment, 
circadian rhythms need to be entrained by Zeitgebers. The most important and 
potent Zeitgeber for the central SCN clock in mammals is light (Bell-Pedersen et al., 
2005). The light-input is perceived by specialized retinal ganglion cells in the eye 
using a photo pigment called melanopsin (Berson et al., 2002). This photo pigment 
differs from the rhodopsin in the rods and cones, used mainly for vision. The photic 
signal is transmitted by the retinohypothalamic tract to the hypothalamus, which 
projects to the SCN. Depending on the timing of the light exposure, the circadian 
rhythm will delay or advance, resulting in e.g. waking up later or earlier, respectively 
(Warman et al., 2003, Duffy et al., 1996). Whereas light can affect timing of the 
clock in the SCN, timed food intake has been shown to entrain circadian rhythms 
of peripheral clocks, independent of the SCN (Carneiro and Araujo, 2012). Social 
cues are also sufficient to entrain human circadian rhythms (Aschoff et al., 1971). 
Furthermore, melatonin is best known as output of the biological clock, but in turn 
can also entrain or phase shift the clock in several species (Redman, 1997).
These circadian rhythms are endogenous, meaning that the rhythm persist under 
constant conditions with a period of approximately 24 hours. The circadian rhythm 
is self-sustaining and regulated on a molecular level by a molecular oscillator 
composed of clock genes (described in Box 1). The circadian rhythm in the absence 
of Zeitgebers such as light is called free running rhythm. In humans, the average 
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free running period has been shown to be slightly longer than 24 hours (Czeisler 
et al., 1999). In contrast, most mouse strains have an internal rhythm that is slightly 
shorter than 24 hours, with variation between the strains (Pfeffer et al., 2015, 
Schwartz and Zimmerman, 1990). As described previously, this internal rhythm is 
synchronized with the environment by Zeitgebers. The relationship between the 
timing of the biological clock and the timing of an external time cue is called the 
phase angle of entrainment and determines chronotype; whether an individual is 
an early type or a late type (Emens et al., 2009).
Box 1. Molecular clock
At the molecular level, the circadian rhythms are generated by an auto-regulatory 
transcriptional-translation feedback loop (TTFL) (Lee et al., 2001). In short, the positive 
limb of the TTFL consists of CLOCK and BMAL1 proteins, driving the transcription 
of Period (Per1, Per2) and Cryptochrome (Cry1, Cry2) genes. In the negative limb, 
PER and CRY proteins form a heterodimeric complex that translocates back into 
the nucleus, repressing the CLOCK/BMAL1 driven transcription, thereby inhibiting 
their own gene expression (Ko and Takahashi, 2006, Lee et al., 2001, Reppert and 
Weaver, 2002). This molecular oscillator is coupled to output processes via clock-
controlled genes, including transcription factors (Reppert and Weaver, 2002). 
Micro-array studies have revealed that approximately 10 % of the transcriptome is 
under circadian control (Hughes et al., 2010, Miller et al., 2007, Panda et al., 2002).
Shift work-associated breast cancer risk
Working around the clock strains and disturbs this tightly regulated biological 
clock, which eventually might result in adverse health events. Our 24/7 economy 
demands people to work at irregular times and as a consequence, more and 
more people are involved in atypical working schedules. Recent surveys in 
Europe indicate that approximately 19% of the workers in the European Union 
(EU) work at night and 17% are involved in shift work with permanent or rotating 
shifts (Eurofound, 2012). In the Netherlands, approximately 1.2 million people 
work sometimes or regularly during the night (CBS, 2010). Recent epidemiology 
studies show that long-term shift work increases acute and chronic health risks, 
like fatigue (Akerstedt and Wright, 2009), gastrointestinal complaints (Knutsson 
and Boggild, 2010), and developing diabetes (Suwazono et al., 2006, Pan et al., 
2011) and cardiovascular disease (Gu et al., 2015, Fujino et al., 2006). Importantly, 
work in shifts for many years was associated with an increased breast cancer risk 
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in women (Akerstedt et al., 2015, Schernhammer et al., 2006). Epidemiological 
studies concerning the relation between shift work or night work and breast 
cancer risk have been summarized in several meta-analyses with contradicting 
results (He et al., 2014, Ijaz et al., 2013, Jia et al., 2013, Kamdar et al., 2013, Megdal et 
al., 2005, Wang et al., 2013). In the first meta-analysis Megdal et al. found a pooled 
relative risk (RR) of 1.51 (95% CI, 1.36–1.68) for the association between shift work 
and breast cancer, based on six studies (Megdal et al., 2005). Subsequent meta-
analyses reported lower RRs of approximately 1.2 (He et al., 2014, Jia et al., 2013, 
Kamdar et al., 2013, Wang et al., 2013) or limited to no evidence for a shift work 
breast cancer relationship (Ijaz et al., 2013). 
Shift work is a complex combination of exposures, involving multiple aspects that 
have been suggested to underlie the relationship between shift work and cancer 
(Fritschi et al., 2011). These aspects include internal desynchronization, suppression 
of melatonin or vitamin D levels, sleep disruption and lifestyle disturbances, all 
shown in Figure 1. All suggested hypotheses are extensively discussed by Fritschi 
et al. (Fritschi et al., 2011). In summary, the alternating shifts during shift work may 
cause rhythms in peripheral function to become out of phase with the central 
clock or sleep wake cycle, internal desynchronization. Additionally, both timing and 
the degree of light exposure in shift workers is changed affecting both melatonin 
and vitamin D levels. Light exposure during the night can result in melatonin 
suppression (Davis and Mirick, 2006), which is suggested to increase breast cancer 
development in experimental studies by various mechanisms (e.g. anti-oxidant 
function) (Blask et al., 2005). Individuals working in night shift are suggested to 
have less sunlight exposure, resulting in lowered vitamin D levels (Kimlin and 
Tenkate, 2007), whereas sun exposure has been suggested to be protective of 
several types of cancer (van der Rhee et al., 2013). Vitamin D has been suggested to 
be one of the mediating factors in the preventive effect of sunlight on cancer (van 
der Rhee et al., 2013), for example by inhibition of cell proliferation through various 
mechanisms (Garland and Garland, 2006). Sleep disruption can cause a decrease in 
melatonin levels, decreased immune activity and metabolic disturbance, which all 
have been linked separately with increased cancer risk (Bovbjerg, 2003, Bianchini 
et al., 2002, Blask et al., 2005). Lastly, lifestyle factors such as smoking, unhealthy 
eating, age at first birth and duration of breast-feeding are possibly different for 
shift-workers compared to day-workers and are all factors which increase cancer 
risk.
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Figure 1. Suggested scenarios underlying the relationship between chronic CRD and breast cancer (adapted 
from Fritschi et al. (Fritschi et al., 2011)).
Due to the observational nature of epidemiological studies, it is unknown which 
aspect or combination of aspects is responsible for the observed increased health 
risk in shift workers. Moreover, several factors can be either defined as part of the 
exposure, intermediate factor or be a result of shift work exposure. For example, 
significant differences in socio-economic status, smoking behavior, nulliparity, 
hormone replacement therapy use, and obesity between women that had and 
had not worked at night have been reported (Wang et al., 2012). An important 
drawback of the epidemiological studies is that these studies require several years 
to study effects on chronic diseases prospectively, and the ability to control the 
aspects related to shift work is limited. 
Additionally, exposure assessment of shift work is often lacking or incomplete due 
to the retrospective nature of many studies and the diversity of shift work schedules 
used. The first line of epidemiological studies, such as the Nurses’ Health Study 
(Schernhammer et al., 2006), have been able to identify associations between shift 
work and breast cancer using relatively crude exposure assessment metrics such 
as ‘ever/never conducted shift work’ or ‘duration of working on a rotating schedule’. 
Molecular epidemiology studies, as performed by Papantoniou et al. assessed the 
exposure to shift work in more detail, reporting diurnal preference, light exposure, 
circadian variation in melatonin, and sex hormone production (Papantoniou et al., 
2014). The findings of this cross-sectional study among day and night workers show 
that night shift workers have decreased melatonin levels and differences herein 
result from diurnal preference and intensity of light-at-night exposure. However, 
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it will take many years before specific exposures during shift work are proven 
to be causal for cancer risk in human studies. To study the causal relationship 
between circadian disturbance resulting from shift work and increased breast 
cancer risk, confounding factors should be excluded or taken into account and 
circadian disturbance exposure should be clearly defined or controlled. 
Animal studies on the shift work-cancer relationship
Animal studies allow detailed analysis of individual aspects of shift work, by 
allowing the exclusion (melatonin, lifestyle factors) or measurement (internal 
desynchronization, sleep disruption, vitamin D) of these individual factors. 
Additionally, such studies can identify underlying changes in biological processes 
that could provide targets for the development preventive measures. Animal 
studies have a number of advantages compared to epidemiological studies. Firstly, 
inter individual variation can be minimized in animal studies. Exposure models can 
be developed to mimic human shift work allowing controlled uniform exposure, 
in a genetically homogenous study population. Animal studies are therefore not 
hampered by the environmental or lifestyle confounding factors, or exposure 
assessment difficulties and therefore are better suited to study causality. Secondly, 
in comparison to prospective cohort studies, the effects of shift work on long-
term health effect can be determined in a relatively short (1 year) time window. 
Moreover, in shift work many environmental factors have changed, such as altered 
light exposure, changed sleep-wake cycle (Grundy et al., 2009) and differently 
timed food intake (Lennernas et al., 1995). In animal studies, these aspects can be 
studied separately or in combination, providing insight into which disturbance(s) 
of the circadian system is (are) (mostly) responsible for the observed health effects. 
When using animals to study the relation between circadian rhythm disturbance 
(CRD) and breast cancer risk, one can manipulate both sides of the equation: 
circadian rhythm and breast cancer development. Disruption or disturbance of 
circadian rhythms can be accomplished by alternating or shifting light schedules, 
constant (dim) light exposure or disruption of the endogenous circadian rhythm. 
The endogenous circadian rhythms can be disrupted through genetic modification 
of the molecular clock, by mutating one of the core clock genes. Removing the 
pineal gland will also result in the loss of circadian rhythmicity. In literature circadian 
(rhythm) disruption is often used to describe manipulation of the circadian system. 
In this thesis we differentiate between disruption and disturbance. The models 
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in which the endogenous circadian system is modified either genetically or 
anatomically, resulting in a completely or partially non-functional circadian system 
are referred to as circadian disruption models. Whereas, circadian disturbance 
refers to strain or stress imposed on the functional circadian system by exogenous 
exposure, including but not limited to jet lag, altered timing of food intake and 
day-time sleep.
Most studies make use of circadian disruption models or constant light exposure, 
of which the majority shows an increase in breast tumor growth. The increased 
tumorigenesis after disruption of the endogenous circadian rhythm or by the 
“unnatural” constant light exposure model, which is known to desynchronize 
mammalian clock neurons, resulting in behavioral and physiological arrhythmicity 
(Ohta et al., 2005), emphasizes the relation between the circadian clock and tumor 
development. However, altered light schedules provide a more realistic tool to 
mimic constant disturbance of the circadian system resulting from shift work. Such 
an approach has previously been employed by exposure to a nightly light pulse 
(Travlos et al., 2001) or infusion with blood of women exposed to a nightly light 
pulse (Blask et al., 2005). Whereas the first study found no effect on chemically 
induced tumor growth, the latter showed a significant increase in MCF-7 xenograft 
growth. Additionally, other circadian rhythm disturbance (CRD) models have been 
described that mimic human shift work, including altered timing of 1) food intake, 
2) activity and 3) sleep. A large variety of these models, as well as altered light 
exposure, have been used to study the metabolic effects of human shift work with 
a substantial number of indecisive results (Opperhuizen et al., 2015). Previously, 
altered light schedules have shown to increase chemically induced liver tumor 
growth (Filipski et al., 2009), but have not yet been employed in combination with 
breast cancer induction models. 
Since breast tumors are relatively rare in animals, studying breast cancer risk in wild 
type animals requires a large number of animals. Therefore, breast cancer animal 
models are used to reduce the number of animals needed. Breast cancer models 
can be divided into chemically induced tumor development and xenografted 
mammary gland tumors or tumor cell lines. Importantly, carcinogenesis comprises 
three different stages, namely initiation, promotion and progression (Box 2 and 
Fig. 2). The majority of the previous studies used chemically induced or xenografted 
tumors provide evidence that CRD causes enhanced tumor growth and thus 
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affect promotion and/or progression, but the studies could not give insight into 
the effect of CRD on tumor initiation. 
Box 2. Carcinogenesis
The multistage carcinogenesis theory is generally accepted and describes 
three different stages between the initial carcinogenic stimulus and the final 
manifestation of cancer (Berenblum, 1975). Following this theory, carcinogenesis 
can be divided into initiation, promotion and progression. During the initiation 
stage, a carcinogenic stimulus causes irreversible damage to the DNA, resulting in 
potential for neoplastic development. The mutations causes either the activation 
of a proto-oncogene or the inactivation of a tumor-suppressor gene. However, 
without stimulation to proliferate the initiated cell will not develop into a 
malignant tumor. The promotion stage is characterized by prolonged exposure to 
promoting stimuli (Upton et al., 1986), causing the selective clonal expansion of the 
initiated cell, resulting in a pre-neoplastic lesion. These cells become increasingly 
unresponsive to cellular signals that regulate cell growth and proliferation. Further 
genetic changes will result in more heterogeneity and aggressive characteristics 
during the progression stage. The proliferation rate increases and tumor growth 
becomes invasive, eventually resulting in distant metastasis. In this stage, 
angiogenesis is required for tumor growth beyond 2 mm size (Folkman, 1985).
 
The circadian clock is involved in several aspects of carcinogenesis. DNA repair 
pathways are in place to prevent irreversible damage to the DNA, resulting in 
tumor initiation. It has been suggested that all aspects of the cellular response 
to DNA damage are controlled or influenced by the circadian clock (Sancar et al., 
2010). Furthermore, it has been shown that the rate of tumor growth is highly 
rhythmic during the day (You et al., 2005).
Overall, many animal experiments have been performed to elucidate the causal 
relationship between circadian rhythm disturbance and mammary gland tumor 
development (for references see Table 2). Table 1 summarizes all breast cancer 
specific animal experiments published up to June 2015. The majority of the studies 
used an exposure model resulting in disruption of the endogenous circadian 
rhythm (n=13) or complete suppression of the circadian rhythm by continuous 
light (n=11). Breast cancer induction in the majority of the studies involved 
mouse models with rapidly growing tumors, either induced chemically (n=16) or 
xenografted (n=5). 
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Figure 2. Carcinogenesis (Adapted from Weston & Harris Cancer Medicine 6th edition). Carcinogenesis 
comprises three stages: initiation, promotion and progression. In the initiation stage, a mutation occurs in a 
gene of one of the key regulatory pathways of the cell. Subsequently, the initiated cell selectively proliferates 
during promotion. Due to the genetic instability, additional mutations occur resulting in malignant cell 
growth: progression and ultimately to metastasis. 
Overall, many animal experiments have been performed to elucidate the causal 
relationship between circadian rhythm disturbance and mammary gland tumor 
development (for references see Table 1). Table 1 summarizes all breast cancer 
specific animal experiments published up to June 2015. The majority of the studies 
used an exposure model resulting in disruption of the endogenous circadian 
rhythm (n=13) or complete suppression of the circadian rhythm by continuous 
light (n=11). Breast cancer induction in the majority of the studies involved 
mouse models with rapidly growing tumors, either induced chemically (n=16) or 
xenografted (n=5). 
Table 1. Studies investigating the relationship between CRD and breast cancer development, shown as 
studies with positive outcome/all studies.
Circadian disruption / 
disturbance model
Breast cancer 
Induction
Altered light 
schedules
Continuous 
light 
exposure
Endogenous 
circadian rhythm 
disruption
Total
Spontaneous cancer development - 1/3 2/2 3/5
Chemically induced cancer 0/1 4/6 4/9 8/16
Xenografted tumors 1/1 2/2 2/2 5/5
Total 1/2 7/11 8/13 16/26
Although various animal models show increased tumor development or growth 
upon circadian disruption, none of these studies fully recapitulate the human shift 
work and carcinogenesis situation. For the circadian disruption models holds that 
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the lack of a functional clock is different from the shift work situation where a 
functional circadian clock is continuously strained or disturbed. Obviously, models 
using xenografted tumors or tumor cell lines can only study tumor growth and 
chemical induction of tumors is extremely potent, leaving limited space for tumor 
initiation by CRD. Moreover, the window of exposure in these models is limited 
to weeks due to the rapid tumor development, which does not allow mimicking 
long-term exposure scenarios as experienced by shift workers. Interestingly, no 
studies were performed combining spontaneous breast tumor development with 
an exposure protocol focused on disturbing rather than disrupting the circadian 
rhythm. Consequently, there is a need for studies that combine relevant models 
for CRD exposure and breast tumor development to provide experimental 
evidence for the shift work-cancer connection.
Li-Fraumeni mouse model
A mouse model with a predisposition for human relevant breast cancer provides 
a unique tool to experimentally study the shift work breast cancer relationship. 
Mutations in the tumor suppressor gene p53 are associated with increased tumor 
development (Coles et al., 1992), progression (Borresen-Dale, 2003), recurrence 
(Norberg et al., 2001) and decreased response to therapy. Additionally, Li-
Fraumeni syndrome patients, carrying germ line p53 mutations, are predisposed 
to developing breast cancer at a relatively early age (Varley et al., 1997). Given 
the apparent important role of p53 in preventing breast tumor development in 
humans, a mouse model with a similar defect in p53 is a valuable tool to study 
breast tumor development. Therefore, a transgenic mouse model was developed 
with mammary gland specific expression of the p53.R270H mutation, resulting in 
spontaneous mammary gland tumorigenesis mimicking human breast cancer 
development (Wijnhoven et al., 2005). Expression of the mutation in mammary 
tissue was achieved by crossing p53.R270H mutant mice with mammary-specific 
Cre transgenic mice having Cre recombinase under the control of the hormone-
inducible Whey Acidic Protein (WAPCre mice; (Wagner et al., 1997)). This mouse 
model has been shown to develop human relevant mammary gland tumors, 
including hormonal receptor status, with a latency time of approximately one 
year. This combination provides a human relevant endpoint and sufficient time 
for exposure to study the relationship between chronic CRD and breast cancer 
development experimentally. 
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Monitoring CRD for interventions
Given the wide variety of observed health effects, biomarkers are needed that 
detect chronic CRD (long) before adverse health effects occur. Biomarkers are a 
valuable source of information, enabling early or non-invasive detection of disease 
or disease risk factors. Currently available or gold standard biomarkers for circadian 
rhythm studies are melatonin, corticosterone and body temperature. These 
markers are often used in studies to assess the effect of shift work (Niu et al., 2015, 
Papantoniou et al., 2014, Sack et al., 1992), but have several limitations for the use in 
large populations. An overall drawback of these classical markers of the circadian 
rhythm is the need for around the clock measurement. In relation to this circadian 
rhythmicity, for melatonin and body temperature the peak of the rhythm depends 
on chronotype (Lack et al., 2009), which in turn alters with age, complicating the 
use of these markers in longitudinal studies. Additionally, melatonin peak serum 
levels can be suppressed by light exposure during the night (Davis and Mirick, 
2006) making routine assessment more difficult. Moreover, classical markers are 
acutely altered after impingement on the circadian system and are not related 
to the (chronic) adverse health outcomes. Therefore, universal biomarkers for 
circadian rhythm disturbance are needed to compare CRD models, to evaluate 
the effect of preventive measures and to measure the personal risk of a shift 
worker.
Aim and outline of this thesis
The aim of this thesis is to study the causal relationship between chronic circadian 
disturbance and adverse health effects. Additionally, identifying underlying 
mechanisms and potential biomarkers for CRD to aid the development and study 
of preventive measures are objectives as well. Finally, a new model to study health 
effects of shift work in animal studies is presented. 
In chapter 2 we used a unique breast cancer-prone mouse model to study the 
causal relation between chronic CRD and breast cancer development. Besides 
breast cancer risk, the effects of CRD on body weight gain, sleep probability and 
classical circadian markers were investigated. As described previously, several 
scenarios have been suggested to underlie the relationship between shift work and 
cancer, in this chapter we show the relevance or irrelevance of these mechanisms.
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The presence of a causal relationship between shift work and adverse effects, 
warrants the detection of biomarkers for early detection of disturbance in order 
to develop preventive measures. Transcriptomic studies provide a valuable tool 
to obtain a complete overview of gene activity in tissues of interest. In chapter 3, 
a proof of principle is given using a comparative transcriptomics approach to 
identify potentially blood detectable biomarkers for breast cancer. A similar 
approach was used to identify biomarkers for CRD, independent of time of day, 
in chapter 4. Besides using biomarkers for CRD, in large cohort studies one could 
opt for the use of biomarkers related to disease outcome. The measurement of 
these biomarkers in a molecular epidemiology-like setting requires knowledge 
of their daily blood level patterns. Chapter 5 provides a descriptive study of the 
daily variation of hormonal and lipid biomarkers, often used in large scale studies. 
Development of evidence-based preventive measures further require insight into 
underlying biological mechanisms. 
In chapter 6, hepatic gene expression was analyzed to identify genes and 
processes affected by chronic CRD. Both the effects on genes that show circadian 
rhythmicity under normal conditions and on overall gene expression are described. 
Subsequently, the role of these genes in biological processes relevant for the 
observed phenotype was investigated.
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Chronically alternating 
light cycles increase 
breast cancer risk in 
mice
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Summary
Although epidemiological studies in shift workers and flight attendants have 
associated chronic circadian rhythm disturbance (CRD) with increased breast 
cancer risk, causal evidence for this association is lacking (Pukkala et al., 1995, 
Schernhammer et al., 2006). Several scenarios have been proposed to contribute 
to the shift work-cancer connection: (i) internal desynchronization, (ii) light at 
night (resulting in melatonin suppression), (iii) sleep disruption, (iv) lifestyle 
disturbances and (v) decreased vitamin D levels due to lack of sun light (Fritschi 
et al., 2011). The confounders inherent in human field studies are less problematic 
in animal studies, which are therefore a good approach to assess the causal 
relation between circadian disturbance and cancer. However, the experimental 
conditions of many of these animal studies were far from the reality of human 
shift workers. For example, some involved xenografts (addressing tumor growth 
rather than cancer initiation and/or progression) (Blask et al., 2003, Filipski et 
al., 2004), chemically induced tumor models (Hamilton, 1969, Shah et al., 1984) 
or continuous bright light exposure, which can lead to suppression of circadian 
rhythmicity (Anisimov et al., 2004, Wu et al., 2011). Here, we have exposed the 
breast cancer-prone p53R270H©/+ WAPCre conditional mutant mice (in a FVB genetic 
background) to chronic CRD by exposing them to a weekly alternating light-dark 
(LD) cycle throughout their life. Animals exposed to the weekly LD-inversions 
showed a decrease in tumor suppression. In addition, these animals showed an 
increase in body weight. Importantly, this study provides the first experimental 
proof that CRD increases breast cancer development. Finally, our data suggest 
internal desynchronization and sleep disturbance as mechanisms linking shift 
work with cancer development and obesity.
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Experimental Procedures
Experimental set-up
To study the effect of chronic circadian disturbance (CRD) on the development of 
breast tumors, breast cancer-prone female p53R270H©/+WAPCre conditional mutant 
mice in an FVB genetic background were chronically exposed to a LD-inversion 
protocol. The p53 R270H mutation in human Li-Fraumeni patients occurs in 
their germline and patients consequently develop tumors in a variety of tissues, 
including breast cancer. Since we are specifically interested in breast tumor 
development in the current study, we used the conditional p53R270H©/+ model, in 
which the mutation was specifically activated in mammary gland tissue through 
WAP-driven cre-recombinase. The generation of these mice has been previously 
described (Wijnhoven et al., 2005). Cre recombinase expressing mammary gland 
cells have been shown without pregnancy (Derksen et al., 2011), therefore virgin 
mice were used in this study. At 8 weeks of age, mice were randomly assigned to 
remain under a normal 12:12 hour light-dark (LD) cycle or to undergo a weekly 
alternating 12:12 hour light-dark cycle. After approximately 18 shifts, on day 7 of 
the last shift, a cross-sectional sample of animals was sacrificed around the clock, 
with 4 hour intervals (cross-sectional study, n=4 per time point). Blood and tissues 
were collected for further analysis. The remainder of the animals (longitudinal 
study, n=25 per group) stayed under LD or weekly LD-inversion (CRD) conditions 
and were sacrificed after when tumors reached approximately 1 cm3 or when 
animals were found moribund. Due to premature animal loss, 21 animals per 
condition were available for further analysis in the cross-sectional experiment. 
In the longitudinal study, 20 and 21 animals were available for body weight and 
tumor-free survival analyses for the control and CRD groups, respectively. In an 
additional group of mice (n=5 per group), a radio transmitter (Physio Tel, TA11 TA-
F10; Data Sciences, St. Paul, MN) was implanted in the peritoneal cavity to record 
locomotor activity and core body temperature every ten minutes.
The animal handling in this study was performed in compliance with national 
legislation, including the 1997 Dutch Act on Animal Experimentation, and the 
experiments were approved by the institute’s Animal Experimentation Ethical 
Committee.
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Breast tumor development
Mice were palpated once a week to check for tumor development. The time of first 
mammary tumor detection was registered and used to determine latency times. To 
confirm the presence of a tumor and determine tumor type, paraffin-embedded, 
formalin-fixed tumor sections were stained with H&E for histopathological 
evaluation. 
Body weight and food intake
Mice and food were weighed weekly to determine body weight gain and food 
intake. Body weight gain was expressed as percentages of body weight at the start 
of the experiment and was statistically analyzed at 28 weeks of exposure, the last 
time point without tumor-bearing animals. Animals were group-housed with three 
to four animals per cage; therefore, food intake was expressed as average weekly 
food intake. Food intake was measured between 8 and 15 weeks of exposure in 
the cross-sectional study.
Gene expression, corticosterone and vitamin D levels
Circadian expression levels of clock genes Bmal1, Per1, Per2, Dbp and cell cycle 
control gene c-Myc were determined in livers of control and weekly alternated 
LD cycle exposed cross-sectional animals, using quantitative reverse transcription 
polymerase chain reaction (RT-PCR). All oligonucleotide primers were obtained 
from Life Technologies (Bleiswijk, The Netherlands). Total RNA was extracted from 
RNAlater (Invitrogen, Grand Island, NY, USA) protected liver tissues using the 
miRNeasy Mini Kit (Qiagen Benelux, Venlo, The Netherlands). Clock gene expression 
was given as relative expression compared to a reference pool containing all 
samples. Corticosterone and vitamin D serum levels were determined using ELISA 
assays (Yanaihara Institute Inc. Shizuaka, Japan and Immunodiagnostics Systems, 
Frankfurt am Main, Germany, respectively). 
Body temperature and activity
Body temperature and behavioral activity were recorded for 2 weeks at baseline, 
after 1 shift and after 18 shifts. Cosine curves were fitted using the R statistical 
software environment (http://www.r-project.org) to determine the acrophase of 
activity and body temperature rhythms (i.e., peak time). Acrophase was expressed 
in External Time (ExT) (Daan et al., 2002), with ExT 0 indicating mid-dark. Sleep 
patterns were determined using mice telemetry data as described previously for 
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human wrist actimetry data (Juda et al., 2013b). In short, telemetric activity data 
were collected in 10-min bins, and sleep episodes were automatically detected by 
the method described earlier. Based on a non-rhythmic trend (calculated by using 
centered moving 24-h averages), sleep (=1) and wake (=0) t were dichotomized 
according to being below or above a selected threshold (15% of the trend). Onsets 
and offsets of sleep episodes were then assessed by a correlation method as earlier 
described in detail (Juda et al., 2013a, Roenneberg et al., 2015). 
Statistics
All data are expressed as means ± standard error of the mean (SEM) and were 
visualized and statistically analyzed using GraphPad Prism software version 6.04 
for Windows (GraphPad Software, San Diego California USA, www.graphpad.com). 
Differences in body weight gain at 28 weeks, tumor latency time and vitamin D 
serum levels were statistically tested using Kolmogorov-Smirnov test. Differences 
between LD-inversion and LD animals in food-intake, gene expression and 
corticosterone serum levels were analyzed using a two-way analysis of variance 
(ANOVA) followed by Sidak’s posttest. Linear regression was performed to analyze 
changes in total sleep, sleep in light and sleep in dark over time. Subsequently, 
differences between the slopes for the LD and CRD group were analyzed. CircWave 
Batch v5.0 software (Roelof Hut, www.euclock.org) was used to analyze circadian 
rhythmicity of gene expression and serum levels. The ChronoSapiens software was 
used to analyze behavioral data (Roenneberg et al., 2015).
Results
Classical circadian rhythms
To investigate the potential causal links between chronic CRD and enhanced cancer 
risk in more detail, we placed breast cancer prone p53R270H©/+ WAPCre conditional 
mutant mice (further referred to as p53R270H©/+ WAPCre mice (Wijnhoven et al., 
2005) in a 12 hour light, 12 hour dark cycle (LD 12:12). At the end of every week, 
the light or dark phase was extended to 24 hours to invert the LD cycle. Mice were 
sacrificed after tumor development (longitudinal study) or around the clock after 
approximately 18 LD-inversions (cross-sectional study). To monitor the extent to 
which this protocol affected the circadian steady state, we recorded locomotor 
activity and core body temperature (CBT) in an additional group of animals. Under 
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baseline LD schedules, all p53R270H/+ WAPCre animals showed regular daily activity and 
CBT rhythms (Fig. 1a for CBT; activity data not shown). The temperature maximum 
is reached approximately at External Time (ExT) 20. After the LD-inversions, the CBT 
rhythm re-established a stable phase of entrainment after 3-4 days of transients, 
which appeared to be more gradual after the first inversion (Fig. 1b) compared 
to inversion-week 18 (Fig. 1c). On day 7 after the 18th LD-inversion, representing 
steady state, CBT showed a circadian rhythm, but its peak was significantly delayed 
by 2 hours compared with age-matched control animals (p = 0.010).
Long-term health effects
In the longitudinal experiment, as shown in Figure 2a, mice exposed to weekly 
LD-inversions showed a larger increase in relative body weight compared to the 
animals kept in a stable LD cycle (RM-ANOVA, group: p = 0.0319; time: p < 0.0001; 
interaction: p < 0.0001). Although already apparent at week 6, group differences 
only became significant after week 24 (Sidak’s posttest p < 0.05). The difference 
in body weight gain between the groups did not reach significance in the cross-
sectional experiment (RM-ANOVA, group: p = 0.1410; time: p < 0.0001, interaction, 
p = 0.4049), probably due to a shorter experiment time and fewer LD-inversions 
(Fig. S1a). Differences in the amount of food-intake cannot explain the general 
weight-gain in the LD-inversion groups, since we even found a small, significant 
decrease in food intake in these animals compared to the stable LD controls (Fig. 
S1b). 
The latency to mammary gland tumor development was reduced by 17% in the 
CRD-exposed mice compared to the LD control mice (Fig. 2b, median latency time: 
42.6 versus 50.3 weeks, respectively; Kolmogorov-Smirnov p = 0.0127). Chronic 
LD-inversion affected neither the number of tumor-bearing mice nor tumor 
type (mammary gland tumors or other tumors). In both groups, approximately 
80% of the animals developed mammary tumors, including carcinomas and 
carcinosarcomas (Table S1).
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Figure 1. Peak temperature phases under LD and CRD conditions. (A-C) of p53R270H/+WAPCre animals 
maintained under stable LD 12:12 conditions (closed symbols) or weekly alternating light cycles (open 
symbols) (n=5 animals per group) (a) before start of the light inversions, (b) at the first LD-inversion and (c) 
after 18 LD-inversions. Per graph, subsequent days are plotted from top to bottom. Time of day on the x-axis 
is expressed as External Time (ExT), with ExT 0 corresponding with mid-dark. The upper axis indicates the ExT 
before the LD-inversion. Values represent the mean ± SEM. Diamonds indicate the average temperature 
peak times of animals maintained under normal LD conditions. Data are presented as double plots to help 
visualizing phase shifts (day 0+1, day 1+2, day 2+3 etc. on consecutive lines). Grey areas indicate darkness. 
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Figure 2. Long-term health effects resulting from CRD exposure. (a) Relative body weight gain of 
p53R270H/+WAPCre animals exposed to a regular LD cycle (closed symbols, n=20) or weekly alternating LD 
cycles (open symbols, n=21) in the longitudinal study. Note the significantly stronger weight gain of animals 
exposed to chronically alternating light cycles compared with animals maintained under a regular LD cycle 
in the longitudinal study (RM-ANOVA, group: F(1, 39) = 4.950, p=0.0319; time: F(27, 1053) = 42.48, p<0.0001; 
interaction: F(27, 1053) = 3.738, p<0.0001). Values represent the mean ± SEM. (b) Percentage of mice with 
palpable tumor in normal LD cycles (n=20; closed symbols) or chronic CRD conditions (n=21; open symbols). 
Black color indicates mammary gland tumor, whereas red color indicates other tumor types. See Table S1 for 
pathology data.
Investigating proposed mechanisms of shift work-related carcinogenesis
To gain more insight into these increased health risks resulting from chronically 
alternating light cycles, we focused on the proposed mechanisms linking shift 
work to cancer (Fritschi et al., 2011). We analyzed clock (Per1, Per2, Bmal1) and 
clock-controlled (Dbp, c-Myc) gene expression in liver and corticosterone serum 
concentrations (Fig. 3) to identify alterations and desynchronization among organ-
specific clocks and/or between central and peripheral clocks. In line with behavior 
and CBT, Per1, Per2 and Dbp hepatic gene expression re-entrained within 7 days in 
the new LD regime (tested after 18 LD-inversions; CircWave all p-values smaller than 
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0.05; Two-way ANOVA all p-values larger than 0.05). Only Bmal1 showed significant 
interaction between group and time, clearly resulting from increased expression in 
the CRD group at ExT10. In contrast to the unimodal 24-hr corticosterone rhythm 
in control animals, we found a significant bimodal (12-hr) rhythm in the CRD mice 
with a major peak at ExT 14 and a minor peak at ExT 2. We also analyzed the cell 
cycle control gene c-Myc, which was previously suggested to be clock-controlled 
and to play a role in accelerated tumor growth after chronic jet-lag (Filipski et al., 
2005, Fu et al., 2002). Although a slight phase advance appears to be induced by 
CRD exposure, no significant differences in expression kinetics were observed 
between the two groups. 
We did not find an effect of CRD on 25-hydroxy-vitamin D levels (data not shown). 
This might be well explained by the fact that laboratory animals are not exposed 
to sun light, and accordingly are not stimulated to synthesize vitamin D.
To study whether chronically alternating light cycles caused sleep disruption, we 
used the activity recordings to determine the total amount of predicted sleep. 
As we estimated sleep based on periods of inactivity, in our study, sleep refers to 
sleep probability rather than actual sleep. As shown in Figure 4 (left panels), the 
total amount of sleep showed a significant increase both in CRD mice (p < 0.0001; 
slope = 0.01543) and controls (p < 0.05; slope 0.003814) with increasing time in the 
experiment. However, the increase over time was significantly different (p < 0.001) 
between the two groups. While the controls increased their total sleep over the 
course of the experiment by 10%, CRD mice slept 50% more. Under LD conditions, 
the slight increase in sleep results mostly from sleep consolidation during the light 
phase (upper middle panel). In contrast, CRD-exposed animals increased their 
sleep in both light and darkness (lower left panels).
As to be expected from the frequent need to re-entrain after LD-inversions (see 
also Fig. 1), sleep in light was reduced to half of baseline levels after the inversion 
(day 0; Fig. S2, lower panels) and consequently increased to 150% in the dark 
phase. However, while sleep in dark returned to approximately baseline after 4 
days in the new regime, sleep in light almost increased to 175% of baseline. This 
imbalance shows that the increase of total sleep shown in Figure 4 is mainly due 
to overcompensation during the normal sleep times of this nocturnal rodent. LD 
controls showed normal variations in sleep timing across the week (for separate 
analyses of the recorded weeks, see Fig. S3a and Fig. S3b).
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Figure 3. Circadian expression of clock genes and c-Myc and corticosterone serum levels. Closed 
symbols = LD, open symbols = chronic LD-inversions. Circadian expression of clock genes Bmal1, Per1, Per2, 
Dbp and cell-cycle control gene c-Myc in liver and serum corticosterone levels (n= 3 or 4 mice per time 
point). Chronic LD-inversions did not significantly affect circadian expression of clock genes. Only minor 
differences were found at an individual time point for Bmal1 (*Sidak’s posttest p<0.05). The expression of 
c-Myc appears to show a phase advance in CRD-exposed animals, however no statistical differences were 
found. Corticosterone levels, however, were affected by the alternating light cycles. In contrast to the 
circadian rhythmicity in LD animals, corticosterone exhibits a significant 12-hr rhythm after 18 LD-inversions 
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with a major peak at ExT 14 and a minor peak around ExT 2 (p<0.05). Values at “lights on” were double plotted 
to help visualize circadian patterns. Values represent the mean ± SEM. Time of day on the x-axis is expressed 
as External Time (ExT), with ExT 0 corresponding with mid-dark.
Figure 4. Amount of predicted asleep per 
day (total sleep), in the light and dark 
phase, relative to baseline. Data represent 
means of animals per day, whereas linear 
regression analysis was performed on 
individual data points. Over time, total 
sleep and sleep in light significantly 
increased compared to baseline in both 
the LD (closed symbols) and LD-inversion 
(open symbols) group (Linear regression 
analysis: LD, total: p = 0.0492, light: p = 
0.0002; LD-inversions, total: p < 0.0001, 
light: p < 0.0001). The amount of sleep in 
dark only increased after exposure to 
chronically alternating LD cycles (Linear 
regression analysis: LD: p = 0.5474 and LD-
inversions: p = 0.0005). This gain of sleep 
was significantly larger for animals 
exposed to weekly LD-inversions 
compared to LD controls (comparison of 
slopes: total: F(1, 583) = 15.197, p = 0.0001; 
light: F(1, 583), p = 0.0391; dark: F(1, 583) = 
8.744, p = 0.0032).
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Discussion
Human field studies only offer limited insights into potential causalities between 
shift work and cancer due to the complex network of influencing variables, 
such as different shift work schedules, genetic heterogeneity, or individual shift 
work history (including the healthy workers phenomenon) – to name only a few 
(IARC, 2010). The p53R270H©/+ WAPCre mouse model for spontaneous breast cancer 
development allowed us to study the effects of chronically alternating light cycles 
on breast cancer initiation and/or progression; thus, this model differs from previous 
xenograft and chemically induced tumor models that do not reliably recapitulate 
the human situation (Blask et al., 2003, Cos et al., 2006). To our knowledge, this 
is the first study that unequivocally shows a link between chronic LD-inversions 
and breast cancer development. It thereby provides experimental evidence for 
previous epidemiological data associating shift work and jet-lag with increased 
breast cancer risk. Epidemiological studies have also indicated an association 
between social jet-lag, shift work and body weight, although conflicting data exist 
(Kubo et al., 2011, Nabe-Nielsen et al., 2011, Roenneberg et al., 2012, Parsons et 
al., 2014). Various mouse studies have shown that circadian disturbance induced 
by continuous light, forced activity or a disrupted LD cycle causes an increase in 
body weight (Coomans et al., 2013, Oishi, 2009, Salgado-Delgado et al., 2008). Our 
study, enforcing circadian strain by using changes in the environmental LD cycle 
supports the relationship between CRD and weight-gain. The finding that CRD-
exposed animals sleep more than controls, logically correlates with less activity 
and could thus contribute to a stronger weight gain. But to what extent are the 
results presented here for a causal link between CRD and increased breast cancer 
risk in a nocturnal rodent also relevant to human shift work?
Shift work involves many aspects that could be involved in the causal mechanisms 
that lead to increased health risks: internal desynchronization, melatonin 
suppression due to light at night, sleep disruption, lifestyle disturbances (such as 
smoking, [lack of ] breastfeeding, unhealthy diet, altered timing of food, etc.), and 
decreased vitamin D levels due to lack of sunlight exposure (Fritschi et al., 2011). 
The current study provides further insight into the relevance of these separate 
aspects (for an overview: see Fig. S4). Melatonin suppression, decreased vitamin D 
levels nor lifestyle disturbances (absent in mice) cannot account for the enhanced 
cancer risk in animals kept under LD-inversion conditions: (i) p53R270H©/+ WAPCre 
mice (FVB background) are melatonin-deficient; (ii) neither CRD mice nor controls 
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were exposed to sunlight, and we found no difference in 25-hydroxy-vitamin D 
between groups. This is consistent with a study in night shift workers which found 
no difference in vitamin D levels between fixed daytime workers, rotating shift 
workers without night shift and rotating shift workers with night shift (Itoh et al., 
2011). (iii) Lifestyle factors did not differ (amount of food intake) in the LD-inversion 
mice and the controls or were absent (e.g. breast feeding, smoking). Given the 
combination of decreased breast tumor latency time and increased body weight 
after chronic LD-inversions, it is tempting to speculate on the role of timing of food 
intake. Potentially, changed timing of food intake disrupts metabolic processes, 
resulting in adverse health effects. Previous studies have shown that timed feeding 
can indeed (partially) rescue tumor and obese phenotypes (Filipski et al., 2005, 
Fonken et al., 2010). 
Desynchrony between the sleep-wake cycle and endogenous circadian 
rhythmicity was recently shown to disrupt the circadian regulation of the 
human transcriptome (Archer et al., 2014a) and suggested to be an important 
factor underlying shift work-mediated breast cancer risk (Fritschi et al., 2013). In 
the present study, 7 days after the last LD-inversion, we found a disturbance of 
the circadian rhythmicity of corticosterone levels. It should be noted that blood 
samples were taken under ketamine/xylazine anesthesia, known to slightly increase 
corticosterone levels (Arnold and Langhans, 2010). However, as mice in the control 
and LD-inversion group were treated in similar manner, anesthesia is unlikely to 
explain the disturbed corticosterone rhythm in LD-inversed mice. In contrast to 
the disturbed corticosterone rhythm, on day 7 after the last inversion, we did 
not observe alterations in the daily patterns of hepatic clock gene expression, 
indicating that the liver clock reentrained within one week. However, disturbance 
of circadian rhythms at earlier time points is inherent of the re-entrainment to the 
new LD cycle. Minor differences in c-myc expression could be indicative of larger 
differences at earlier time points. This would be in line with other studies in which 
phase advances induce c-myc expression directly and three days after exposure 
(Filipski et al., 2005, Iwamoto et al., 2014). Previous studies have shown effects on 
both corticosterone rhythm and liver clock gene expression by other circadian 
disturbance protocols (Filipski et al., 2004, Barclay et al., 2012). Corticosterone 
has been shown to be involved in the entrainment and resynchronization of 
locomotor activity and peripheral clocks (Kiessling et al., 2010, Sage et al., 2004, 
Sujino et al., 2012). Liver clock gene expression is more sensitive to input of feeding 
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for entrainment (Sujino et al., 2012), which might explain the discrepancy and thus 
desynchrony between the disrupted corticosterone rhythm and reentrained clock 
gene expression in liver. 
Sleep duration, sleep timing and sleep quality are central elements of human shift 
work studies, both as outcome variables (in the form of descriptives of shift work-
related strain (Akerstedt, 2003) or post-intervention measures, (Neil et al., 2014, 
Vetter et al., 2015)) and as a proposed countermeasure (e.g., schedule-specific sleep 
strategies (Petrov et al., 2014)). As long-term sleep analysis in mice is challenging, 
sleep was estimated based on inactivity, and accordingly refers to sleep probability 
rather than actual sleep. However, there is a good consensus in the literature that 
extended bouts of inactivity highly correlate with actual electroencephalogram 
(EEG) and/or polysomnogram (PSG) detected sleep. In the Drosophila literature, 
5-minute bouts of inactivity are considered sleep (Shaw et al., 2000) and 
experiments in mice have shown that inactivity periods of 40 sec highly correlate 
with EEG-scored sleep (Pack et al., 2007). Similarly high correlations are reported 
for video-recorded immobility and EEG-scored sleep (Fisher et al., 2012). Since the 
sleep analysis conducted here is based on relative immobility within 10-min bins, 
we likely underestimate rather than overestimate the duration and frequency of 
sleep episodes. Despite the potential risk of mistaking immobility in a wake mouse 
for sleep, we consider our sleep-assessments as a good correlate for actual sleep 
duration. 
In human shift workers, sleep timing constantly changes, which results in shorter 
sleep (and reduced sleep quality). In contrast, we observed that mice exposed 
to chronic LD-inversions – not accompanied by forced sleep deprivation due to 
work – sleep more. The finding that CRD-mice appear to sleep more than control 
animals seems to contradict findings in shift-workers, who usually sleep less than 
day-workers (Juda et al., 2013a). However, unlike real shift workers, the CRD protocol 
in our animal study only involved changes in the LD cycle without the additional 
sleep restrictions enforced by work-shifts impinging on usual rest times. Assuming 
that the correlation between inactivity and sleep in mice is not influenced by the 
exposure to chronically alternating light cycles, we propose that the increase in 
amount of sleep observed upon CRD represents compensation for the constant 
perturbations of circadian timing and sleep. Future studies, addressing sleep and 
wakefulness by EEG rather than sleep probability, should provide a definite answer 
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to what extend sleep time and quality are affected upon chronically alternating 
light cycles.
The search for the underlying mechanisms that link shift work and health detriments 
(including increased cancer prevalence) is difficult in human shift work studies due 
to the network of potentially mediating factors. Controlled laboratory experiments, 
though performed in a nocturnal mouse model, allow the identification, isolation 
and quantification of individual contributors. The present study provides additional 
evidence for the role of internal desynchronization and sleep disruption in the 
etiology of CRD-associated health risks and pathologies (e.g., obesity and cancer; 
see Fig. S4). Female p53R270H©/+ WAPCre conditional mutant mice are ideal for 
investigating this etiology for breast cancer risk in depth. Furthermore, the highly 
controlled experimental conditions allow us to identify molecular biomarkers for 
CRD or other (shift work-related) exposures. Despite being based on a nocturnal 
mouse model, our results strongly suggest that individuals with hereditary (breast) 
cancer predispositions should not be exposed to frequently changing Zeitgebers 
as they exist for example in shift work or trans-meridian aviation. Due to the 
growing 24/7 economy, shift work will become increasingly part of our society and 
will, therefore, increasingly affect public health outcomes. Our experimental setup 
provides a unique tool for exploring underlying mechanism as well as devising 
countermeasures.
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Abstract
Identification of biomarkers for early breast cancer detection in blood is a 
challenging task, since breast cancer is a heterogeneous disease with a wide 
range of tumor subtypes. This is envisioned to result in differences in serum 
protein levels. The p53R270H/+WAPCre mouse model is unique in that these mice 
spontaneously develop both ER− and ER+ tumors, in proportions comparable 
to humans. Therefore, these mice provide a well-suited model system to identify 
human relevant biomarkers for early breast cancer detection that are additionally 
specific for different tumor subtypes. Mammary gland tumors were obtained 
from p53R270H/+WAPCre mice and cellular origin, ER, and HER2 status were 
characterized. We compared gene expression profiles for tumors with different 
characteristics versus control tissue, and determined genes differentially expressed 
across tumor subtypes. By using literature data (Gene Ontology, UniProt, and 
Human Plasma Proteome), we further identified protein candidate biomarkers for 
blood-based detection of breast cancer. Functional overrepresentation analysis 
(using Gene Ontology, MSigDB, BioGPS, Cancer GeneSigDB and proteomics 
literature data) showed enrichment for several processes relevant for human 
breast cancer. Finally, Human Protein Atlas data were used to obtain a prioritized 
list of 16 potential biomarkers that should facilitate further studies on blood-based 
breast cancer detection in humans.
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Introduction
Breast cancer is the most frequently diagnosed cancer and leading cause of cancer 
death among women worldwide (Ferlay et al., 2010). The most efficient way to 
reduce cancer mortality and morbidity is detection at an early stage, allowing 
effective therapeutic intervention. One way to improve cancer detection could 
be by means of a non-invasive test based on blood biomarkers. Preferably, these 
serum markers detect breast cancer across multiple tumor types regarding 
histopathology or diagnostic marker status, in an early stage of the disease. 
Currently, CA15-3, CA27-29 and CEA are clinically used breast cancer serum 
biomarkers for postoperative surveillance in patients with no evidence of disease 
and monitoring therapy in patients with advanced breast cancer rather than early 
detection (Sturgeon et al., 2008, Ludwig and Weinstein, 2005). Additionally, the 
use of HER2/neu/ERBB2 (in shed form) in serum for disease monitoring in patients 
without elevation of other tumor markers and for monitoring of Trastuzumab 
treatment is under evaluation (Sturgeon et al., 2008), and CA125 has also been 
suggested as tumor marker for advanced breast cancer (Norum et al., 2001). 
However, these clinical serum biomarkers are only used for disease monitoring and 
prognosis, and there are currently no FDA approved biomarkers for early detection 
of breast cancer. Therefore, much international effort is put into identification and 
validation of novel serum biomarkers for early breast cancer diagnosis (EDRN, 
Kretschmer et al., 2011, Böhm et al., 2011, Opstal-van Winden et al., 2011).
Breast cancer is a heterogeneous disease, with a large variety of tumor subtypes 
(Sorlie et al., 2001). Due to this heterogeneity, the identification and use of a 
single biomarker for breast cancer detection is challenging. Here, we focus on 
the identification of a panel of biomarkers which allows for detection with high 
specificity and sensitivity across various kinds of breast cancer tumor types to 
maximize screening applicability. In addition to a biomarker panel for all tumor 
types, it would be beneficial to be able to distinguish between tumor subtypes, 
as the prognosis and therapeutic approach is different for each subtype. Such 
additional information on prognosis and therapy could lead to better follow-up and 
referral of newly diagnosed patients. Relevant information in this respect would be 
e.g. estrogen receptor alpha (ER) and HER2/neu status as well as histopathological 
classification.
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A growing body of evidence demonstrate that mouse models for cancer 
(summarized in (Kelly-Spratt et al., 2008)) show common molecular, biological 
and clinical features compared to human cancers and as such these models are 
considered a promising tool for identification of cancer biomarkers (Kelly-Spratt et 
al., 2008). The human relevance of this approach is shown in a mouse model for 
breast cancer where the overlap of the plasma proteome is compared to proteomics 
studies of human breast cancer cell lines (Pitteri et al., 2008). However, mouse 
models used thus far for breast cancer biomarker identification (Whiteaker et al., 
2007, Pitteri et al., 2008, Schoenherr et al., 2011, Whiteaker et al., 2011) exclusively 
develop ER negative mammary gland tumors, while estrogen is thought to play 
an important role in breast tumors development (Nandi et al., 1995). Moreover, 
the majority of human breast tumors are ER positive. In our study, we use an 
innovative mouse model developed previously in our laboratory (Wijnhoven et al., 
2005) which spontaneously develops ER positive and negative tumors, resembling 
the human situation. This p53R270H/+WAPCre mouse model develops tumors of two 
different histopathological types: carcinomas and carcinasarcomas. Carcinoma is 
the most common tumor type found in women and therefore most relevant in 
this study. Although carcinosarcomas are rare in humans, this subclass shows a 
poor prognosis and early detection is highly necessary, since 5-year overall survival 
reaches zero if detected at later stages (Gutman et al., 1995). In addition to the 
estrogen receptor status, and the two histological subtypes, we were also able 
to determine different HER2/neu status based on gene expression data. HER2/
neu amplification in human breast cancers is associated with lower 5-year survival 
(Sotiriou and Pusztai, 2009). However, a positive HER2/neu status makes women 
eligible for trastuzumab treatment which improves survival significantly (Gianni et 
al., 2011). As such, HER2/neu based differentiation is highly important.
In this study, we use a genomics approach on this mouse model mimicking 
heterogeneous breast tumor development in humans, to identify candidate 
protein biomarkers relevant for early blood-based detection of human breast 
cancer. First, we compare different types of tumor and control tissue from the 
p53R270H/+WAPCre mouse model to determine genes which are informative across 
multiple tumor subtypes versus control, or which are able to distinguish between 
tumor subtypes. In the next step, we determine which of these mouse genes have 
a human equivalent that encodes for a protein potentially detectable in human 
serum. Finally, we compare the obtained lists with relevant information in other 
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databases to functionally characterize and prioritize the proteins for follow-up 
studies.
Materials and Methods
Animal experiment
This study was approved by the Animal Experimentation Ethical Committee of 
our institute. Animal handling in this study was carried out in accordance with 
relevant Dutch national legislation, including the 1997 Dutch Act on Animal 
Experimentation. 
Generation of p53R270H/+WAPCre mice and the phenotypic characteristics have 
been described previously (Wijnhoven et al., 2005). Heterozygous p53R270H 
and WAPCre mice, originally in a hybrid background (Wijnhoven et al., 2005), 
were crossed to FVB mice to generation F6. Female p53R270H/+WAPCre mice 
were generated by crossing female heterozygous p53R270H mice with male 
heterozygous WAPCre mice. All mice were weighed weekly and checked for the 
development of tumors by palpation. Mice were sacrificed immediately after 
detection of a palpable tumor (62±12 weeks of age), since our analysis was aimed 
at the identification of biomarkers for early detection of breast cancer. All tumors 
were dissected and weighed, the tumor size ranged from 52 to 988 mg with a 
median tumor weight of 328 mg. Control mammary glands were isolated from 
the same animals at the opposite site of the tumor. Tumors were processed for 
histopathology following standard procedures. For comparison with control tissue 
from a wild type strain, female FVB/N mice were sacrificed at 55 weeks of age and 
mammary tissue was collected. 
Histology and immunohistochemistry
Paraffin-embedded, formalin fixed tumor sections were stained with H&E for 
histopathological evaluation. ER expression was analyzed using the rabbit 
polyclonal antibody MC-20 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA). In 
this study we found that 74 percent of the mammary tumors showed ER positivity, 
which is comparable to earlier studies with this mouse model and the human 
situation (Wijnhoven et al., 2005). 
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Erbb2/HER2/neu status
In clinical diagnosis, mRNA expression levels have been shown to be a reliable 
method for the determination of HER2/neu status of breast tumors (Capizzi et al., 
2008). Therefore, we used our microarray expression data for Erbb2 (the murine 
form of HER2) to determine the HER2/neu status of the mammary gland tumors 
in our study. We used a cutoff value of mean log transformed expression of normal 
mammary gland tissue plus 3 standard deviations (Capizzi et al., 2008) to define 
which tumors were HER2/neu positive. In our data, this corresponded to a three-fold 
up-regulation of Erbb2 compared to control tissue. Using this cutoff, we found that 
21 percent of the mammary tumors were HER2/neu positive, which is close to the 
average reported value of 26% in human breast cancer (Revillion et al., 1998). Please 
note that we will use the phrase HER2 positive/negative throughput the paper to 
relate murine Erbb2 gene expression to the terms used in human clinical diagnostics.
Microarray analysis
RNA was extracted from control mammary glands and mammary tumors using the 
miRNeasy Mini Kit (Qiagen Benelux, Venlo, The Netherlands). RNA concentrations 
were measured using a NanoDrop spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). The integrity of the RNA samples was determined with the 
BioAnalyzer (Agilent Technologies, Amstelveen, The Netherlands) using the RNA 
nano 6000 kit (Agilent Technologies). RNA was further processed for hybridization 
to Affymetrix HT Mouse Genome 430 PM Array Plates at the Microarray Department 
of the University of Amsterdam, the Netherlands. RNA amplification, labeling and 
genechip hybridization, washing and scanning were carried out according to 
Affymetrix protocols.
Altogether, 30 samples were used for further analysis: 6 control FVB, 5 control 
p53R270H/+WAPCre (Control TG), 9 carcinomas (Car) ER+, 2 carcinomas ER−, 5 
carcinosarcomas (Csc) ER+, and 3 carcinosarcomas ER−. Of the 9 ER+ carcinoma 
samples, 4 were HER2/Neu positive; all other samples were HER2/neu negative.
Data analysis
Affymetrix CEL files were normalized using the Robust Multichip Average 
(RMA) algorithm and the MBNI custom CDF (http://brainarray.mbni.med.umich.
edu/ Brainarray/ Database/ CustomCDF/) for this chip. RMA output consisted 
of 16492 probe sets corresponding to unique Entrez GeneIDs. Quality control 
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consisted of visual inspection of residual plots and other RMA QC parameters. 
Further data analysis such as ANOVA and Principal Component Analysis (PCA) was 
carried out using R software unless indicated otherwise. Gene expression data 
between (two or more) experimental groups were compared using ANOVA, where 
p values < 0.001 and False Discovery Rate (FDR) < 5% were considered significant. 
Additionally, for tumor vs. control comparisons, only genes up-regulated in the 
tumor group(s) were considered in further analyses, as the aim of this study was 
to detect tumor-originating markers for early cancer detection in serum-based 
diagnostics. By making further Boolean combinations of regulated gene lists, we 
obtained genes informative across or between tumor subtypes.
To determine which genes code for proteins potentially detectable in human 
serum, we determined which proteins have a human equivalent that is annotated 
in Gene Ontology as extracellular, in UniProt as secreted, or has been experimentally 
detected in plasma or serum as part of the Human Plasma Proteome project 
(Anderson et al., 2004).
Functional annotation and overrepresentation analysis was carried out using 
DAVID (http://david.abcc.ncifcrf.gov) (Huang et al., 2009) for generally known 
databases such as Gene Ontology and UniProt. Further gene set overrepresentation 
analyses were performed using an in-house developed tool (based on the DAVID 
methodology) for other custom functional gene set libraries based on BioGPS tissue 
expression data (www.biogps.org, (Wu et al., 2009)), MSigDB-C2 gene sets curated 
from genomics literature (www.broadinstitute.org/gsea/msigdb/, (Liberzon et al., 
2011)), MSigDB-C4 cancer gene expression modules (Segal et al., 2004) the cancer 
signatures GeneSigDB (http://compbio.dfci.harvard.edu/genesigdb/, (Culhane et 
al., 2010)), and an in-house made collection of protein lists from mouse blood-
based proteomics literature (Pitteri et al., 2008, Whiteaker et al., 2011, Whiteaker et 
al., 2007, Schoenherr et al., 2011). 
Protein expression in human breast cancer and normal mammary tissue was 
compared using the Human Protein Atlas (www.proteinatlas.org) (Ponten et al., 
2008). This site contains semi-quantitative (absent – weak – moderate – strong) 
data. We considered a protein up-regulated in human tissue if at least 50% of the 
tumor samples in the database displayed an expression level at least one level 
higher than that of normal mammary gland.
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A visual summary of the workflow used in the data analysis is given in Figure 1.
Figure 1. Summary of the data analysis workflow, with cross-references to corresponding table and figures, 
and a summary of the functional enrichment analysis results.
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Results
Principal Component Analysis
Prior to statistical analysis, whole genome transcription profiles were visualized in a 
PCA (Figure 2). This revealed that, on the whole, tumor samples are clearly distinct 
from control samples. Additionally, the PCA indicated that several tumor subclasses 
with regards to histology and receptor status could already be distinguished (e.g. 
carcinoma HER+, carcinoma ER−, carcinosarcoma ER+ versus ER−), whereas the 
two control groups appeared highly similar. This latter finding was confirmed by 
statistical analysis: there are no genes with significant expression changes between 
the two mammary tissue controls groups (Table 1) and therefore these groups 
were combined in further analyses.
Figure 2. Principal Component Analysis on tumor and control tissue gene expression data. 
Similarities in genes expression changes across tumor subtypes
We compared gene expression changes between controls and tumor samples 
for either all tumors or by subset based on histopathology, ER, or HER2 status 
(Table 1, Figure 3). Since this study was set up to specifically identify tumor-
originating markers for cancer detection by means of a blood-based test, we not 
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only considered statistical significance (p < 0.001 and FDR 5%), but also set the 
demand that genes are up-regulated in tumor vs. control. After calculating the 
number of significantly up-regulated genes in tumor groups, we also determined 
how many of these have a human equivalent that is potentially blood-detectable, 
again with eventual screening implementation in mind. Numbers of genes 
meeting these criteria are given in Table 1. For tumor (subtype) versus control 
comparisons, we found between 2185 and 3471 up-regulated genes, of which 
238 to 458 (on average 11%) were potentially detectable in human blood. The fold 
ratio for these up-regulated genes ranged from 1.21 to 39.71 (median 1.85), for the 
potentially blood-detectable markers the fold up-regulation ranged from 1.28 to 
39.71 (median 2.21).
Table 1. Statistical comparisonsa and further combinations
Query Comparison Regulated genes Of which human 
blood detectable
A Control FVB <> Control TG 0 0
B all tumor > all control 2850 313
C carcinoma > all control 2330 238
D carcinosarcoma > all control 3471 458
E ER+ > all control 2768 309
F ER− > all control 2185 247
G HER2+ > all control 2768 307
H HER2− > all control 2749 313
J carcinoma <> carcinosarcoma 350 76
K ER+ <> ER− 0 0
L HER2+ <> HER2− 178 24
Combination Description Regulated genes Of which human 
blood detectable
C AND D carcinoma and carcinosarcoma vs control 1942 200
(C OR D) AND J carcinoma/carcinosarcoma differentiation 197 51b
C AND J specific for carcinoma 53 11
D AND J specific for carcinosarcoma 171 48
(C AND D) AND J applicable for both 27 8
E AND F ER+ and ER− vs control 1815 202
(E OR F) AND K ER+/ER− differentiation 0 0
G AND H HER2+ and HER2− vs control 1887 203
(G OR H) AND L HER2+/HER2− differentiation 117 15c
G AND L specific for HER2+ 109 14
H AND L specific for HER2− 25 2
(G AND H) AND L applicable for both 17 1
ALL (B,C,D,E,F,G,H) Shared across all subtypes 1395 149d
a based on p < 0.001 and FDR < 5%
b Supplementary Table 2
c Supplementary Table 3
d Supplementary Table 1
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Next, we determined the overlap between the various gene lists. We noticed that 
for each of these lists, roughly half (37% - 74%) was present in an overlap with 
other sets (Table 1, Figure 3). This indicated that there is a common set of genes 
that discriminates the various tumor groups from control tissue, but not the sub-
tumor types by themselves. The most comprehensive overlap across all of the 
comparisons resulted in 1395 regulated genes of which 149 met the criteria for 
protein blood detectability. These 149 genes are listed in Supplementary Table 
1. Fold up-regulations ranged from 1.30 to 16.80 (median 2.13) for the set of 
1395 genes, and from 1.39 to 16.34 (median 2.36) for the 149 potentially blood-
detectable genes. As for the single tumor (subtype) versus control comparisons, 
there is a trend in that the potentially blood-detectable subset shows larger fold 
up-regulations.
Figure 3. Venn diagram for the various comparisons made. Overlap of discriminative genes based on 
histological classification (red), ER status (green), HER2 status (blue), and across all tumor subtypes (bold).
GO functional annotation analysis on this list revealed enrichment for terms related 
to the cytoskeleton, extracellular matrix (including remodeling), cell division, 
(negative regulation of ) apoptosis, and immune/inflammatory response (Figure 1). 
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Enrichment analysis on the MSigDB-C2 database showed mainly significance (FDR 
5%) for gene sets related to cancer, including several breast cancer sets (Poola 
et al., 2005, Schuetz et al., 2006, Sotiriou et al., 2006), with other significant gene 
sets being mainly involved in stress and immune responses. Enriched MSigDB-C4 
cancer modules were related to cytoskeleton, extracellular matrix, cell division, and 
inflammatory response. The BioGPS-derived tissue-associated gene set library did 
not reveal a match between normal mammary tissue and the shared 149 marker 
set, but instead showed enrichment for predominantly immune set-related 
signatures, perhaps reflecting the endogenous response to the tumor (Figure 1). 
Comparison to literature mouse plasma breast cancer proteomics sets revealed 
one significant enrichment, namely to Table S6g of Whiteaker et al (Whiteaker et 
al., 2011) which describes their verification of plasma biomarkers on individual 
mice. This overlap comprised six genes (Hsp90b1, Hspa5, P4hb, Pfn1, Tnc, Ywhaz). 
Finally, the cancer GeneSigDB was used to determine if there was significant 
overlap to cancer literature gene sets. The analysis showed significant enrichment 
for 171 of the 2142 cancer signatures. These signatures were derived from several 
tissues, although the fraction of significant breast cancer signatures (63 enriched 
out of 476 breast cancer sets) was relatively highest, being 1.7 times that for the 
overall (171 / 2142) significant fraction. The most significant breast cancer gene 
set was that by Lauss et al (Lauss et al., 2008) containing consensus genes from 
literature studies to predict breast cancer recurrence. Next, we determined which 
genes are most characteristic for the 63 enriched breast cancer signatures versus 
the rest of the database. We found that this enrichment could mainly be ascribed 
to genes involved in cell division. Overall, the high match to literature gene sets 
suggests our marker set has considerable resemblance to marker sets found in 
(predominantly) human breast cancer.
Differences between tumor subclasses
Besides biomarkers common to all tumor subclasses, we also set out to find 
biomarkers that might help to discriminate between various tumor subclasses. 
Indeed, the PCA in Figure 2 indicated this would be possible. For the carcinoma 
vs. carcinosarcoma comparison we found 350 differentially expressed genes, 76 
of which are potentially human blood-detectable (Table 1, Figure 3). Since latter 
implementation would only be practical if a biomarker was increased in either of 
the two subclasses when compared to a control, we determined the overlap of 
the carcinoma vs. carcinosarcoma genes with the sets of genes up-regulated in 
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carcinoma and/or carcinosarcoma to control. This led to 51 genes, which are listed 
in Supplementary Table 2. As can be seen from this table, 48 of these genes show 
higher expression in carcinosarcoma than in carcinoma. Additionally, GO functional 
enrichment analysis showed enrichment for extracellular matrix, extracellular 
matrix remodeling, and angiogenesis. These findings are in line with the more 
aggressive clinical phenotype of this subtype. Of the 51 genes in Supplementary 
Table 2, 8 overlap with the set of 149 shared genes (Supplementary Table 1), 
namely Actn1, Inhba, Msr1, Ncam1, Plau, Pls3, Tpm4, and Wisp1. Enrichment analysis 
on C2, C4 and BioGPS datasets found significance for (breast) cancer, extracellular 
matrix (remodeling), angiogenesis, and immune response gene sets (Figure 1). 
No significant overlap with literature mouse plasma cancer proteomics sets was 
found. In the GeneSigDB sets there was enrichment for 79 sets, 26 of which were 
breast cancer related. Here the breast cancer-specific enrichment was mainly due 
to extracellular matrix (remodeling) associated genes. 
When the analogous comparison was made for ER+ and ER− tumors vs. each 
other and the control, no differentially expressed genes were found. Apparently, 
following the genomics strategy described here, no potential biomarkers are 
identified to discriminate between ER+ and ER− breast cancers in human blood.
For the HER2 status, 178 genes were differentially expressed between HER2+ 
and HER2− tumors, 117 of which were up-regulated in either subtype to control 
(Table  1, Figure 3). Of these, 15 were potentially blood-detectable (Supplementary 
Table 3). Of these, 14 were higher expressed in HER2+ tumors, including, as could 
be expected, the Erbb2 gene itself. Mutual comparisons showed no overlap 
between this list and the list of 149 markers shared across tumor subtypes versus 
control, nor the 51 genes discriminating carcinoma from carcinosarcoma. No GO 
enrichment was found for these 15 genes. Additional enrichment analyses only 
showed enrichment for one gene set across all five databases, namely the C2 entry 
for an amplification hot spot in the human chromosome 17q11.1-q21; 17q25 
region described by Myllykangas et al (Myllykangas et al., 2006), which indeed 
contains the (human homolog of the) Erbb2 gene (Figure 1).
Further prioritization of potential biomarkers
To translate our results obtained using a mouse model to the human situation 
and prioritize the markers for further human follow-up studies, we used the data 
40036 Dycke, Kirsten.indd   51 11-04-16   11:02
Chapter 3
52
3
available on the Human Protein Atlas to compare protein expression in human 
breast cancer tissue and normal mammary gland for the 149 shared genes in 
Supplementary Table 1. For the 116 proteins where such human information was 
available, 16 showed an increased expression in human cancer tissue compared 
to normal mammary gland. These 16 proteins are given in Table 2. Their gene 
expression fold up-regulations ranged from 1.81 to 7.28 (median 2.13) with 
standard deviation values (see also Supplementary Table 1) being approximately a 
third of the fold up-regulation (median relative SD 36%). A relatively high standard 
deviation (5.62, 77% relative SD) was found for VCAN. Functionally, the majority of 
these 16 proteins are associated with the cytoskeleton.
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Discussion
Breast cancer is the leading cause of cancer death worldwide (Ferlay et al., 2010). 
Early diagnosis of cancer is necessary for improvement of survival and reduction 
of morbidity. Therefore, there is a need for sensitive testing strategies specifically 
for early detection. For improvement of current early detection rates, blood-
based diagnostics could be a valuable addition to (or next to) existing screening 
programs, because of their low costs and flexible logistics. The first step towards 
implementing such blood-based detection is the identification of biomarkers that 
detect across multiple tumor types, to increase overall sensitivity. A secondary step 
would be the identification of biomarkers that are able to differentiate between 
tumor subtypes to improve follow-up and referral of newly diagnosed patients, 
i.e. a more personalized approach. In the study described here, we use a genomics 
approach on tumor tissue compared to normal mammary gland to identify 
protein candidate biomarkers relevant for blood-based early detection of human 
breast cancer. Interestingly, we hereby differentiated the mammary tumors with 
regards to histological subtype and receptor status, to reflect human variation in 
these tumor characteristics. Moreover, we used an experimental set up specifically 
aimed at the early detection of cancer, rather than a set up with more progressed 
cancers.
Mouse models are frequently applied in biomarker discovery research (Kelly-
Spratt et al., 2008). Earlier studies have shown that although both human and 
mouse breast tumors have a heterogeneous profile, similarities can be found and 
therefore, mouse models are useful in human breast cancer biomarker discovery 
studies (Klein et al., 2007, Pitteri et al., 2008). In recent years, some studies have 
focused on early detection, such as a plasma proteomics study between PyMT 
transgenic tumor-bearing mice and matched controls by Pitteri et al. (Pitteri et al., 
2008), and several between tumor and normal mammary tissue from a conditional 
HER2-driven mouse (Schoenherr et al., 2011, Whiteaker et al., 2011, Whiteaker et 
al., 2007). However, these literature studies are limited in number, and none have 
taken into account the differentiation between tumor subtypes within a single 
mouse model. Here, we first report the use of a humanized mouse model for breast 
cancer that represents the heterogeneity of breast cancer, within an identical 
genetic background. Two different histological subtypes, and ER as well as HER2 
positive and negative tumors are represented in this model. We did not determine 
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progesterone receptor (PR) status, as clinically PR expression has little prognostic 
value and is merely used as an additional factor next to ER for the response to 
hormonal therapy (Sotiriou and Pusztai, 2009). 
In this study we identified 149 potentially blood-detectable biomarkers 
(Supplementary Table 1). The identified genes were significantly up regulated in all 
tumor types compared to normal mammary gland tissue and potentially blood-
detectable according to GeneOntology, Uniprot or the Human Plasma Proteome 
Project. Moreover, we compared protein expression in human breast tumors and 
normal breast tissue using the Human Protein Atlas. With these steps we translated 
mouse mammary gland tumor gene expression to 16 prioritized candidate blood-
detectable human breast cancer markers (Table 2). 
Our biomarker panel is enriched for several biological functions, such as 
cytoskeleton, extracellular matrix (including remodeling), cell division, (negative 
regulation of ) apoptosis, and immune/inflammatory response (Figure 1). These 
terms are related to cancer processes in general, although not specifically to breast 
cancer. This is corroborated by the enrichment for MSigDB-C2 and GeneSigDB 
signatures for breast- but also other types of cancers. If the intended use of the 
biomarker panel would be specifically breast cancer, biomarkers specific for breast 
cancer (or other tumors) should also be included. Additionally, it can be noted that 
several immune/inflammatory response markers can also be triggered by other 
diseases and such markers would need to be combined with non-immunological 
markers to provide sufficient specificity for (breast) cancer. 
We did not detect any significant differential expression for the clinically used 
markers CA15-3, CA125, CEA, and CA27-29. This can probably be attributed to 
the fact that – in line with our aim of finding early detection biomarkers – we 
dissected mice as soon as a palpable tumor was detected. These clinical markers 
are more often found at more advanced tumor stages and are considered more 
useful for tumor monitoring and prognosis rather than early detection (Ludwig 
and Weinstein, 2005, Zeiwar et al., 2007, Molina et al., 2010, Tampellini et al., 2006).
We identified more potential biomarkers across tumor types than we did for 
discrimination between tumor types. As mentioned before, breast cancer is a 
heterogeneous disease and in this study several tumor types were represented. It 
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seems that despite this heterogeneity there are still substantial similarities across 
tumors types, which involve known cancer deregulated processes such as cell 
division and tissue invasion. This would be advantageous to finding biomarkers to 
improve current breast cancer screening. In the future, additional differentiation 
between tumor subtypes based on tumor type specific biomarkers or genetic 
make-up may be beneficial. 
Although our mouse model represents the heterogeneity found among human 
breast tumors and the regulated genes found in this study are involved in 
mechanisms relevant for human breast cancer, the use of any mouse model for 
human breast cancer has inherent limitations and application of our biomarker 
panel in a large-scale screening setting would require several validations steps. 
Therefore, naturally, our potential biomarker panel needs to be tested in human 
blood samples, to determine the usefulness, and subsequently sensitivity and 
specificity of this panel for early detection of breast cancer. The main potential 
limitation in human samples is that the variation between individuals is much 
larger and statistical power for early tumor detection would decrease considerably. 
In fact, studies have shown that it is even difficult to find reproducible markers 
within a clinically homogenous group of patients due to the individual variations 
and heterogeneities (Ein-Dor et al., 2005). Further studies in small human cohorts 
or humanized mouse models, using multi-marker assay methods such as Luminex 
or antibody arrays are therefore needed to determine which markers in our panel 
are sufficiently robust for eventual testing on a larger human cohort.
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Abstract
Frequent shift work causes disturbance of the circadian rhythm and might on 
the long-term result in increased health risk. Current biomarkers evaluating the 
presence of circadian rhythm disturbance (CRD), including melatonin, cortisol 
and body temperature, require 24-hr (“around the clock”) measurements, which is 
tedious. Therefore, these markers are not eligible to be used in large-scale (human) 
studies. The aim of the present study was to identify universal biomarkers for CRD 
independent of time of day using a transcriptomics approach. Female FVB mice 
were exposed to six shifts in a clockwise (CW) and counterclockwise (CCW) CRD 
protocol and sacrificed at baseline and after 1 shift, 6 shifts, 5 days recovery and 14 
days recovery, respectively. At six time-points during the day, livers were collected 
for mRNA microarray analysis. Using a classification approach, we identified a set of 
biomarkers able to classify samples into either CRD or non-disrupted based on the 
hepatic gene expression. Furthermore, we identified differentially expressed genes 
14 days after the last shift compared to baseline for both CRD protocols. Non-
circadian genes differentially expressed upon both CW and CCW protocol were 
considered useful, universal markers for CRD. One candidate marker i.e. CD36 was 
evaluated in serum samples of the CRD animals versus controls. These biomarkers 
might be useful to measure CRD and can be used later on for monitoring the 
effectiveness of intervention strategies aiming to prevent or minimize chronic 
adverse health effects.
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Introduction
Human behavior, physiology and metabolism are subject to daily rhythms, 
which are controlled by the circadian clock. This endogenous time keeping 
system provides a temporal organization of our body functions in relation to 
environmental time and allows us to anticipate to daily recurring events (Mohawk 
et al., 2012). Chronic circadian rhythm disturbance (CRD), as encountered by 
frequent night shift work or multi time zone travelling might result in an increased 
risk for long-term health effects. Indeed, epidemiological studies among shift 
workers and flight personnel have associated frequent shift work and jet lag 
with an increased incidence of breast cancer, obesity and metabolic syndrome 
(Reynolds et al., 2002, Schernhammer et al., 2006, Kubo et al., 2011). These adverse 
health effects occur after many years of shift work, and at present it is unclear what 
mechanism is causing adverse health effects and how these effects of shift work 
can be minimized. The ability to measure chronic CRD associated with shift work 
would allow measuring effects of interventions on chronic CRD and monitoring 
adversity in shift workers and ultimately will help to design intervention strategies. 
Studies on the beneficial effects of interventions to prevent shift work-driven 
adverse health outcomes assess effects on CRD using classical circadian markers, 
including melatonin, cortisol and body temperature (Mirick and Davis, 2008). 
These markers allow monitoring circadian rhythm and acute CRD using multiple 
measurements around the clock before health effects occur. In addition to classical 
circadian markers, recent research on circadian clock controlled output genes 
has shown that up to 10% of the transcribed genes is under circadian control, 
providing additional rhythmic markers to estimate body time in blood and tissues 
(Panda et al., 2002, Ueda et al., 2004). However, both the classical circadian markers 
and cycling clock and clock-controlled gene markers are non-eligible as CRD 
markers in large-scale human cohort studies due to two important pitfalls. Firstly, 
circadian markers require around the clock measurements, resulting in higher costs 
and larger impact on participating subjects compared to single measurements. 
Secondly, classical biomarkers are useful for demonstrating acute CRD, but provide 
no or only limited information on long-term CRD and accumulation of adversity 
over time. To acquire information on biological adversity of CRD and to explore the 
effectiveness of CRD preventive measures, new biomarkers are needed to evaluate 
the presence of chronic CRD in a time of day independent manner.
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Shift work involves a multitude of aspects, including phase desynchronization, 
light at night, sleep disruption and lifestyle disturbances, all of which potentially 
play a role in causing CRD and associated adverse health effects (Fritschi et al., 
2011). Many different shift work schedules are in use, varying in rotation speed 
and direction, including forward (counterclockwise) or backward (clockwise) 
rotating shift schedules. Experimental studies in which mice were subjected to 
(chronic) shifts in the light-dark cycle (as such resembling jet lag), have shown 
that both counterclockwise (CCW) and clockwise (CW) schedules cause CRD 
(McGowan and Coogan, 2013). Additionally, several human studies have shown 
disturbed circadian rhythms by both CCW and CW work schedules, without major 
differences between the schedules (Barton et al., 1994, Boquet et al., 2004, Tucker 
et al., 2000). However, in aged mice CCW shifts appeared more disruptive than CW 
shifts, as evident from the increased mortality (Davidson et al., 2006). 
The aim of the present study was to identify universal biomarkers for CRD 
independent of rotation direction and time of day. Two different rotations of chronic 
jet lag were used to induce CRD. Since blood biomarker discovery is technically 
challenging, we selected the liver to identify biomarkers, as the target tissue of 
metabolic effects of CRD and as previously used for circadian transcriptomics 
studies (Ueda et al., 2004). By comparing the liver transcriptome of animals under 
normal, CW rotating and CCW rotating light schedules, we identified a set of 
hepatic gene expression markers that report on the presence of CRD. Additionally, 
we identified non-circadian, age-independent genes differentially expressed after 
CRD compared to baseline that are potentially blood detectable. One candidate 
biomarker i.e. CD36 was validated in blood, allowing future use in large-scale 
human studies.
Methods
Study design
Animal studies were performed in compliance with national legislation, including 
the 1997 Dutch Act on Animal Experimentation, and experiments were approved 
by the Animal Experimentation Ethical Committee of the National Institute for 
Public Health and the Environment in Bilthoven. All surgery was performed under 
isoflurane anesthesia and appropriate analgesics were used to minimize suffering.
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Female FVB mice, 8 to 12 weeks of age, were kept under a normal 12:12 hour 
light-dark (LD) cycle for approximately three weeks, with Zeitgeber Time 0 (ZT0) 
corresponding to lights on. Animals were group-housed and food and water 
were provided ad libitum. Prior to the first shift, animals (n=24) were sacrificed 
around the clock at four hour intervals (n=4 at each time point). Subsequently, 
the remaining group of animals underwent six shifts in either a clockwise (CW) or 
counterclockwise (CCW) rotating light schedule. Specifically, mice were exposed 
to a phase delay or phase advance of eight hours every five days, respectively (S1 
Figure). Hereafter, mice were again kept under LD, referred to as recovery. After 
one shift, six shifts, five days recovery and fourteen days recovery n=30 animals 
per group were sacrificed around the clock with four hour intervals (n=5 per time 
point) by orbital bleeding under Ketamine/Xylazine anesthesia. Liver and blood 
were collected for transcriptomics and serum analyses, respectively. A detailed 
overview of the experimental design is depicted in S1 Figure. 
Four additional mice per group received a radio transmitter (Physio Tel, TA11 
TA-F10; Data Sciences, St. Paul, MN) in the peritoneal cavity to record core body 
temperature every ten minutes. Body temperature was recorded throughout the 
experiment. Cosine curves were fitted using the R statistical software environment 
(www.r-project.org) to determine the phase (i.e., peak time) of activity and body 
temperature rhythms.
Microarray analysis
RNA was extracted from livers (n=4 per time point at baseline and n= 2 per time 
point for the CCW and CW groups) using the miRNeasy Mini Kit (Qiagen Benelux, 
Venlo, The Netherlands). RNA concentrations were measured using a NanoDrop 
ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA), and 
RNA quality was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Amstelveen, the Netherlands). 
RNA was processed for gene expression analysis at the Microarray Department 
of the University of Amsterdam, the Netherlands, using methods described in 
Pennings et al (Pennings et al., 2011). Experimental samples (each corresponding 
to RNA from one individual mouse) were labelled with Cy3 and the common 
reference sample (made by pooling equimolar amounts of RNA from experimental 
samples) was labelled with Cy5. Samples were hybridized to Nimblegen Mus 
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musculus 12 x 135 k microarrays (Roche NimbleGen, Germany). This type of 
microarray contains 44,170 gene probes with three spots per probe. Slides were 
scanned with an Agilent G2565CA DNA microarray scanner. Feature extraction 
was performed with NimbleScan v2.5 (Roche NimbleGen), resulting in a table 
containing individual probe signal intensities for both dyes.
The raw data were subjected to a set of quality control checks to ensure comparable 
signal average and distribution. Raw microarray data for gene-coding probes 
were normalized in R (www.r-project.org) using a four step approach (Pennings 
et al., 2011): (1) natural log-transformation, (2) quantile normalization of all scans, 
(3) correcting the sample spot signal for the corresponding reference spot signal 
and (4) averaging data from replicate probe spots. The normalized data of 44,170 
probes were further analyzed in R and Excel (Microsoft Corporation, USA). Probe 
to gene annotation data was downloaded from NCBI. Classification and statistical 
analysis was performed on the probe level. Significantly predictive or regulated 
probe sets were annotated to the corresponding genes for further biological 
interpretation. To this end, when multiple probes corresponding to the same 
gene were significant, they were counted as one gene in further analysis; probes 
that did not correspond to genes according to the current NCBI database were 
excluded from further analysis.
Complete raw and normalized microarray data and their MIAME compliant 
metadata have been deposited at GEO (www.ncbi.nlm.nih.gov/geo) under 
accession number GSE65346.
Classification approach
After normalization, a classification approach was applied to identify a set of genes 
able to classify samples into either circadian rhythm disrupted (CRD) or non-
disrupted (ND) 14 days after the last shift. Three different algorithms were used: 
Random forests (RF) (Breiman, 2001), Support vector machine (SVM) (Rifkin et al., 
2003) and Prediction analysis for Microarrays in R (PAM-R) (Tibshirani et al., 2002) (R 
statistical software). To ensure time-of-day independence of the classifier, for each 
classification algorithm, a ‘leave-one-time point-out’ cross-validation approach 
was used for the classification. Here, time point refers to ZT time point. To this end, 
the data were repeatedly split into a training set and a test set, in which the training 
set comprised the data for all-but-one time point, and the test set the data for the 
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remaining time point. The prediction model obtained for the training set was used 
to predict the test set data. This approach keeps replicate (time point) samples 
together and therefore gives a more reliable estimation of the prediction accuracy 
than cross-validation with random sample selection. The prediction accuracy was 
calculated as the average over all the test set predictions. As each classifier builds 
a different prediction model (potentially using different genes) for each training 
set, genes included in the majority of the models for each classifier were taken as 
consensus gene set for each type of classifier. 
As we aim to find biomarkers which applicability does not depend on a specific 
choice of algorithm, only genes present in all three classifiers consensus sets were 
considered potentially valuable biomarkers to classify CRD versus non-disrupted 
(van der Veen et al., 2013, Vandebriel et al., 2010). To validate prediction accuracy of 
the consensus gene set after one shift, six shifts and after 5 days recovery, the 14 
days recovery dataset was used as the training set to build the prediction model. 
Sequential approach
To identify differentially expressed genes (as compared to baseline) after 14 days 
recovery for the CCW and CW protocol separately, we performed a one-way 
ANOVA with Qlucore Omics Explorer (Qlucore AB, Lund, Sweden) in which p<0.001 
was considered statistically significant. CircWave Batch v5.0 software (Hut, R., www.
euclock.org/results/item/circ-wave-batch.html) was used to analyze circadian 
rhythmicity of gene expression. P-Values were false discovery rate (FDR) corrected 
(Benjamini and Hochberg, 1995); genes with an FDR <0.05 were considered 
rhythmically expressed. Genes that were rhythmically expressed at any time 
point during the experiment (baseline, 1 shift, 6 shifts 5 or 14 days recovery) were 
excluded as potential biomarker. The GenAge Database of ageing-related genes 
(www.genomics.senescence.info) was used to identify (human) age-dependent 
genes, which were excluded also. 
To determine which candidate biomarker genes are potentially detectable 
in human serum or plasma, we determined which genes code for proteins 
that are annotated in Gene Ontology as extracellular or in UniProt as secreted. 
Additionally, we determined which genes have human equivalents that have 
been experimentally detected with high confidence in plasma or serum (Farrah et 
al., 2011) or as part of the Human Plasma Proteome Project (Nanjappa et al., 2014). 
40036 Dycke, Kirsten.indd   65 11-04-16   11:02
Chapter 4
66
4
Biomarker serum levels
Corticosterone serum levels were determined using ELISA assays (Yanaihara 
Institute Inc. Shizuaka, Japan) and subsequently visualized and analyzed using 
GraphPad Prism software version 6.04 for Windows (GraphPad Software, San Diego 
California USA). Five outliers (out of 251 samples) were excluded based on Grubbs 
analysis (alpha 0.1). Phase and circadian rhythm were analyzed using CircWave 
Batch v5.0 software. CD36 was determined in serum with a dedicated ELISA assay 
(Abcam, Cambridge, United Kingdom). Differences between CRD exposed groups 
and baseline were statistically tested using a two-sided student’s t test. P-values 
<0.05 were considered statistically significant.
Results
Classical circadian markers
First, we evaluated whether the two different schedules, counterclockwise (CCW) 
and clockwise (CW), affected circadian rhythm by analyzing classical circadian 
markers: core body temperature and corticosterone rhythms. At baseline, animals 
showed regular daily body temperature rhythms, with peaks at approximately 
ZT12. Core body temperature rhythms re-entrain to the new light-dark cycle after 
the first shift and following shifts, for both CCW and CW groups (Fig. 1, panels 
A & B, respectively). 
As expected, corticosterone serum levels at baseline showed a major peak at ZT12. 
Additionally, a minor peak at ZT0 was also observed, corresponding with a small 
increase in activity at this time point specific for FVB mice (CircWave tau = 12, 
p = 0.0003). Differential effects between the two schedules could be observed 
after peak phase analysis of corticosterone rhythms (Fig. 2). After the first shift, the 
corticosterone rhythm shows peak levels at ZT16 for the CW group, representing 
an incomplete shift (p = 0.005). In the CCW group peak time was at ZT20, indicative 
of a lack of phase shift at this time point (p = 0.052). Although there is a tendency 
toward circadian rhythm, no significant circadian corticosterone rhythm could be 
detected in either group upon six shifts (CCW: p = 0.369, CW: p = 0.700). At 5 days 
and 14 days after the last shift, rhythms were detected in both groups. After 14 
days recovery these rhythms were less robust for CCW and CW (p = 0.093 and p = 
0.105, respectively) compared to 5 days after the last shift (CCW: p = 0.007, CW: p = 
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0.003). Overall, these results show that circadian rhythms of corticosterone levels 
heavily disturbed upon prolonged exposure to CRD, but reappear when animals 
are back under normal LD conditions.
Figure 1. Double plots of peak phase of core body temperature rhythms. A. the counterclockwise 
schedule and B. the clockwise schedule. A cosine function was fitted to determine peak phase (n=4 mice 
per group). Data are presented as mean peak phase ± sd. Grey areas indicate periods of darkness.
A B
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Figure 2. Corticosterone serum levels for the counterclockwise (CCW) and clockwise (CW) jet lag 
protocols. Serum levels were determined at baseline, after 1 shift, 6 shifts, 5 days recovery and 14 days 
recovery. Data are presented as mean ± SD. For the first shift, the light dark schedule before the shift is 
depicted in grey. At baseline a significant 12-hr rhythm was detected, due to the major peak at ZT12 and 
another peak at ZT0. CircWave peak phases were indicated with (ê). Note: as circadian rhythmicity of serum 
corticosterone levels was lost after 6 shifts, peak phases at the 6th shift are just indicative of the best cosine 
fit.
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In summary, both experimental jet lag schedules, CCW and CW rotation affected 
the classical circadian markers, indicating CRD. Minor differences in classical 
circadian markers were found between the two schedules directly after a shift. 
However, for both schedules the effects were transient, largely recovering within 
14 days after the last shift.
Predictive set op hepatic transcriptome markers
Since liver is the target tissue of metabolic effects and can be used for future studies, 
we performed an around the clock analysis of the liver transcriptome at baseline 
and after 14 days recovery. To identify a predictive set of hepatic transcriptome 
markers for chronic CRD with time of day-independent expression levels, we 
applied a classification approach. Three different classification algorithms were 
used: RF, SVM and PAM-R (complete overview in Fig. 3a). Using a ‘leave-one-time 
point-out’ cross-validation approach, we identified one consensus set of genes per 
algorithm optimally classifying samples as CRD versus non-disrupted, after 14 days 
recovery independent of time of day. The SVM approach resulted in a consensus 
set of 226 probes, RF in 42 and PAM-R in 46. Only the 18 probes, corresponding 
to 15 individual genes, present in all three classifiers were considered potentially 
robust biomarkers to classify CRD versus non-disrupted (van der Veen et al., 2013, 
Vandebriel et al., 2010) (Table 1, S2 Figure). Based on this consensus gene set 
prediction accuracy was achieved ranging from 90 % to 98% (S1 Table) showing 
that the set of 15 genes could distinguish CRD-exposed animals from non-
disrupted controls with high accuracy independent of sampling time. 
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Figure 3. Schematic overview of the microarray analyses. A. Overview of the classification approach, 
resulting in a set of transcriptomics biomarkers including 15 individual genes. B. Outline of the sequential 
approach of the data-analyses from hepatic gene expression profiles to 9 potential blood-detectable protein 
biomarkers. 
Subsequently, the ability of the consensus gene set to detect CRD after one shift, 
6 shifts and 5 days recovery was determined. Detection of acute CRD was limited, 
as after the first shift only 29% to 33% of the samples of phase shifted animals 
were correctly classified as CRD samples, depending on classification method. 
Accumulation of CRD was detected in the samples taken after six shifts, here, 92% 
to 88% of the samples were correctly classified as CRD exposed. Samples taken 
five days after the last shift were also well classified by the gene set, 75% to 88% 
depending on the algorithm (S2 Table). Overall, this hepatic transcriptome marker 
set is well able to detect chronic CRD independent of the time point the sample is 
collected within 14 days recovery.
40036 Dycke, Kirsten.indd   70 11-04-16   11:02
Biomarkers for CRD
71
4
Table 1. Potential biomarkers for CRD as identified by classification and sequential approach
Gene symbol Function Consensus gene 
set (classification 
approach)
Non-invasive 
blood detectable 
marker (sequential 
approach)
Cyp2c29 Cytochrome P450 epoxygenase x x
Cyp2b10 Cytochrome P450 x
Rbp1 Vitamin A transport x x
Sult2a1 Sulfotransferase x
Cd36 Scavenger receptor x x
Ntrk2 Kinase signaling x x
Tusc3 Tumor suppression x
Armcx3 Tumor suppression x
Gspt2 Cell cycle progression x
Snrpn Transcription x x
Tceal8 Transcription x
Fkbp11 Protein folding x
Orm2 Acute phase plasma protein x
Gm3787 Unknown x
Gm9299 Unknown x
D630033O11Rik Unknown x
Igh-VJ558 Immune x
Srgap3 GTPase activity x
Tram1 Translocation proteins x
Non-invasive biomarkers for CRD
Although predictive of CRD, use of hepatic gene expression markers is still invasive, 
where non-invasive methods are preferable. However, direct biomarker discovery 
in blood is technically challenging. To find non-invasive biomarkers eligible to 
monitor CRD, we aimed to identify potential blood markers for CRD from the gene 
expression dataset. Therefore, we selected genes of which expression (i) increased 
or decreased with accumulating CRD exposure and (ii) remained deregulated after 
14 days recovery. Furthermore, we excluded genes with circadian expression levels 
as these have drawbacks earlier described. Compared to control animals, 339 genes 
were differentially expressed in mice exposed to the CCW schedule. For mice in 
the CW rotation schedule (p <0.001) 129 were differentially expressed, of which 42 
genes were significantly expressed in both groups. Of these 42 genes, only genes 
with a fold change (FC) larger than 1.2 or smaller than 0.8 were considered relevant 
to increase the probability of detectable differences in blood protein levels. This 
resulted in 17 genes all showing an approximate pattern of up or down regulation 
with accumulating shifts and remaining differentially expressed after 14 days 
recovery compared to baseline.
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Of these 17 genes, 9 genes were found to encode potentially blood-detectable 
biomarkers according to (i) annotation as “secreted” or “extracellular”, and/or (ii) 
previous proteome-based experimental detection in human plasma or serum: 
Cd36, Ntrk2, Igh-VJ558, Srgap3, Tram1, Snrpn, Rbp1, Cyp2b10 and Cyp2c29 (see Fig. 3b 
and S3 Table for the sequential flow of gene selection). A substantial overlap with 
the classification consensus gene set was found, 5 genes were identified by both 
approaches (Table 1). Four out of the 9 genes showed increasing up regulation 
with number of shifts and remained up-regulated during recovery and five genes 
showed a similar pattern in the opposite direction (Fig. 4). 
Figure 4. Potentially blood-detectable marker for CRD. Fold ratio of selected differentially expressed genes 
encoding potentially blood-detectable protein biomarkers for CRD. Expression of these genes is up-
regulated or down-regulated by both the CCW and the CW schedule and remains up or down regulated 
during recovery. 
Based on expression patterns and the availability of a serum ELISA assay, CD36 
was selected for validation in blood. At 14 days after the last shift, CD36 serum 
levels showed a significant increase of 18% in animals exposed to CCW shifted 
light schedules independent of time of day, compared to animals at baseline (Fig. 
5). For the animals exposed to the CW light schedule, an 11% increase was found. 
For both shifting schedules, the increase in blood levels was less pronounced than 
the increase observed in the gene expression data.
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Figure 5. Serum levels of the CD36 protein. Serum levels were determined at baseline and 14 days after the 
last shift for animals subjected to CCW and CW shifted light schedules. Error bars indicate mean ± sd.
Discussion
Frequent shift work results in a disturbance of the circadian rhythm (CRD) and might 
on the long-term result in increased health risk. Epidemiologic studies among shift 
workers and flight personnel have shown increased risk of breast cancer, obesity 
and metabolic syndrome (Kubo et al., 2011, Reynolds et al., 2002, Schernhammer 
et al., 2006). The growing 24/7 economy will only lead to increase in shift work and 
consequently will adversely affect health. Ideally, the level of chronic CRD should 
be detected before the negative health effects occur. To limit potential health 
effects, preventive measures to minimize CRD are an attractive option. For these 
purposes, measuring the presence of chronic CRD is of importance, however, tools 
to measure chronic CRD are currently lacking. The present study aimed to identify 
universal biomarkers for chronic CRD using a transcriptomics approach.
To date, CRD and the beneficial effects of preventive measures on CRD are mainly 
determined using classical circadian markers such as melatonin, cortisol or body 
temperature (Neil et al., 2014). There is a need of markers that show the cumulative 
effects of CRD, since the effects on available markers are transient showing only 
acute effects of CRD. Corticosterone rhythms were heavily disturbed after six 
subsequent shifts of the light dark schedule and reappear after 5 days recovery, 
whereas body temperature remains rhythmic and was found to re-entrain to the 
new light dark schedule within 4-5 days, even after multiple shifts. The present 
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study identified chronic, non-transient biomarkers for chronic CRD 14 days after 
the last shift, based on hepatic gene expression. The potentially blood detectable 
biomarkers report on the presence of chronic CRD, showing an increase or 
decrease after multiple shifts and non-reversible deregulation upon recovery. The 
classification markers (consensus gene set) could be used directly after multiple 
shifts and 5 or 14 days after the last shift, which makes good candidates to 
determine acute shift work related CRD.
Ideally, for large-scale molecular epidemiology and experimental studies 
biomarkers of CRD are time-independent. The current available circadian markers 
require 24-hr measurements, which is challenging in both experimental and 
field studies. Recent attempts have been made to identify transcriptomics- and 
metabolomics-based time of day independent biomarkers. In these studies, jet 
lag and clock mutant mice were used (Minami et al., 2009, Ueda et al., 2004), 
allowing detection of acute and transient effects of jet lag but not chronic 
effects. It is challenging to model human shift work since it involves a multitude 
of aspects, including phase desynchronization, changed social patterns, activity, 
sleep, nutrition light exposure and sun exposure. Using a chronic jet lag model in 
mice, and as such mainly mimicking phase desynchronization, we were able to 
identify biomarkers detecting chronic CRD that can be studied in a single sample, 
collection of which is independent of time of day. Further studies should point out 
whether other aspects of shift work (e.g. changes in activity, light-at-night, altered 
nutritional timing) will affect the same genes.
The set of liver-transcriptome based biomarkers includes genes with a variety of 
functions. The current study suggests that CD36 could potentially be a blood-
detectable biomarker for CRD. CD36 is a scavenger receptor present on many 
mammalian cell types with a broad range of cellular functions (Febbraio et al., 
2001). It has been suggested that CD36 in plasma might represent a marker of the 
metabolic syndrome (Handberg et al., 2006), a condition that was found associated 
with frequent shift work (Wang et al., 2014). Furthermore, CD36 was shown to play 
an important role in breast tumorigenesis (DeFilippis et al., 2012, Uray et al., 2004) 
potentially associated with the observed increase in breast cancer risk found in 
shift workers (Wang et al., 2013). Although CD36 is interesting as CRD biomarker, 
other potentially blood-detectable biomarkers should not be neglected. 
Especially, the genes that were found upregulated upon CRD are of interest for 
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further investigation. For example, Ntrk2 shows a similar induction pattern as CD36 
and has also been shown to play a role in breast cancer cell survival and obesity 
(Xu et al., 2003, Vanhecke et al., 2011). In depth analysis of biological relevant data 
in this study is limited due to our aim to select non-circadian biomarkers, for which 
circadian genes were excluded. Full analysis of biological processes affected by 
CRD requires inclusion of these circadian genes and is subject for further studies. 
Our study represents two approaches to identify the most valuable CRD markers 
based on hepatic gene expression; firstly, an optimal CRD classification set and 
secondly, a selection of potentially blood detectable biomarkers. An important 
step that needs to be taken before the identified biomarkers can be applied in 
experimental and large-scale cohort studies is validation for CRD in humans. For 
blood-detectable markers, the challenge of the transcriptomics approach is the 
translation of hepatic gene expression to protein levels in blood. We found that in 
our homogenous mouse model, CD36 serum levels were also increased in animals 
exposed to CCW and CW shifted light schedules; however, the increase was 
smaller compared to gene expression. Potentially, serum CD36 originates from 
other sources than liver alone, since CD36 is present in many mammalian cell types 
(Febbraio et al., 2001). Another part of the validation process is the exclusion of post-
translational rhythmicity, which is not precluded by the lack of a transcriptional 
rhythm. In human samples, heterogeneity and variation between samples is much 
larger and small increases in biomarker blood levels may remain undetected in 
cross-sectional studies. Preferably, to obtain less inter-individual variation one 
would opt for longitudinal measurements including baseline measurements per 
individual before commencing shift work rotations. Furthermore, anchoring with 
phenotypic endpoint is required to use the selected biomarkers for intervention 
studies without the need for long-term end-point studies. For this, it should be 
noted that previous studies have shown that comparable chronic CRD protocols 
increased negative health effects in mice (Davidson et al., 2006, Filipski et al., 2004). 
In conclusion, our study identified a chronic CRD gene-set, comprising 15 genes, 
potentially useful to study CRD induction by different aspects of shift work and 
reduction by interventions. Furthermore, we identified 9 candidate genes for 
blood-detectable biomarkers of CRD, including CD36. Upon validation, these 
biomarkers provide valuable tools for evaluating CRD in both experimental animal 
and human studies set up to identify preventive measures for adverse health 
effects.
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Abstract
Introduction
Many molecular epidemiology studies focusing on high prevalent diseases, such 
as metabolic disorders and cancer, investigate metabolic and hormonal markers. 
In general, sampling for these markers can occur at any time-point during the day 
or after an overnight fast. However, environmental factors, such as light exposure 
and food intake might affect the levels of these markers, since they provide input 
for the internal time-keeping system. When diurnal variation is larger than the 
inter-individual variation, time of day should be taken into account. Importantly, 
heterogeneity in diurnal variation and disturbance of circadian rhythms among 
a study population might increasingly occur as a result of our increasing 24/7 
economy and related variation in exposure to environmental factors (such as light 
and food). 
Aim
The aim of the present study was to determine whether a set of often used 
biomarkers shows diurnal variation in a setting resembling large molecular 
epidemiology studies, i.e. non-fasted and limited control possibilities for other 
environmental influences. 
Results
We show that markers for which diurnal variation is not an issue are 
adrenocorticotropic hormone, follicle stimulating hormone, estradiol and high-
density lipoprotein. For all other tested markers diurnal variation was observed 
in at least one gender (cholesterol, cortisol, dehydroepiandrosterone sulfate, free 
fatty acids, low-density lipoprotein, luteinizing hormone, prolactin, progesterone, 
testosterone, triglycerides, total triiodothyronine and thyroid-stimulating 
hormone) or could not reliably be detected (human growth hormone). 
Discussion: Thus, studies investigating these markers should take diurnal variation 
into account, for which we provide some options. Furthermore, our study indicates 
the need for investigating diurnal variation (in literature or experimentally) 
before setting up studies measuring markers in routine and controlled settings, 
especially since time – of- day likely matters for many more markers than the ones 
investigated in the present study.
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Introduction
Many molecular epidemiology studies focusing on high prevalent diseases, such 
as metabolic disorders and cancer (Danaei et al., 2011, WHO, 2013), make use of 
metabolic and hormonal markers (for examples see references (Hadji et al., 2014, 
Jiang et al., 2014). Metabolic markers might serve as important (early) indicators 
for metabolic disorders, including cardiovascular diseases and type 2 diabetes, and 
hormonal disbalance is often studied in large epidemiological settings since these 
are associated with high incidence cancers, such as breast cancer (Mester et al., 2010, 
Stevens, 2005, Ferlay et al., 2015). In general, for these markers sampling can occur 
at any time-point during the day or after an overnight fast. However, environmental 
factors, such as light exposure and food intake might affect the levels of these 
markers, since they provide input for the internal time-keeping system (Carneiro 
and Araujo, 2012, Dibner et al., 2010, Hastings et al., 1998, Mohawk et al., 2012). 
Several markers are well known for their diurnal variation, for example cortisol and 
melatonin (Gamble et al., 2014). Importantly, heterogeneity in diurnal variation and 
disturbance of circadian rhythms among a study population might increasingly 
occur as a result of our increasing 24/7 economy and related variation in exposure 
to environmental factors (such as light and food). For example, previous studies 
have indicated that there are substantial changes in the blood transcriptome after 
experiencing insufficient or mistimed sleep (Archer et al., 2014b, Moller-Levet 
et al., 2013). This might render accurate determination of markers in molecular 
epidemiology studies challenging. When the diurnal variation is larger than the 
inter-individual variation, time of day should be taken into account in molecular 
epidemiology studies. In this study, we determine whether a set of biomarkers 
relevant for metabolic disorders and hormone-associated cancers, consisting of 
endocrine and sex hormones and lipids, shows diurnal variation.
The diurnal variation of various blood markers has previously been studied in 
different settings, ranging from a relatively uncontrolled routine setting to very 
tightly controlled laboratory settings. Most information on diurnal variation is 
derived from these controlled laboratory studies in which factors influencing 
diurnal variation (such as food intake and/or sleep/wake cycle) are controlled 
(for example see references (Klingman et al., 2011, Li et al., 2013, Jung et al., 2010, 
James et al., 2007, Davies et al., 2014, Ang et al., 2012, Dallmann et al., 2012)). Due 
to the large-scale set up of some molecular epidemiology studies, the possibility 
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for standardization of sample collection to time of day and food consumption is 
limited. Therefore, most molecular epidemiology studies collect blood samples to 
study biomarkers for adverse health outcomes without standardization for time-
point, food intake or sleep.
The aim of the present study was to investigate diurnal variation of a set of 
markers (relevant for metabolic disorders and hormone-associated cancers) in a 
routine setting in males and females, resembling molecular epidemiology studies: 
namely, non-fasted and limited control for other environmental influences. In 
addition, classical markers to study circadian rhythms in chronobiology research 
are measured: cortisol and components of the molecular biological clock i.e. ‘clock 
genes’. We determined cortisol levels and clock gene expression levels in blood 
throughout the day to study diurnal variation of these classical markers in a routine 
setting. 
Methods
Study design and ethics statement
Approval for all procedures was obtained from the ethical committee of the Goce 
Delchev University in Stip, Republic of Macedonia. All participants signed an 
informed written consent. This was provided in Macedonian and the translation 
would be as follows: “I confirm that I am informed about the goals of the Circadian 
study and voluntary participate in it. I also confirm that all information that I provided 
with regards to my general health condition and lifestyle is correct”. Samples of 17 
healthy volunteers, 10 women and 7 men were analyzed in this study. Inclusion 
criteria were: -age over 21 years old, - apparently healthy without any acute or 
chronic disease (general medical examination without laboratory analyses), - not 
taking any drugs, multivitamins and/or supplements, -non-smoking, - not more 
than 1 (for women) or 2 (for men) alcoholic beverages per day, - no shiftwork and 
have a normal circadian rhythm (sleeping at nighttime). 
The mean age of the males was 24.9 ± 7.2 years and 21.7 ± 0.5 years for the female 
volunteers. The mean weight was 84.1 ±13.9 kg for the males and 58.5 ±13.6 kg 
for the females. For more participants characteristics and individual data, see S1 
Table. The samples were collected around the clock at four-hour intervals. The first 
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sample was collected at 08:00 AM after overnight fasting. Participants were asked 
when they slept between the first and last sampling times (8:00 - 4:00 AM). Total 
sleep duration between these time-points was 3.4 ± 0.9 hr for males and 3.2 ±1.9 
for females. For individual sleeping duration and timing of sleep episodes, see 
S1 Table. Volunteers were asked to consume their meals one hour after sample 
collection and otherwise continue their normal daily routines. Meal timing and 
composition was not further restricted or standardized and meals were consumed 
at home. EDTA plasma and buffy coat samples (2.7 mL) and serum samples (7.5 
mL) were collected in a routine clinical chemistry laboratory by venipuncture 
of the antecubital vein, using the commercial blood sampling method Sarstedt 
(Sarstedt AG & Co., Nümbrecht, Germany). Individuals were allowed to leave the 
laboratory after sample collection and thus were required to wake up and come 
to the laboratory for sample collection at night. 
Plasma and serum analyses
Two methods were used to determine hormonal and lipid biomarkers, an 
overview can be found in S2 Table. Free fatty acids (FFA), high-density lipoprotein 
(HDL), low-density lipoprotein (LDL), triglycerides (TG) and cholesterol (CHOL) 
were determined with an auto-analyzer (Unicel DxC 800, Beckman-Coulter, 
Woerden, the Netherlands), using kits from Beckman-Coulter. Cortisol (CORT), 
dehydroepiandrosterone sulfate (DHEAS), estradiol (E2), human growth 
hormone (hGH), prolactin (PRL), progesterone (PRG), testosterone (TEST), total 
triiodothyronine (TotT3), thyroid-stimulating hormone (TSH) were determined 
with an immune-analyzer (Access-2, Beckman-Coulter) using dedicated kits 
from Beckman-Coulter. Levels of adrenocorticotropic hormone (ACTH), follicle 
stimulating hormone (FSH), and luteinizing hormone (LH) were determined using 
commercially available Milliplex Kits (Millipore Corporation, Billerica, MA, USA). All 
measurements were performed on the same day. The intra-assay variation was 
determined with three quality control samples (8 tests) for markers measured 
on the auto-analyzer and with two quality control samples (5 tests) for markers 
measured on the immune-analyzer. The CVs of markers measured with the 
Luminex technique were obtained from the manufacturer. See S2 Table for all CVs.
Blood RNA analysis
Expression levels of clock genes BMAL1 and PER1 were determined in buffy coats 
of a subset of volunteers (n=6, female), using quantitative reverse transcription 
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polymerase chain reaction (RT-PCR). All oligonucleotide primers were obtained 
from Life Technologies (Bleiswijk, The Netherlands). Total RNA was extracted from 
buffy coats stabilized with Qiazol, using the miRNeasy Mini Kit (both Qiagen 
Benelux, Venlo, The Netherlands). cDNA was made using the high capacity cDNA 
reverse transcription kit (Applied Biosystems by Life Technologies, Bleiswijk, 
The Netherlands). qPCR was performed on the 7500 Fast Real-Time PCR System 
(Applied Biosystems by Life Technologies, Bleiswijk, The Netherlands) using 
Taqman Fast Universal PCR Master Mix and Taqman Gene Expression assays for 
BMAL1 (Hs00154147_m1) and PER1 (Hs01092603_m1) all according to protocol of 
manufacturer (Applied Biosystems by Life Technologies, Bleiswijk, The Netherlands). 
Statistics
To detect all types of diurnal variation, parameters were tested using two types 
of analyses: cosine fitting analysis and Repeated Measures ANOVA (RM-ANOVA). 
Depending on the shape of the day curves, these analyses can be overlapping 
and/or complementary. The RM-ANOVA detects effects of time, i.e. are the levels 
of the marker different among time-points. The cosine analysis enables detection 
of rhythms that follow a cosine curve, in manner that is occasionally more sensitive 
than the RM-ANOVA. For the cosine analysis, CircWave Batch v5.0 software (Roelof 
Hut, www.euclock.org) was used. A closer fit to cosine gives lower p-value, p < 
0.05 is assumed a significant cosine curve fit. . Repeated Measures ANOVA (RM-
ANOVA) was performed using GraphPad Prism software version 6.04 for Windows 
(GraphPad Software, San Diego California USA, www.graphpad.com). The 
Greenhouse-Geisser epsilon indicated that sphericity could not be assumed in 
most analyses, therefore, Greenhouse- Geisser correction was applied. For the RM-
ANOVA, p < 0.05 was considered statistically significant. If CircWave analysis, RM-
ANOVA, or both indicated that signification variation was present, we identified 
the markers as having diurnal variation in our experiment. Gene expression of PER1 
and BMAL1 was given as relative expression compared to the mean.
Considering the known difference in levels of several makers between genders, 
all statistical analyses were performed separately for males and females. The aim 
of this study was to identify markers with diurnal variation, therefore, differences 
between males and females were not statistically tested. For all raw data, see S1 
File. 
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Results
We investigated diurnal variation of a set of markers (relevant for metabolic 
disorders and hormonal cancers) in a routine setting in males and females. To 
determine the diurnal variation we performed two analyses: 1) Cosine fitting 
analysis: using CircWave software we determined whether the level of the marker 
follows a cosine rhythm; 2) RM-ANOVA analysis: determine effects of time of day 
on parameter levels. If analysis 1, analysis 2 or both indicated that significant 
variation was present we identified the markers as having diurnal variation in our 
experiment. 
Hormones
Cosine analysis showed that for two of the eleven investigated hormonal markers, 
a significant cosine curve fit was present in both genders: thyroid-stimulating 
hormone (TSH) and total triiodothyronine (totT3) (Fig.1). The levels of TSH are 
highest during the middle of the night, where in males (m) the peak is observed 
slightly earlier (Clock Time (CT) = 01:54, p = 0.001, amplitude as percentage of the 
median = 75.89%) compared to females (f ) (CT = 03:32, p = 0.006, amplitude = 
74.26%). Levels of totT3 are highest at the beginning of the day (m: CT = 06:18, p 
0.025, amplitude = 10.14%; f: CT = 07:04, p = 0.041, amplitude = 8.08%). Progesterone 
(PRG) had a significant cosine curve fit in males, but not in females (m: CT = 07:52, 
p = 0.003, amplitude = 117.78%; f: p = 0.870) (Fig. 1). For testosterone (TEST), a 
trend towards a cosine curve fit was present in males, but not females (m: CT = 
07:33, p = 0.055, amplitude = 38.38%; f: p = 0.282) (Fig. 1). For a complete overview 
of CircWave analyses for all 11 hormonal markers, see Fig 1-3 and S3 Table.
For the two markers with a significant cosine fit in both genders, TSH and TotT3, 
an effect of time was observed with RM-ANOVA as well (for statistics see S3 Table), 
although for TotT3 in females only a trend is observed (p = 0.078). In addition, for 
four markers where a cosine curve could not significantly be fitted, a significant 
effect of time was observed, for TEST, DHEAS, PRG and prolactin (PRL) (Fig. 1 + 2). 
RM-ANOVA shows that TEST and DHEAS are present at different levels during the 6 
time-points in both genders (TEST: m: p 0.021, f: p = 0.023; DHEAS: m: p = 0.045, f: p 
= 0.002). Furthermore, PRL and PRG are significantly different over the time-points 
in one gender: PRL (m: p = 0.014, f: p = 0.118) and PRG (m: p = 0.020, f: p = 0.272). 
For complete overview of the results of the RM-ANOVA on all time-points, see 
Fig 1-3 and S3 Table. 
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Figure 1. Levels of TSH, TotT3, PROG, and TEST during the day, measured at four-hour intervals for male (left 
panels) and female (right panels) volunteers. Time indicates clock time. Values at 8-hr were double plotted to 
help visualize daily patterns. Data represent mean ±sd.
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Figure 2. Levels of DHEAS, PRL, LH, and FSH during the day, measured at four-hour intervals for male (left 
panels) and female (right panels) volunteers. Time indicates clock time. Values at 8-hr were double plotted to 
help visualize daily patterns. Data represent mean ±sd.
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Figure 3. Levels of ACTH, hGH, and E2 during the day, measured at four-hour intervals for male (left panels) 
and female (right panels) volunteers. Time indicates clock time. Values at 8-hr were double plotted to help 
visualize daily patterns. Data represent mean ± sd.
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Figure 4. Levels of different lipids during the day, measured at four-hour intervals for male (left panels) and 
female (right panels) volunteers. Time indicates clock time. Values at 8-hr were double plotted to help 
visualize daily patterns. Data represent mean ±sd.
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Lipids
Five types of lipids were examined; free fatty acids (FFA), triglycerides (TG), total 
cholesterol (CHOL), low-density lipoprotein (LDL), and high-density lipoprotein 
(HDL) (Fig. 4). CircWave analysis indicated that FFA levels follow a cosine curve in 
males (p = 0.012, amplitude 74.91%), but not significantly in females (p = 0.359, 
amplitude = 80.70%). The levels of FFA were highest at the beginning of the active 
period in males (CT = 08:31). A trend towards a cosine curve fit was observed 
for TG in females (p = 0.050, amplitude = 50.33%), but not in males (p = 0.105, 
amplitude = 70.36%) (Fig. 4). Visual inspection of the levels of FFA and TG in Fig. 4 
implies that the differences between males and females for these markers is likely 
related to the variation observed within the groups, since the highest levels are 
observed at similar time-points for both genders. For complete overview of all 
markers, see Fig. 4 and S4 Table.
Despite the limited presence of significant cosine curve fits observed among the 
different lipid markers, for several markers RM-ANOVA shows significant effects of 
time: for CHOL and LDL in both genders (CHOL: m: p = 0.003, f: p = 0.003; LDL: m: 
p = 0.002, f: p = 0.006), for TG in males and a trend was present in females (m: p 
= 0.048, f: p = 0.063) (S4 Table). The levels of FFA show a trend towards an effect 
of time in males (m: p = 0.069, f: p = 0.221). For HDL, no significant effect was 
observed in any gender (m: p = 0.110, f: p = 0.213). The highest level of most lipids 
including FFA, LDL, and CHOL was observed at the beginning of the active phase, 
the highest level of TG in males was observed during the middle of the day (Fig. 4).
In summary, for all lipid markers, except HDL significant or trends towards diurnal 
variation are observed.
Classical circadian markers 
The levels of cortisol were investigated in all participants (n=17), clock genes 
PER1 and BMAL1 were investigated in a subset (n=6, females) to gain insight in 
classical circadian markers in uncontrolled conditions (Fig. 5). Cortisol levels show 
a significant cosine curve fit, are highest at the beginning of the day (m: CT = 
07:47; f: CT = 07:29), and the rhythm has a relative large amplitude (m: p < 0.0005, 
amplitude = 129.11%; f: p < 0.0005, amplitude = 161.63%) (Fig. 5, upper panels). 
The levels of PER1 and BMAL1 mRNA show a significant cosine curve fit as well 
(PER1 p = 0.002, amplitude = 80.15%; BMAL1 p = 0.035, amplitude = 35.55%). Levels 
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of PER1 were highest during the morning (CT = 8:07), while levels of BMAL1 were 
highest during the afternoon (CT = 14:12). For complete overview of statistics see 
S5 Table. 
Figure 5. Around the clock levels for classical circadian markers cortisol, PER1 and BMAL1. Upper panels 
show cortisol levels in male (left panels) and female (right panels) volunteers, determined in serum. mRNA 
expression of BMAL1 and PER1 in buffy coats are depicted in the lower panels (females subset n=6). All were 
measured at 4 hour intervals, where time indicates clock time. Values at 8-hr were double plotted to help 
visualize daily patterns. Data represent mean ±sd. 
Discussion
The aim of the present study was to investigate diurnal variation in a set of 
hormones, metabolic markers, and classical circadian markers in serum, plasma 
and peripheral blood mononuclear cells (PBMCs), in a routine non-fasted molecular 
epidemiology-like setting, with no restrictions on sleep or diet. 
Hormones
Markers without diurnal variation
For markers without diurnal variation, taking the time-point of sampling into 
account is not required. This study observed no diurnal variation or trends towards 
40036 Dycke, Kirsten.indd   89 11-04-16   11:02
Chapter 5
90
5
diurnal variation in any gender in four of the eleven hormonal markers investigated, 
ACTH, hGH, E2, and FSH. Previous published studies performed in a different type 
of setting than the present study, namely a controlled (laboratory) settings do show 
diurnal variation in ACTH levels in males , with the highest level being observed at 
CT 4.00 h (Li et al., 2013) or CT 7.00 h (Nicolau and Haus, 1989), whereas no diurnal 
was observed in females (Nicolau and Haus, 1989). Interestingly, in the present 
study, levels were also highest at CT 4.00, indicating similar patterns. However, 
in our study larger amount of variation is expected than a controlled laboratory 
setting potentially causing the diurnal variation of ACTH undetectable within the 
inter-individual variations. Since during day time-points, when sampling is usually 
performed in a cohort study, variation in ACTH levels is minimal. Thus, diurnal 
variation seems not to be a major issue for ACTH in a molecular epidemiology 
setting. However, considering the previous studies on ACTH and that in a large 
cohort setting power will be increased, diurnal variation might become larger than 
the inter-individual variation and caution is required. In addition, if subjects are 
investigated which possibly have a circadian disturbance (e.g. night shift workers), 
variation in levels of the markers during night time-points should be taken into 
account as well (see recommendations section for suggestions). 
For hGH, former reports in controlled settings have shown diurnal variation in 
males (Mazzoccoli et al., 2011, Nicolau and Haus, 1989). However, it is important 
to note that it is known that hGH is released in pulses with levels varying up to 4 
times (Riedel et al., 1995). Hence, in the present study with sampling intervals of 4 
hours these pulse releases might interfere with the detection of diurnal variation. 
Indeed, in the present study at several time-points large variations in the levels of 
hGH are observed, particularly in males. This indicates that hGH is a difficult marker 
to measure in a non-time-controlled cohort setting, since possible differences are 
easily masked by the large amount of variation present for this marker.
For estradiol, the absence of diurnal variation in the present study is in line 
with previous studies that reported the absence of diurnal variation in females 
(Brambilla et al., 2009, Mortola et al., 1992), although diurnal variation is observed 
in estradiol levels in elderly females (mean age 77 years) (Nicolau and Haus, 1989). 
Together, these data indicate that in a cohort study with non-elderly adults, diurnal 
variation of estradiol is not an issue. 
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For FSH, conflicting data have been published previously. In females, the absence 
of a diurnal variation was reported in studies using (mildly) controlled settings 
(Klingman et al., 2011, Nicolau and Haus, 1989), while a third study reported 
diurnal variation in females during different phases of the menstrual cycle, with 
the highest levels of FSH being observed during the afternoon (Mortola et al., 
1992). For males, conflicting results have been reported as well: a study by Spratt 
et al. showing the absence of diurnal variation in males (Spratt et al., 1988), while 
Nicolau et al., reported the presence of a diurnal variation in elderly males (Nicolau 
and Haus, 1989). Possibly, age has a role in the diurnal variation of FSH. However, 
the present study indicates that in a routine setting, time of day is not a major 
source of variation for FSH levels. 
Markers with diurnal variation
For eight of the twelve investigated hormonal markers, diurnal variation was 
observed in at least one gender. Markers with the most robust diurnal variation in 
both genders were TSH and T3. This is in line with previous findings for these markers 
(Hirschfeld et al., 1996, Klingman et al., 2011, Mazzoccoli et al., 2011, Nicolau and 
Haus, 1989). For DHEAS, a previous study reported circadian rhythmicity in males 
and females (Nicolau and Haus, 1989), however, in the present study the rhythm of 
DHEAS could not be fitted to a cosine curve. The levels of DHEAS differed among 
the time-points and the pattern of expression (e.g. highest levels in the afternoon) 
is comparable to the previously published results, confirming diurnal variation of 
DHEAS. 
For testosterone, diurnal variation was not robust, but significant changes were 
observed when the time-points were compared in both genders. Diurnal variation 
in testosterone is in line with previous findings (Diver et al., 2003, Nicolau and Haus, 
1989, Ostrowska et al., 1998, Plymate et al., 1989, Spratt et al., 1988, Brambilla et al., 
2009). The study by Spratt et al. showed that the robustness of the diurnal variation 
of testosterone was largely dependent on the frequency of sampling. 
For several of the other markers, the robustness of diurnal variation varied among 
genders. Diurnal variation was often more pronounced in males. Since in the 
present study menstrual period was not assessed, nor was the use of contraceptives, 
this might explain the less robust results in females. For example, progesterone 
showed diurnal variation in males, but not females. For females, it has been shown 
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that the rhythmicity of progesterone varies with the menstrual period, including 
the timing of the highest levels (Fujimoto et al., 1990, Nicolau and Haus, 1989, 
Veldhuis et al., 1988). Interestingly, 5 females show high progesterone levels, 
which are indicative of the luteal phase. Of these females, two show a significant 
or trend (p-value between 0.05 and 0.1) towards an individual cosine curve fit 
(#6: p=0.0059 and #7: p=0.05222). These results suggest that indeed variation in 
menstrual period, and possibly contraceptives use, interfere with measurements 
of progesterone in a cohort setting. 
For the final two markers, LH and PRL, only mild amounts of diurnal variation 
were observed. For LH previous studies in females have shown that rhythmicity 
is dependent on the menstrual cycle and that peak timing differs among women 
(Klingman et al., 2011, Mortola et al., 1992, Veldhuis et al., 1988), which likely 
explains the results of the present study. For prolactin, in the present study only 
a trend towards a cosine curve fit was observed in females and effects of time 
(by RM-ANOVA) in males. This is in line with previous studies that have shown 
diurnal variation of prolactin in females in controlled settings (Birketvedt et al., 
2012, Fujimoto et al., 1990), and higher levels of prolactin during the night in males 
(Miyatake et al., 1980). Together, these results indicate that for prolactin time of 
day should be taken into account (see recommendations section for suggestions). 
Lipids
Of the 5 lipid markers, only HDL showed no diurnal variation (no cosine curve fit 
and no effect of time by RM-ANOVA). Previously, it has been shown that a large 
subset of lipids shows diurnal variation (for examples see references: Miida et al., 
2002, Chua et al., 2013, for review see reference: Gooley and Chua, 2014), however, 
the rhythmicity of these markers is highly variable among individuals (Chua et 
al., 2013). Furthermore, it is known that many lipids are directly regulated by the 
endogenous circadian clock (Dallmann et al., 2012, Ang et al., 2012, Gooley and 
Chua, 2014), lipid metabolism is related to sleep (Davies et al., 2014, Ollila et al., 
2012), and that levels of FFA, TG and LDL are dependent on meal-timing (Yoshino 
et al., 2014, Niklowitz et al., 2006) The results of the present study, diurnal variation 
in LDL, TG, FFA and total cholesterol are thus in line with previous findings. These 
results show that for these markers time of day needs to be taken into account (see 
recommendations section below for suggestions). Previously, diurnal variation has 
been observed for HDL in a controlled setting (Miida et al., 2002), however, our 
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study indicates that this variation does not exceed the inter-individual variation in 
a routine setting. 
Classical circadian markers
In chronobiology research, several markers are often used to study circadian 
rhythm. Hence, these can be named as ‘classical circadian markers’. One of these 
markers is cortisol, which is often used to study circadian rhythm in humans. In 
addition, components of the molecular biological clock can be used to study 
circadian rhythm, i.e. ‘clock genes’. Since these genes are part of the core clock 
mechanism in cells, their rhythm reflects the circadian rhythm in these cells. We 
show that the ‘classical circadian markers’ investigated in this study (cortisol and 
the clock genes PER1 and BMAL1) have a robust cosine curve fit in our study 
population, which resembles a routine non-fasted molecular epidemiology 
setting. Our findings for cortisol (rhythmic expression with high levels during the 
early morning), are in line with previous literature. Multiple studies, in a range of 
different settings, have reported similar findings (for review see reference (Gamble 
et al., 2014), for examples see references (Kusanagi et al., 2008, Takimoto et al., 2005, 
Teboul et al., 2005)). 
In our study PER1 expression fits to a cosine curve with the highest levels in the 
morning, which is also consistent with previous studies. For example, James et 
al. observed rhythmic PER1 expression with peak levels on average 2:36 h after 
waking (±1:47 h) in PBMCs (James et al., 2007), Kusanagi et al. observed rhythmic 
PER1expression with peak expression on average at 7:42 h in PMBCs (Kusanagi et 
al., 2008), and Takimoto et al. reported peak levels at 06:00 h in whole blood cells 
(Takimoto et al., 2005). For BMAL1, previous studies have indicated that rhythmicity 
of BMAL1 gene expression in PBMCs is highly variable amongst individuals (Teboul 
et al., 2005, James et al., 2007). For example, BMAL1 expression has been reported 
to be high during the middle of the day (comparable to our study) (James et 
al., 2007, Teboul et al., 2005), during the night (Takimoto et al., 2005), during the 
evening (Teboul et al., 2005), or not being rhythmic (Kusanagi et al., 2008). Teboul 
et al. suggested that this variation might be related to chronotype, since in their 
study two groups of individuals could be distinguished: peak expression of BMAL1 
during the middle of the day (12:30 hr) or during the evening (21:45 hr). 
Together, our results shows that thediurnal variation, including the acrophase of 
the fitted cosine curves, of several classical markers in our study is comparable to 
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previous studies using (mildly) controlled settings (James et al., 2007, Kusanagi et 
al., 2008, Takimoto et al., 2005, Teboul et al., 2005). 
Concluding remarks and reccomendations
The present study showed that markers for which diurnal variation (circadian 
rhythms and/or time-of-day-effects) is not an issue in a routine setting are ACTH, 
FSH, E2 and HDL. For all other tested markers diurnal variation was observed, which 
exceeded the inter-individual variation in a routine setting. It is important to note 
that we tested this in a small test group (n=17). In a large cohort with numerous 
subjects, levels of inter-individual variation might decrease due to larger sample 
sizes, making the contribution of diurnal variation relatively larger. Hence, for some 
of the markers without detectable diurnal variation in the present study, diurnal 
variation might play a role in larger studies. Nevertheless, our study provides an 
indication for which markers diurnal variation needs to be taken into account in a 
routine setting.
Taking diurnal variation into account can be done in several ways depending on 
the study design and marker characteristics (such as dependent on food intake, 
sleep/wake cycle etc.). For example, measurements can be taken at a single time-
point or if sampling at a single time-points is not possible, registration of sampling 
time and their relevant time-points (e.g. timing of food intake) is an alternative 
method to take into account diurnal variation. Apart from a research setting, 
several of the markers in our study are measured in a clinical setting as well. In 
general, a substantial amount of variance is incorporated in reference levels for 
diagnostic purposes. However, for biomarkers with large diurnal variation it might 
be beneficial to take multiple samples during the day or define reference levels 
that take into account time-of-day. 
Our finding that most markers tested show diurnal variation is in line with recent 
studies showing that many genes are regulated by the circadian clock. For example, 
a recent study has shown that 43% of the protein coding genes shows diurnal 
variation in at least one organ in mice (Zhang et al., 2014a), as a consequence 
one could expect diurnal variation in many serum or plasma protein levels as well. 
This large set of markers with diurnal variation indicates the need for investigating 
diurnal variation before setting up studies measuring markers in routine and 
controlled settings, since time- of- day likely matters for many more markers than 
the ones investigated in the present study.
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Abstract
Disturbance of circadian rhythms in shift workers results in increased health 
risks, including obesity and cancer. Previously, we have shown that mice gain 
more weight when chronically exposed to conditions that cause circadian 
rhythm disturbance (CRD). The aim of the present study was to understand the 
mechanism(s) underlying the observed overweight phenotype in mice. As the liver 
is a key metabolic organ and regulator of energy metabolism, liver transcriptome 
analysis enables the identification of disturbed processes involved in the obese 
phenotype. Mice were exposed to a weekly alternating light-dark schedule for 
18 weeks and 7 days after the last shift gene expression was analyzed over a 24-
hour period to allow identification of more permanent affected processes upon 
long-term CRD. Overall, the effects on gene expression were minor compared to 
previous studies where the transcriptome was studied directly after impingement 
on the circadian system. However, an overall attenuation of circadian rhythmicity 
was found in hepatic gene expression, associated with a wide variety of processes, 
including cell cycle control and DNA damage processes. The largest decrease in 
amplitude was found in genes involved in the balance between lipid and glucose 
metabolism: Ppard, Pdk4, Slc16a5 and Igfbp-1. In conclusion, metabolic flexibility 
might be compromised by long-term exposure to CRD, resulting in increased 
weight gain in mice. Further research should elucidate the relevance of acute 
versus more permanent disturbed processes for adverse health outcomes to 
develop evidence based preventive measures. 
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Introduction
The circadian system imposes 24 hour rhythmicity on behavior, physiology and 
metabolism and allows us to anticipate daily recurring changes in our environment. 
This internal timekeeping system is composed of a light-entrainable central clock 
in the suprachiasmatic nucleus (SCN) located in the brain, and peripheral clocks in 
all other tissues in the body. On a molecular level, circadian rhythms are generated 
by a set of clock genes that act in an auto-regulatory transcriptional-translation 
feedback loop (TTFL) and confer rhythmicity to biological output processes via 
clock-controlled genes (Lee et al., 2001). Various expression profiling studies have 
shown that, depending on the tissue, up to 10% of the transcriptome is under 
circadian control (Akhtar et al., 2002, Bozek et al., 2009, Panda et al., 2002, Storch 
et al., 2002). Accordingly, it is not surprising that long lasting circadian rhythm 
disturbance (CRD), e.g. by chronically alternating light cycles, result in a loss of 
homeostasis in addition to the acute disturbances as shown in several studies 
(Archer et al., 2014a, Barclay et al., 2012, Moller-Levet et al., 2013).
As a consequence of chronic circadian rhythm disturbance (CRD), long-term shift 
workers are at risk for various adverse health effects. Various studies indicated an 
association between social jet-lag, shift work and increased body weight, although 
conflicting data exist (Kubo et al., 2011, Nabe-Nielsen et al., 2011, Roenneberg et 
al., 2012, Parsons et al., 2014). These human studies, however, are hampered by 
difficulties with exposure assessment and confounding factors, such as unhealthy 
food intake. Animal studies can limit the influence of these factors, as specifically 
designed CRD exposure protocols allow exclusion of or strict control over 
confounding factors. Previously, we have shown that chronically alternating light 
cycles cause an increased breast cancer risk and body weight gain in breast cancer 
predisposed mice (Van Dycke et al., 2015). This model provides a unique tool to 
further analyze mechanisms that underlie the relationship between shift work and 
cancer and increased body weight. 
Shift work involves a multitude of aspects, including internal desynchronization, 
melatonin suppression, sleep disruption, lifestyle disturbance and decreased 
vitamin D levels (Fritschi et al., 2011). A number of these aspects, including circadian 
desynchrony, lifestyle disturbance and timing of food intake, have been proposed 
to underlie the relationship between shift work and increased body weight (Fonken 
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et al., 2010, Salgado-Delgado et al., 2010). Unravelling the mechanisms that link 
shift work with adverse health effects is a requisite for developing evidence-based 
interventions that minimize health risks. Especially, understanding the underlying 
metabolic changes could provide targets for preventive measures, since food 
intake can be adjusted. 
Transcriptomics studies provide a useful tool to investigate a wide variety of 
processes and several studies show that CRD affects animal and human gene 
expression profiles (Archer et al., 2014a, Barclay et al., 2012, Moller-Levet et al., 
2013). In human laboratory studies, mistimed sleep and insufficient sleep cause 
the majority of the rhythmically expressed mRNAs in the blood transcriptome to 
become arrhythmic (Archer et al., 2014a, Moller-Levet et al., 2013). Timed sleep 
restriction in mice was shown to disrupt global liver gene expression, with many 
genes associated with lipid and glucose metabolism processes (Barclay et al., 2012). 
Furthermore, in these studies the exposure period was limited to weeks, whereas 
shift workers are involved in irregular working hours for many years. Although 
these human and animal studies show (semi)acute effects on both circadian and 
non-circadian biological processes, directly or shortly after impingement on the 
circadian system, they fail to provide insight into the constitutively disturbed 
processes underlying long-term health effects such as obesity and cancer. 
Therefore, to gain more knowledge on processes involved in chronic CRD we 
performed a mouse study in which we chronically altered light cycles and focused 
on changes in longer term expression patterns, which may explain the observed 
weight gain phenotype. 
Methods
Experimental set-up
Animal experiments were performed in compliance with national legislation, 
including the 1997 Dutch Act on Animal Experimentation, and were approved by 
the institute’s Animal Experimentation Ethical Committee. Food and water were 
available ad libitum throughout the whole experiment.
The experimental set-up of the study has been described previously (Chapter 2) 
(Van Dycke et al., 2015). In short, breast cancer-prone female p53R270H/+WAPCre mice 
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(Wijnhoven et al., 2005) in an FVB genetic background were kept under normal 
LD conditions or chronically exposed to a weekly alternating 12:12 hour light-
dark cycle. After 18 inversions, on day 7 of the last shift, animals were sacrificed at 
4 hour time intervals over a 24-hour period (n=4 animals per time point). Blood 
and tissues were collected for further analysis. Due to premature animal loss, 21 
animals per condition were available for further analysis. In an additional group of 
mice (n=5 per group), a radio transmitter (Physio Tel, TA11 TA-F10; Data Sciences, 
St. Paul, MN) was implanted in the peritoneal cavity to record locomotor activity 
and core body temperature every ten minutes (Van Dycke et al., 2015).
Micro-array analysis
Total RNA was extracted from RNAlater (Invitrogen, Grand Island, NY, USA) 
protected liver tissues using the miRNeasy Mini Kit (Qiagen Benelux, Venlo, The 
Netherlands). RNA concentrations were measured using a NanoDrop ND-1000 
Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA), and RNA 
quality was assessed with an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Amstelveen, the Netherlands). 
RNA was processed for gene expression analysis at the Microarray Department 
of the University of Amsterdam, the Netherlands, using Agilent SurePrint G3 
Mouse GE 8x60K arrays (Amstelveen, the Netherlands). This type of microarray 
contains 55,681 probes for biological features such as mRNAs and ncRNAs. RNA 
amplification and labeling were carried out according to the manufacturer’s 
protocol. Experimental samples (each corresponding to RNA isolated from one 
individual mouse) were labelled with Cy3 and the common reference sample 
(made by pooling equimolar amounts of RNA from experimental samples) was 
labelled with Cy5. Slides were scanned with an Agilent G2565CA DNA microarray 
scanner, followed by automated feature extraction, resulting in a table containing 
individual probe signal intensities for both dyes.
Data analysis
The raw data were subjected to a set of quality control checks to ensure comparable 
signal average and distribution. Raw microarray data for gene-coding probes were 
normalized in R (www.r-project.org) using a four step approach (Pennings et al., 
2011): (1) natural log-transformation, (2) quantile normalization of all scans, (3) 
correcting the sample spot signal for the corresponding reference spot signal and 
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(4) averaging data from replicate probe spots. The normalized data of 55,681 probes 
were further analyzed in R and Excel (Microsoft Corporation, USA). Probe to gene 
annotation data was downloaded from NCBI. Significantly regulated probes were 
annotated to the corresponding genes for further biological interpretation. To this 
end, when multiple probes corresponding to the same gene were significant, they 
were counted as one gene in further analysis; probes that did not correspond to 
genes according to the current NCBI database were excluded from further analysis.
To identify differentially expressed genes for chronic CRD exposed animals 
compared to controls, we performed a one-way ANOVA with Qlucore Omics 
Explorer (Qlucore AB, Lund, Sweden) in which p<0.001 was considered statistically 
significant. CircWave Batch v5.0 software (Hut, R., www.euclock.org/results/
item/circ-wave-batch.html) was used to analyze circadian rhythmicity of gene 
expression under regular LD conditions and after prolonged exposure to weekly 
LD-inversions. Enrichment of selected gene lists was analyzed with MetaCore GO 
Processes from GeneGo, Inc. (http://www.genego.com/). Gene expression data 
were imported into Metacore using their NCBI Entrez GeneID as identifier; therefore 
only genes annotated with a GeneID in the current NCBI database were used 
for pathway enrichment analysis. To ensure biological relevance, only processes 
including between 10 and 1000 genes were taken into account. GO Processes 
were considered significantly enriched with a p<0.001. Gene Set Enrichment 
Analysis allowed us to identify significant up- or downregulation of enriched gene 
sets (P<0.05 and FDR<0.25) (Mootha et al., 2003, Subramanian et al., 2005).
Results
Attenuation of circadian rhythmicity in gene expression
The alternating light cycle protocol to chronically disturb the circadian rhythm 
(CRD protocol) used in this study has previously been shown to shorten tumor 
latency times, increase body weight and affect sleep timing (Van Dycke et al., 
2015). Although the weight gain phenotype is already apparent at week 6, 
group differences only became significant after week 24. Given the overweight 
phenotype, we analyzed possible transcriptional changes in the liver. Since we were 
interested in processes that are involved in the observed overweight phenotype 
early on, we analyzed gene expression 18 weeks after start of the exposure, before 
the differences in body weight gain were significant. Clock and clock-controlled 
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genes, as well as temperature rhythms, were re-entrained 7 days after the final 
light-dark shift whereas corticosterone serum levels showed a bimodal rhythm 
upon chronic CRD (Van Dycke et al., 2015). This re-entrainment of the majority 
of these classical parameters allowed investigation of more permanent disturbed 
genes and processes. 
The observed re-entrainment of temperature and clock gene expression, in 
contrast to altered serum corticosterone rhythms suggest that chronic CRD results 
in internal desynchronization. Therefore, we determined circadian rhythmicity of 
all genes using CircWave, for the control light-dark (LD group) and chronic CRD 
groups separately. Significant circadian gene expression (p<0.001) was observed 
for 594 genes in LD controls and only in 133 genes in chronic CRD exposed animals. 
The overlap between the two groups was limited to 33 genes, including several 
clock or clock controlled genes (for a complete overview, see Supplemental Table 
S1). Interestingly, 561 genes lost significant circadian expression after chronic CRD 
based on p-value. However, closer examination of the expression profiles revealed 
that oscillation was not completely abolished for these genes (Fig. 1). Rather, the 
majority of these genes showed a lower amplitude oscillations, as compared to 
LD controls (Fig. 1) and the average amplitude of all 561 genes was significantly 
decreased in chronic CRD exposed animals (Fig. 2a, Mann Whitney test, p < 0.001). 
This lower amplitude explains the lack of significant circadian rhythmicity in gene 
expression. Furthermore, a limited effect on phase was found (Fig. 2b). These 
findings are indicative of a re-entrained, yet attenuated circadian rhythmicity in 
gene expression upon prolonged exposure to weekly LD-inversions.
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Figure 1. Heatmap of 561 genes that lost significant circadian rhythmicity in gene expression after prolonged 
exposure to CRD, according to CircWave analysis. It is clearly shown that the circadian rhythm of these genes 
is not abolished, however the amplitude is decreased in the majority of these genes.
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Figure 2. Overview of circadian parameters of genes with significant circadian gene expression under 
regular LD conditions, lost upon chronic CRD. A. The amplitude of these genes was significantly reduced in 
chronic CRD animals compared to controls B. Acrophase was comparable between no large phase shifts 
were found. All indicative of an attenuated circadian gene expression resulting from chronic exposure to 
CRD. 
Mice exposed to weekly LD-inversions showed a larger increase in relative body 
weight compared to the animals kept in a stable LD cycle (Van Dycke et al., 2015). 
To gain insight in mechanisms underlying the observed increased weight gain, 
we determined enrichment of the 561 genes that lost significant circadian gene 
expression upon chronic CRD exposure compared to LD conditions in biological 
processes. Chronic CRD caused attenuation of circadian rhythmicity in genes 
involved in 237 processes (p <0.001, >10 and <1000 genes in process). The 
largest groups of processes involve hormonal regulation, response to exogenous 
compounds and metabolism, comprising both lipid and glucose metabolism (Fig. 
3). In addition, the affected genes were associated with circadian rhythm, cell cycle, 
and signaling processes (Fig. 3). A complete list of significantly enriched processes 
is given in Supplemental Table S2. 
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Figure 3. Significantly enriched processes for genes with attenuated circadian rhythmicity in gene 
expression upon chronic CRD exposure, arranged in themes. In relation to the observed overweight 
phenotype it is interesting to see decreased amplitude in genes involved in glucose and lipid metabolism 
processes, especially in glucose transport and storage and also lipid storage.
In addition to chronic CRD affected biological processes, we investigated the top 
20 rhythmically expressed genes with the largest relative decrease in amplitude 
(Supplemental Table S3) in more detail. Since we study gene expression changes 
7 days after the last light-dark shift, only minor differences might be expected due 
to re-entrainment. Within this group of most affected genes regarding amplitude, 
several metabolic related genes still showed an altered rhythm, including Ppard, 
Pdk4, Slc16a5 and Igfbp-1 (Fig. 4). Under LD conditions, both the nuclear hormone 
receptor Ppard and isoenzyme Pdk4 peak at the dark to light transition. Chronic 
CRD exposure appears to lower peak mRNA expression of these genes, and delay 
acrophase to early light phase. Igfbp-1, which binds IGF and thereby regulates 
IGF action, shows both alteration of phase and attenuation of the rhythm. Under 
normal LD conditions, Igfbp-1 gene expression peaks at the dark to light transition, 
whereas chronic CRD caused a slightly advanced and lower peak expression. 
Moreover, the circadian rhythmicity of monocarboxylate transporter Slc16a5 gene 
expression is completely abolished in chronic CRD exposed animals. 
Disturbance of non-circadian genes and processes
In addition to disturbance of circadian rhythmicity of gene expression, chronic 
disturbance of the circadian system might also affect non-circadian processes. 
Using one-way ANOVA, we compared the overall expression of each gene of CRD 
mice to that of the LD controls, not taking into account time-of-day. The latter was 
accomplished by combining all time-points per group, comparing the average 
expression of all CRD exposed mice to the average expression of all LD controls. 
Surprisingly, we found only 18 genes to be differentially expressed (p <0.001) in 
CRD exposed animals, as compared to controls (Supplemental Table S4), with 
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Figure 4. Altered circadian gene expression of Ppard, Pdk4, Igfbp-1 and Slc16a5, involved in the balance 
between glucose and lipid metabolism. Ppard and Pdk4 both show a phase delay and decreased amplitude 
upon chronic CRD (open symbols) compared to LD controls (closed symbols). CRD caused a slight advance 
and decrease of peak Igfbp-1 gene expression, with a distinct trough at the light to dark transition. For 
Slc16a5 the rhythm is completely abolished in CRD exposed animals. 
minor diff erences in average gene expression. This number is limited, and does 
not allow pathway analysis. Therefore, Gene Set Enrichment Analysis (GSEA) was 
used, to identify subtle diff erences in GO processes or canonical pathways, again 
using all time-points per group combined. In the GSEA analysis, the complete 
gene expression dataset is used to study signifi cant overrepresentation of up 
or down regulated genes between CRD exposed animals and LD controls in 
gene sets representing GO Processes and other online databases (C2 gene sets). 
GSEA identifi ed 36 upregulated processes or pathways, mainly involved in DNA 
replication, transcription, translation and metabolism (Supplemental Table S5). 
The majority of the 75 downregulated processes identifi ed represented immune, 
cell cycle and proliferation processes (Supplemental Table S5). Interestingly, 
also downregulation of several catabolic processes was observed. This analysis 
indicates that although no major diff erences in average gene expression between 
CRD animals and LD controls were found, genes involved in a wide variety of 
processes are aff ected by CRD. 
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Figure 5. Using Gene Set Enrichment Analysis significant overrepresentation of regulated genes between 
CRD exposed animals and LD controls in GO processes or the C2 gene sets is studied. The majority gene sets 
with significant overrepresentation of down regulated genes is involved in immune processes, whereas the 
up regulated genes are mainly involved in DNA replication.
Discussion
Due to the growing 24/7 economy, shift work will become increasingly part of our 
society and will, therefore, have an incremental effect on public health outcomes. 
Understanding mechanisms underlying the adverse health effects originating 
from chronic circadian rhythm disturbance (CRD) is of prime importance to 
develop preventive measures for shift work. An experimental set-up inducing 
CRD, along with a mouse model at risk for the development of breast cancer 
risk, weight gain and other morbidities, provides a unique tool to identify such 
underlying disturbed processes (Kubo et al., 2011). The major advantage of this 
model is the ability to control the exposure and to exclude confounding factors, 
which both hamper human observational studies. Importantly, we aimed to find 
constitutively disturbed processes upon long-term exposure to CRD. As such, we 
studied the hepatic transcriptome of mice exposed to 18 weeks of CRD compared 
to LD controls, 7 days after the last shift. We focused on identifying disturbances in 
both circadian and non-circadian genes and processes. 
Studying rhythmically expressed genes, we observed weaker rhythmicity in hepatic 
gene expression upon chronic CRD exposure, affecting a wide variety of molecular 
processes. This could be indicative for an overall loss of homeostasis, resulting from 
constant re-entrainment to the chronically alternating light cycle. Although this 
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finding is generally in line with previous studies that have shown a loss of circadian 
rhythmicity in the human blood transcriptome resulting from insufficient sleep 
(Moller-Levet et al., 2013) and mistimed sleep (Archer et al., 2014a), our findings are 
less pronounced. This can be explained by the fact that we monitored effects only 
7 days of recovery after the last shift. This resulted in re-entrainment of classical 
circadian parameters such as clock gene expression and core body temperature. 
The loss of significant circadian gene expression is mainly due to a decrease in 
amplitude, indicating that overall circadian gene expression is also re-entrained, 
but rhythmicity is attenuated. In short-term experiments as performed by others 
(Barclay et al., 2012), melatonin, clock genes and clock controlled genes were 
found to be disturbed, directly after impingement on the circadian system. 
In relation to the weight gain phenotype observed in mice under CRD conditions, 
we found that genes with attenuated circadian expression upon CRD were 
enriched for processes involved in mainly glucose but also lipid metabolism. 
Under normal conditions both carbohydrate and lipid metabolism show distinct 
time-of-day dependent rhythms (Bailey et al., 2014). The attenuation in glucose 
metabolism processes is in line with recent findings that the circadian system 
is largely responsible for daily rhythms in glucose tolerance and that separately 
circadian misalignment reduces glucose tolerance (Morris et al., 2015). Furthermore, 
GSEA analysis revealed down regulation of catabolic processes, which shows that 
energy metabolism is also affected in non-circadian genes.
The largest decrease in amplitude was found in genes involved in the balance 
between lipid and glucose metabolism: Ppard, Pdk4, Slc16a5 and Igfbp-1. The 
nuclear receptor Ppard has been shown to be a key regulator of Pdk4 (Degenhardt 
et al., 2007). This direct regulation could explain the similar changes in circadian 
expression of both genes. A similar decrease in amplitude of Pdk4 expression was 
observed in animals kept on a high fat diet (Eckel-Mahan et al., 2013), and animals 
that underwent timed sleep restriction (Barclay et al., 2012), both indicative of an 
interaction between circadian clock and metabolism. Furthermore, Pdk4 plays an 
important role in the metabolic flexibility under various nutritional conditions 
(Zhang et al., 2014b). In response to starvation Pdk4 mRNA and protein levels in liver 
increase (Wu et al., 2000). The conversion of pyruvate into Acetyl-CoA is inhibited 
by Pdk4 as it inactivates the pyruvate dehydrogenase complex, maintaining blood 
glucose levels under fasting conditions (Jeoung and Harris, 2010). The observed 
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circadian rhythm in Pdk4 expression under LD conditions correspond with daily 
rhythms in feeding and fasting. Attenuated rhythms in Pdk4 resulting from chronic 
CRD exposure might result in limited ability to regulate blood glucose levels. 
Little is known about the function of Slc16a5, and mainly described as a 
transporter for diuretics (Murakami et al., 2005). However, other monocarboxylate 
transporters are involved in energy balance processes (Lengacher et al., 2013). 
The Insulin-like Growth Factor-1 (IGF-1) axis, including Igpbp-1, is likely involved 
in glucose metabolism, as it can acutely regulate glucose levels (Katz et al., 2002). 
The combination of decreased amplitudes in Pdk4, Ppard, Igfbp-1 and Slc16a5 
and increased body weight gain upon long-term exposure to CRD suggests an 
imbalance between nutritional status and lipid and glucose metabolism, resulting 
in obesity. Future studies should specify this imbalance and investigate which 
interventions could help balance nutritional intake and metabolism to prevent 
obesity. For example studying the metabolome could indicate which metabolic 
processes have increased or decreased activity based on the metabolites found to 
be linked to these processes.
In conclusion, chronic CRD results in weaker circadian rhythmicity of a wide variety 
of circadian and non-circadian processes, including processes that could be related 
to the body weight gain phenotype observed in shift workers. Attenuation in 
circadian rhythmicity of both glucose and lipid metabolism processes and genes 
involved in their balance provide a preliminary target for intervention. However, 
the chronic effects are minor compared to the acute effects shown by previous 
transcriptome analyses (Barclay et al., 2012, Moller-Levet et al., 2013). Taken 
together, based on these observations one could speculate that the weakened 
circadian rhythmicity 7 days after the last shift is only a remainder of more severe 
disturbance at earlier time points e.g. 1 or 2 days after the shift. The relevance of 
acute and more permanent disturbance of biological processes for adverse health 
outcomes remains to be determined. Insights herein would provide important 
input for the discussion whether slow or fast rotating shift schedules should be 
employed. Additionally, in depth analysis of affected genes and processes and 
metabolome data should provide further insights in the role of the constitutively 
disturbed processes in the relation between CRD and increased weight gain.
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Summary
Working around the clock as a consequence of our growing 24/7 economy strains 
and disturbs the tightly regulated circadian system. In epidemiological studies, 
shift work was associated with many adverse health effects, such as cancer, obesity 
and cardiovascular disease. These observational human studies are hampered by 
confounding factors, difficulties with exposure assessment and take many years to 
complete. Yet, due to the similarities in carcinogenesis (Balmain and Harris, 2000) 
and the circadian system (Lowrey and Takahashi, 2011) between mice and human, 
mice provide a unique tool to study the relationship between shift work and 
cancer. Animal studies are less influenced by confounding factors and therefore 
provide the ability to study the causal relationship between chronic circadian 
disturbance and adverse health effects. Additionally, animal studies provide the 
ability to study the different aspects of shift work and to identify underlying 
mechanisms and potential biomarkers for circadian rhythm disturbance (CRD) to 
aid the development and study of preventive measures. 
In chapter 2 the effect of chronically alternating light cycles on breast cancer 
development and body weight was studied using a unique breast cancer-prone 
mouse model. We observed alterations in the classical circadian markers body 
temperature and serum corticosterone, preceding health effects. Whereas age-
matched breast cancer prone Li-Fraumeni female mice, housed under normal light 
dark conditions, displayed a tumor latency time of 50.3 weeks, animals exposed 
to weekly light-dark (LD) inversions showed a markedly shortened tumor latency 
time of 42.6 weeks. In addition, CRD animals showed an increase in body weight. To 
our knowledge this is the first study providing experimental evidence for a causal 
relationship between circadian rhythm disturbance and breast tumorigenesis.
These findings warrant the identification of biomarkers that evaluate the presence 
of circadian rhythm disturbance (CRD) and health risk before adverse health effects 
occur. The use of whole genome gene expression analysis is a valuable approach 
to identify differentially expressed genes upon CRD in the tissue of interest and 
select genes that qualify as useful biomarkers. In chapter 3, we provided a proof 
of principle for a comparative transcriptomics approach to identify potentially 
blood detectable biomarkers for breast cancer using the Li-Fraumeni mouse 
model. By comparing gene expression profiles of tumor samples with different 
characteristics to control mammary gland tissue, we determined differentially 
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expressed gene across tumor subtypes. Subsequently, candidates were prioritized 
based on possible blood-detectability as determined by cross-referencing with 
literature databases. Finally, a set of 16 candidate markers for breast cancer was 
selected based on the expression in tumor compared to normal mammary gland.
As the transcriptomics approach proved to be able to select potentially blood-
detectable biomarkers for breast cancer, we employed a similar approach to identify 
biomarkers for CRD. Although blood-detectable biomarkers for CRD, independent 
of time of day, can facilitate studies regarding preventive interventions, these 
biomarkers have not yet been identified. In chapter 4, we exposed female mice 
to 6 shifts in a clockwise (CW) and counterclockwise (CCW) rotating CRD protocol. 
Hepatic gene expression analysis using a classification approach resulted in a 
consensus set of 15 genes, able to predict CRD with an accuracy ranging from 90% 
to 98%. Additionally, to find candidate markers that allow non-invasive detection 
of CRD, we applied a sequential approach selecting 9 potentially blood-detectable 
markers. One of these candidates, CD36 was found to be significantly increased 
in serum, although less pronounced than expected from the gene expression 
upregulation.
Future research into the adverse health effects of CRD will also require the 
measurement of disease related biomarker in large-scale cohort studies. 
Chapter 5 provides a descriptive study of the daily variation of hormonal and 
lipid biomarkers in males and females, in a molecular epidemiology-like setting. 
Using two analysis methods: 1) Cosine fitting analysis and 2) RM-ANOVA, we found 
diurnal variation in many markers for at least one gender, which exceeded the 
inter-individual variation. Consequently, when investigating these markers one 
should take into account diurnal variation. Furthermore, since time-of-day likely 
matters for additional markers, these findings warrant the need for investigating 
diurnal variation before setting up studies measuring markers in routine and 
controlled settings.
In chapter 6 we describe experiments where mice were exposed to weekly 
alternating light-dark cycles and the liver transcriptome was analyzed to identify 
disturbed processes involved in the body weight gain phenotype as observed in 
chapter 2. We found an overall attenuation of circadian rhythmicity in hepatic 
gene expression, which was less pronounced than previous studies investigating 
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the effect of insufficient or mistimed sleep on the blood transcriptome. Amplitude 
was particularly decreased in genes involved in the balance between lipid and 
glucose metabolism: Ppard, Pdk4, Slc16a5 and Igfbp-1. Thus, compromised 
metabolic flexibility might underlie the body weight gain phenotype observed in 
chapter 2 and the overweight phenotype in shift workers and therefore provide a 
preliminary target for intervention.
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Discussion
The existence of our 24-hour economy is irreversible and will require an increasing 
number of individuals to work at irregular hours. This might put them at risk 
for adverse health effects by constantly straining and disturbing the tightly 
regulated biological clock. The relationship between the circadian system and 
cancer has been studied extensively, both in epidemiological studies and animal 
experiments. Most epidemiological studies point towards an association between 
shift work and breast cancer, as well as other adverse health effects (IARC, 2010). 
Unfortunately, the complex mixture of exposures we call shift work hampers the 
accurate assessment of causality. Furthermore, large scale prospective studies are 
costly and labor intensive due to the use of classical circadian markers such as 
melatonin, requiring around the clock measurement. To date, animal studies have 
emphasized the relationship between the circadian system and cancer. Overall, 
they have shown that a partially or completely non-functional circadian system 
result in increased tumor growth. However, studies are lacking that combine 
relevant models for CRD exposure and adverse health effects such as breast cancer 
to provide experimental proof for the shift work cancer connection. Notably, there 
is a gap between epidemiological and animal studies concerning the experimental 
proof that shift work causes an increased cancer risk. In this thesis we aimed to 
elucidate the causal relationship between circadian rhythm disturbance and 
breast cancer development and to provide candidate biomarkers and targets for 
interventions for future studies. 
Causality between CRD and breast cancer and obesity 
The findings described in chapter 2 show that chronic circadian rhythm 
disturbance (CRD) induced by chronically alternating light schedules decreased 
latency times of tumor development and increased body weight gain in a 
breast cancer-prone mouse model. Previous animal experiments, studying the 
relationship between CRD and cancer differed from this study in the combination 
of CRD induction methods and the breast cancer models used. For example, some 
studies addressed tumor growth rather than cancer initiation and progression 
by using xenograft models (Blask et al., 2003, Filipski et al., 2004) and chemically-
induced tumor models (Hamilton, 1969, Shah et al., 1984). Additionally, ‘unnatural’ 
continuous bright light exposure and endogenous circadian rhythm disruption 
models were employed, which result in arrhythmicity (Anisimov et al., 2004, Wu 
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et al., 2011). To our knowledge, the study as described in chapter 2 unequivocally 
shows a link between chronic CRD and breast cancer development, relevant for 
the human situation. 
Shift work is a complex mixture of exposure and different aspects of these exposures 
have been suggested to underlie the observed cancer risk in individuals involved 
in shift work. Fritschi et al. proposed five mechanisms that should be considered 
for comprehensive investigation: (i) internal desynchronization, (ii) light at night 
(resulting in melatonin suppression), (iii) sleep disruption, (iv) lifestyle disturbances 
and (v) decreased vitamin D levels due to lack of sun light (Fritschi et al., 2011). In 
chapter 2 the relevance of these hypotheses was tested and the findings suggest 
that internal desynchronization and sleep disruption are important in the etiology 
of CRD-associated health risks and pathologies. The other factors (melatonin 
suppression, lowered vitamin D levels and life style factors) could be excluded 
in our study and therefore appear to be less relevant in the shift work cancer 
relationship. Consequently, sleep disruption and internal desynchronization are 
targets for preventive measures.
Apparently, the process of carcinogenesis is induced by circadian rhythm 
disturbance and additional experiments could further elucidate which specific 
aspects of carcinogenesis is affected. It has been suggested that all aspects of the 
cellular response to DNA damage are controlled or influenced by the circadian 
clock (Sancar et al., 2010). Consequently, chronic disturbance of the circadian 
system is likely to affect these DNA damage control systems in place to prevent the 
accumulation of mutations, which eventually result in uncontrolled or neoplastic 
cell growth (Berenblum, 1975). Alternatively, the accumulation of mutations could 
be the result of increased exposure to endogenous DNA damaging agents. For 
example, the disturbance of metabolic processes by CRD could increase the 
amount of reactive oxygen species and consequently increase mutations. Based 
on the decreased latency time to tumor development observed in chapter 2 
one could hypothesize that the number of mutations increased faster under 
CRD conditions compared to LD conditions. This hypothesis can be addressed by 
evaluating the mutation frequency in vivo using a plasmid based transgenic mouse 
model (Dolle et al., 1996). Besides DNA repair processes, the immune system also 
plays an important role in breast tumorigenesis (Standish et al., 2008), and circadian 
disturbance has been shown to affect the immune response (Phillips et al., 2015), 
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increasing vulnerability for environmental stressors. Furthermore, epigenetic 
changes resulting from prolonged exposure to CRD could lead to increased tumor 
development, for example by silencing of tumor suppressor genes. 
Besides the increased risk of cancer, epidemiological studies have also indicated 
an association between social jet-lag, shift work and body weight gain, although 
again conflicting data exist (Kubo et al., 2011, Nabe-Nielsen et al., 2011, Roenneberg 
et al., 2012, Parsons et al., 2014). Various mouse studies and the findings described 
in chapter 2 have shown that circadian disturbance induced by continuous 
light, forced activity or a disrupted LD cycle causes an increase in body weight 
(Coomans et al., 2013, Oishi, 2009, Salgado-Delgado et al., 2008). In the liver, a key 
organ in glucose and lipid metabolism, approximately 10% of the transcriptome is 
rhythmically expressed, including metabolic processes (Akhtar et al., 2002, Panda 
et al., 2002). Furthermore, under normal conditions both carbohydrate and lipid 
metabolism show distinct time-of-day dependent rhythms (Bailey et al., 2014). 
We hypothesized that long-term CRD results in more permanent alterations in 
biological processes relevant for the observed phenotype. 
In chapter 6, using the transcriptomics technique, we found an overall attenuation 
of circadian rhythmicity in gene expression 7 days after the last shift. The overall 
attenuation of circadian gene expression is similar, although less pronounced, 
in comparison with other studies using an omics approach to find the effects of 
disrupted sleep (Archer et al., 2014a, Barclay et al., 2012, Moller-Levet et al., 2013). 
The main difference between our study and others is the timing when the effects 
are observed. Where others studied circadian rhythmicity of gene expression 
directly after impingement on the circadian system, we studied the transcriptome 
7 days after the last shift of long-term CRD exposure. One could speculate that the 
weakened circadian rhythmicity 7 days after the last shift is only a remainder of 
more severe disturbance at earlier time points e.g. 1 or 2 days after the shift. Follow-
up studies should further investigate whether the number of genes that show an 
attenuation in circadian rhythmicity in gene expression and the magnitude of the 
amplitude decrease correlate with the magnitude of CRD and subsequent health 
effects. 
The largest decrease in amplitude was observed in genes involved in the balance 
between glucose and lipid metabolism. Further research to find the exact 
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imbalance in metabolism could provide an interesting target for intervention, 
with timed nutritional intake. Previous animal studies have shown that timed 
feeding can indeed (partially) rescue tumor and obese phenotypes (Filipski et al., 
2005, Fonken et al., 2010, Oike et al., 2015). In all cases food was restricted to the 
active phase and was shown to prevent dim light or jet lag induced body weight 
gain and accelerated xenograft tumor growth by chronic jet lag. The finding that 
advances and delays in meal-timing affect both circadian rhythms as well as 
metabolic parameters underlines the importance and potential of meal-timing 
(Yoon et al., 2012).
Evidence based preventive measures
Due to the high incidence of breast cancer and obesity an increased risk resulting 
from long-term shift work can have major public health implications. However, shift 
work is irreversibly linked to our 24/7 society and consequently evidence based 
interventions to prevent CRD and consequent health effects are needed. Currently 
advised preventive measures are versatile, including controlled light exposure, 
schedule adaptations, and behavioral and pharmaceutical interventions (Neil et 
al., 2014) and underlying philosophies and results are contradictive. Interventions 
using controlled light exposure are aimed at phase shifting the circadian rhythm 
and promoting adaptation to work at night. For example, by exposure to bright 
light during the night shift and wearing dark goggles on the commute home in 
the morning. This was shown to effectively increase day-time sleep (Boivin et al., 
2012, Sasseville and Hebert, 2010) but also without effects on sleep (Budnick et 
al., 1995). In contrast, changing schedules from slow backwards rotating to fast 
forward rotation, are based on the principle of limited circadian rhythm adjustment 
(Knauth, 1996). Implementation of this fast forward rotation schedule has shown 
contradicting effects on sleep and metabolic markers (Boggild and Jeppesen, 
2001, Harma et al., 2006, Viitasalo et al., 2008). A major limitation of these studies 
is the relatively short follow-up and lack of association with adverse health effects. 
It is important to acknowledge that the positive effects of interventions on the 
acute shift work related health complaints, such as sleepiness and gastrointestinal 
symptoms, do not necessarily represent preventive effects on long-term health 
effects, such as cancer and obesity.
The importance of preventive measures is also acknowledged by the Dutch 
government, which requested the Dutch Health council to advice on the availability 
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of preventive measures (Health Council of the Netherlands, 2015). Based on the 
afore mentioned review (Neil et al., 2014) and two additional reviews (Ruggiero 
and Redeker, 2014, Liira et al., 2014), it was concluded that there are no evidence 
based preventive measures to be recommended for shift workers to suppress 
long-term health effects. The council expresses the need for both experimental 
and observational studies that link suggested preventive measures with long-term 
health effects. 
The CRD model in combination with the breast cancer-prone mouse model as 
used in chapter 2, are an ideal starting point to identify evidence based preventive 
measures that decrease long-term health risk. Firstly, because of the relative short 
period needed to evaluate the effect of these interventions on long-term health 
effects compared to human studies. And secondly, the ability to continuously 
measure activity and core body temperature using a telemetry system, enables 
the monitoring of circadian system adaptation. Cross-sectional studies or use of 
reporter mice for clock genes can evaluate whether peripheral clock also adapt, 
similar to locomotor activity and core body temperature rhythms. (Chaves et al., 
2011). Hereby, providing experimental evidence whether interventions promoting 
adaptation or limiting adjustment of the circadian system are best suited to 
prevent disease. Furthermore, sleep patterns can be determined using mouse 
telemetry data as described previously for human wrist actimetry data (Juda et al., 
2013b). This is important since sleep duration, timing and quality are often used 
to describe shift work-related strain (Akerstedt, 2003) or used as post-intervention 
measures (Neil et al., 2014, Vetter et al., 2015). Overall, specialized animals can be 
used to screen the variety of preventive measures proposed (Neil et al., 2014) and 
experimentally proven interventions can be studied in shift workers.
Biomarkers
As described above, many recommendations have been made to alleviate shift 
work related health effects. Although animal models can be used to identify 
interventions that are likely preventing adverse health effects, there is a need for 
scientific evaluation of these preventive measures in shift workers (Richter et al., 
2010). Tools that measure the presence of CRD or evaluate the health risk could aid 
the evaluation of new interventions and provide individual, longitudinal exposure 
assessment in shift workers. In the context of shift work, two types of biomarkers 
can be differentiated: 1) biomarkers that report on the presence and magnitude of 
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circadian disturbance and 2) biomarkers that are associated with disease. The latter 
do not report on CRD, but can identify health risk which allows early intervention 
before adverse health effects occur.
Mouse models are frequently applied in biomarker discovery research (Kelly-
Spratt et al., 2008). Similarities exist between breast cancer mouse models and 
human breast cancer, and these mouse models are therefore useful in biomarker 
discovery studies (Klein et al., 2007, Pitteri et al., 2008). In chapter 3 the Li-Fraumeni 
mouse model mimicking human breast cancer development was used to provide 
proof of principle for the use of transcriptomics in the identification of new blood-
based biomarkers for breast cancer. In this study, we used a genomics approach 
on mammary gland tumor tissue compared to find genes overexpressed in tumor 
tissue compared to control. Blood detectability was determined based on Gene 
Ontology ‘extracellular’ or UniProt ‘secreted’ annotation, or cross-reference with the 
Human Plasma Proteome project (Anderson et al., 2004). Additional selection based 
on actual expression in human breast tumor compared to normal mammary gland 
tissue yielded a set of 16 promising biomarkers for further validation. Importantly, 
circadian rhythmicity and food intake responsiveness should be excluded.
After validation, a panel of blood-based biomarkers for breast cancer as identified 
by this approach appeared a valuable add-on to currently available early detection 
methods for breast cancer screening. Using sensitive detection techniques, blood-
based biomarkers can be detected in small aliquots of blood obtained by a finger 
prick (Pennings et al., 2014), which certainly is less invasive than undergoing 
mammography. Furthermore, blood-based biomarkers are not hampered by high 
density breast tissue, as is the case with mammography. This way, measurement 
of biomarkers is minimally invasive with relatively low costs, which makes them 
applicable for use in a large scale population screening programs. People at high 
risk of breast cancer, including shift workers, could be eligible for a blood test 
using such a panel of early detection biomarkers. Besides prevention, the most 
efficient way to reduce cancer mortality and morbidity is detection at an early 
stage, allowing effective therapeutic treatment. In the future, the breast cancer 
biomarker panel can even be combined with early detection markers for other 
tumor types in a multiplex assay. 
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Upon the proof of principle for a transcriptomics approach in the identification of 
blood-detectable biomarkers for breast cancer, as provided in chapter 3, a similar 
approach was taken to identify biomarkers for circadian rhythm disturbance in 
chapter 4. In the future, these markers are intended for the use in large cohort 
studies, such as the Nightingale Study (Pijpe et al., 2014) or the Doetinchem 
Cohort Study (Verschuren et al., 2008). To be eligible for use in such settings, 
these universal biomarkers should fulfill the following criteria: 1) independent 
of rotation schedule; 2) independent of time of day; 3) age-independent and 
4) blood-detectable. Recently, transcriptomics- and metabolomics-based time 
of day independent biomarkers have been identified using jet lag exposed and 
clock mutant mice (Minami et al., 2009, Ueda et al., 2004), allowing detection 
of acute and transient effects of CRD, but not chronic effects. In chapter 4 we 
identified an optimal CRD classification set based on hepatic gene expression and 
a selection of potentially blood detectable biomarkers, both focused on time-of-
day independent detection of chronic CRD.
Although these selected blood-based biomarkers fulfill the criteria for use in large 
scale cohort studies, they should be further validated. Importantly, researchers 
currently using classical circadian markers need to be convinced of the relevance 
of these markers for CRD and their usefulness in relation to adverse health effects. 
Longitudinal measurements in both animal and human studies are required 
to evaluate the association of these biomarkers with CRD exposure duration. 
In addition to the relationship with exposure, the identified markers should be 
predictive for CRD associated health risk. Previous studies have shown that 
comparable chronic CRD protocols increased negative health effects in mice 
(Davidson et al., 2006, Filipski et al., 2004). Validation of the biomarkers in human 
studies are required to show whether this association with disease also applies to 
humans.
As described above, one could also opt for the measurement of disease associated 
biomarkers in a molecular epidemiology-like setting. Especially the combination 
of biomarkers for CRD and biomarkers for the adverse health effects could identify 
individuals at risk for disease development. Hormonal imbalance is often studied 
in large epidemiological settings since these are associated with high incidence 
cancer (such as breast cancer), and it is well known that metabolic markers might 
serve as important (early) indicators for metabolic disorders (Mester et al., 2010, 
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Stevens, 2005, Ferlay et al., 2015). In relation to shift work, metabolic markers such 
as cholesterol and triglycerides have been used to evaluate the advantageous 
effect of altered shift schedules (Orth-Gomer, 1982, Viitasalo et al., 2008). It is 
known that several disease related biomarkers show a diurnal rhythm in serum 
or plasma levels. However, most information on diurnal variation is derived from 
these controlled laboratory studies in which factors influencing diurnal variation 
(such as food intake and/or sleep/wake cycle) are controlled (for example see 
references (Klingman et al., 2011, Li et al., 2013, Jung et al., 2010, James et al., 2007, 
Davies et al., 2014, Ang et al., 2012, Dallmann et al., 2012)). With limited control 
over environmental factors in large scale cohort studies, it is important to have 
insight into the daily variation of these markers in a routine non-fasted molecular 
epidemiology-like setting, with no restrictions on sleep or diet. 
In chapter 5 we have shown that the majority of the hormonal and metabolic 
markers studied showed a daily variation (circadian rhythms and/or time-of-day-
effects that does not fit a cosine curve) in at least one gender. A recent study also 
showed that 43% of the protein coding genes show diurnal variation in at least 
one organ in mice (Zhang et al., 2014a), this indicates that daily variation in serum 
or plasma proteins is likely. In large molecular epidemiological studies, it should 
be advised to study diurnal variation of markers of interest and take into account 
when present. Preferably, samples should be taken at one time point. Furthermore, 
time of sampling and relevant environmental factors, such as food intake, can be 
registered. 
In shift workers, the measurement of markers with circadian rhythmicity is further 
complicated by variation caused by circadian disturbance, altered sleep timing 
and food intake and other shift work related factors. Consequently, when variation 
within groups is increased due to random sampling or disturbance by work 
schedule, larger group sized are required to increase power do detect differences 
between groups. To limit the additional variation, samples of biomarkers with 
diurnal variation in shift workers should best be taken on the last day shift. This 
way, individuals are least disturbed by work schedule and mostly recovered from 
previous shifts. Although this depends on chronotype, impingement on sleep 
wake rhythms by work hours and social responsibilities is limited. And it take 
several days for disturbed circadian rhythms to reentrain. Preferably, finger prick 
blood samples, urine samples and saliva samples, when applicable for the marker 
40036 Dycke, Kirsten.indd   124 11-04-16   11:02
125
Summary and general discussion
of interest, could be taken at home on free days without the interference of work 
schedule. 
Modelling shift work in animal studies
In this thesis, light schedules were altered to cause circadian rhythm disturbance. 
We have shown that altered light schedules in a mouse model for human breast 
cancer can provide important insights about health effects observed in human 
studies. Another important aspect of shiftwork is the activity at times of the day 
when we would normally be asleep. In humans, this consequently leads to altered 
meal timing and sleep disruption (Grundy et al., 2009, Lennernas et al., 1995). This 
can be mimicked by gently handling the animals and exposing them to new 
objects in their environment during normal sleeping hours, referred to as Timed 
Sleep Restriction (TSR) (Barclay et al., 2012). However, this labor intensive method 
is not compatible with long-term studies in large cohorts of animals. Currently, 
experiments are ongoing with specially developed ‘shift work cages’ in which 
the animals are gently, but continuously forced to be active at predefined time 
windows of the day (mimicking day, evening and night shifts). This set-up has been 
validated with similar sleep analyses as described in chapter 2. In combination 
with the Li-Fraumeni mouse model, the effect of altered sleep-wake cycle resulting 
from rotating shift work on breast cancer risk can be addressed. 
Although the increased breast cancer risk is probably the most extensively studied 
cancer type associated with shift work, other types of cancer, such as colorectal 
and prostate cancer have been prospectively been associated with long-term shift 
work (Kubo et al., 2006, Schernhammer et al., 2003). Accurate exposure assessment 
and control for confounding factors is also limited for these types of cancer. Using 
mouse models for colorectal cancer (Karim and Huso, 2013) or prostate cancer 
(Ittmann et al., 2013), the effect of chronic CRD, either induced by chronically 
alternating light cycles or forced activity, on these cancer types can be studied. In 
addition to the cancer phenotype, other disease pathologies such as diabetes type 
2 and obesity can be studies in animal models. Similarly to cancer, epidemiological 
research for these diseases is confounded by unhealthy habits of shift workers, 
which can be controlled for in experimental studies.
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Future perspectives
The fact that shift work has become an irreversible part of our 24/7 society 
underlines the importance of unravelling which aspects of shift work are relevant 
for the observed health effects and how to develop interventions to prevent 
adverse effects. To further study the relationship between shift work and adverse 
health effects, it is of utmost importance to inventory what shift work entails and 
to study the relevance of these individual aspects. This requires the collaboration 
of researchers with expertise of the circadian system and animal models and 
researchers with the ability to provide detailed information on human shift work 
characteristics, to close the gap between animal studies and epidemiological shift 
work studies in humans. Detailed knowledge on light exposure, food intake, sleep 
timing, duration and quality and other life style or biological characteristics from 
shift workers can be used as input for laboratory animal studies. Cross-sectional 
studies in shift workers and day workers can identify the aspects that are specific 
for individuals working in shifts. Animal experiments allow the comparison of 
these individual aspects of shift work or combinations in relation to health effects 
in a relatively short time frame. 
Alternatively, the findings from these animal studies can provide valuable input 
for the set-up of prospective human research. Upon validation, the candidate 
biomarkers identified in chapter 4 are interesting alternatives for the classical 
markers previously used in human studies. Based on the findings in chapter 6 
and those of others (Filipski et al., 2005, Fonken et al., 2010, Oike et al., 2015) 
we hypothesized that the timing of food intake is important for both increased 
body weight and cancer risk. Therefore, prospective human studies would ideally 
register meal-timing in shift workers to associate this with obesity and cancer risk. 
Additionally, animal studies are in progress to identify the ideal timing of food 
intake in a simulated shift work setting in relation to long term health outcome. 
The most promising findings of such experiments can provide valuable input for 
food intake interventions to be validated and evaluated in cohort studies with shift 
workers. 
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In vrijwel alle organismen is een biologische klok aanwezig, van fruitvliegjes tot 
mensen. De biologische klok wordt gedreven door de master klok in de hersenen, 
de supra chiasmatische nucleus. Deze master klok houdt een ritme aan van 
ongeveer 24 uur, ook wel circadiaan ritme genoemd, en wordt op tijd gezet door 
licht. Lichaamstemperatuur en activiteit zijn voorbeelden van processen die door 
deze master klok geregisseerd worden en dus over de dag variëren. Daarnaast zijn 
er ook hormonen zoals melatonine en cortisocosteron die een ritme hebben van 
ongeveer 24 uur. Moleculair gezien bestaat de klok uit verschillende genen die via 
feedback mechanismen over de dag verschillend tot expressie komen.
Het werken in ploegendienst, als consequentie van onze groeiende 24/7 economie, 
belast en verstoort het strak gereguleerde biologisch ritme. In epidemiologische 
studies is het werken in ploegendienst geassocieerd met vele gezondheidsrisico’s, 
zoals kanker, obesitas en cardiovasculaire aandoeningen. Deze observationele 
humane studies worden gehinderd door verstorende factoren, moeilijkheden 
met het vaststellen van de blootstelling en nemen daarnaast vele jaren in beslag. 
Door de sterke overeenkomsten in het carcinogenese en circadiane proces tussen 
muis en mens bieden muizen een unieke mogelijkheid om de relatie tussen het 
werken in ploegendienst en kanker beter te onderzoeken. Dierstudies worden 
niet beïnvloed door verstorende factoren en bieden daardoor de mogelijkheid 
om de causale relatie tussen chronische circadiane verstoring en lange termijn 
negatieve gezondheidseffecten te bestuderen. Bovendien kunnen de afzonderlijke 
aspecten van ploegendienst arbeid onderzocht worden. Door de toepassing van 
moleculair biologische technieken kunnen ook de onderliggende mechanismen 
en potentiele biomarkers geïdentificeerd worden, welke worden gebruikt voor de 
ontwikkeling en studie van preventieve maatregelen. 
In hoofdstuk 2 wordt beschreven wat het effect is van chronische jetlag op 
borsttumorontwikkeling en lichaamsgewicht, gebruikmakend van een unieke 
muizen met aanleg voor borstkanker. Dit muismodel heeft een mutatie in de 
borstklier die ook bij vrouwen met borstkanker voorkomt, hierdoor ontwikkelen 
deze muizen borsttumoren die vergelijkbaar zijn met humane borsttumoren. Onder 
normale licht-donkercondities ontwikkelden deze vrouwelijke, kankergevoelige 
muizen een borsttumor na gemiddeld 50.3 weken. Wanneer dit type muis werd 
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blootgesteld aan een wekelijkse omkering van het licht-donkerritme ontwikkelden 
borsttumoren significant eerder, al na gemiddeld 42.6 weken. Bovendien lieten ze 
een toename in lichaamsgewicht zien. Voor zover bekend is dit de eerste studie 
die experimenteel bewijs levert voor de causale relatie tussen verstoring van het 
circadiane ritme en borsttumor ontwikkeling.
Deze bevindingen maken het noodzakelijk om biomarkers te identificeren 
die de aanwezigheid van circadiane verstoring evalueren voordat negatieve 
gezondheidseffecten zich openbaren. Hiervoor is het waardevol om de 
expressie van alle genen te vergelijken tussen een controlegroep en een groep 
die is blootgesteld aan circadiane verstoring (CRD). De genen die verschillend 
tot expressie komen, kunnen als basis dienen voor de selectie van bruikbare 
biomarkers. Het tegelijkertijd in kaart brengen van de expressie van alle genen 
noemen we transcriptoomanalyse. In hoofdstuk 3 hebben we een proof-
of-principle gegeven voor het gebruik van transcriptoomanalyse om bij de 
muis biomarkers te identificeren die potentieel in bloed te detecteren zijn. 
Door de genexpressieprofielen van borsttumoren te vergelijken met controle 
borstklierweefsel vonden we genen die differentieel tot expressie kwamen in 
borsttumoren. Vervolgens werden kandidaat biomarkers gerangschikt op basis 
van potentiële detecteerbaarheid in bloed door vergelijking met literatuur 
databases. Uiteindelijk werden de 16 meest humaan relevante kandidaat markers 
geselecteerd.
Tot op heden waren er geen in bloed detecteerbare biomarkers voor CRD 
beschikbaar die onafhankelijk van het tijdstip van de dag gemeten kunnen 
worden. Deze biomarkers zijn nodig om studies naar preventieve maatregelen 
te faciliteren. Omdat transcriptoomanalyse bruikbaar bleek om biomarkers te 
identificeren die potentieel in bloed detecteerbaar zijn, werd een vergelijkbare 
aanpak gebruikt voor het vinden van biomarkers voor CRD. In hoofdstuk 4 
onderwierpen we vrouwelijke muizen aan 6 lichtverschuivingen met de klok mee 
(CW) of tegen de klok in (CCW). Genexpressie analyse van de lever resulteerde 
in een set van 15 genen, waarmee we in staat waren om de aanwezigheid van 
circadiane verstoring te voorspellen met een nauwkeurigheid van 90% tot 98%. 
Daarnaast hebben we een stapsgewijze aanpak gebruikt om kandidaat markers te 
vinden voor niet-invasieve detectie van CRD. Met deze aanpak selecteerden we 9 
potentiële, in bloed detecteerbare markers. Eén van deze markers, CD36 was ook 
in muizen serum significant verhoogd na CRD. 
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Toekomstig onderzoek naar de negatieve gezondheidseffecten van CRD vereist 
ook het meten van ziektegerelateerde biomarkers in grote cohort studies. Het is 
voor een aantal van deze markers bekend dat ze een circadiaan ritme vertonen. 
Echter is dit vaak onderzocht onder streng gecontroleerde condities, die niet 
representatief zijn voor cohort studies. Hoofdstuk 5 geeft een beschrijving van 
de dagvariatie van humane hormonale en lipide biomarkers in een setting met 
beperkte controle over de condities die de variaties beïnvloeden. We vonden een 
dagvariatie in veel markers die groter was dan de interindividuele variatie. Daarom 
zou men bij het bestuderen van deze markers de dagvariatie in ogenschouw 
moeten nemen. Bovendien is het aannemelijk dat het moment van de dag ook van 
belang is voor additionele markers. Dit vereist dat voor het opzetten van nieuwe 
studies met een beperkte controle over de meetcondities, vooraf de dagvariatie 
van de te meten biomarkers bepaald wordt.
 
In de studie beschreven in hoofdstuk 6 zijn muizen blootgesteld aan wekelijks 
alternerende licht donker cycli. Van deze dieren is het transcriptoom van de lever 
geanalyseerd om verstoorde processen te identificeren die ten grondslag liggen 
aan het toegenomen lichaamsgewicht, zoals geobserveerd in de dierstudie 
beschreven in hoofdstuk 2. Een algehele afname van de circadiane ritmiek in 
lever genexpressie werd gevonden, die minder uitgesproken was dan gevonden 
in eerdere studies. De voornaamste afname in amplitude werd gezien in genen 
betrokken bij de balans tussen vet en glucose metabolisme: Ppard, Pdk4, Slc16a5 
and Igfbp-1. Het is dus mogelijk dat verstoorde metabole flexibiliteit ten grondslag 
ligt aan het lichaamsgewichttoename fenotype gezien in hoofdstuk 2 en het 
overgewicht in ploegendienst medewerkers en daarom dus een preliminair 
aanknopingspunt voor interventie is. 
De bevindingen beschreven in dit proefschrift tonen aan dat ploegendienstarbeid 
negatieve invloed heeft op de gezondheid. Omdat ploegendienstarbeid door de 
24/7 economie onlosmakelijk verbonden is aan onze maatschappij, vereist dit 
preventieve maatregelen om de gezondheid van ploegendienstmedewerkers te 
waarborgen. Op dit moment zijn er geen wetenschappelijk bewezen interventies 
beschikbaar, mede doordat langdurig onderzoek nodig is om de effectiviteit 
op lange termijn gezondheidseffecten te besturen. De ontwikkeling van deze 
interventies kan gefaciliteerd worden door biomarkers die in een vroegtijdig 
stadium ziekte of circadiane verstoring kunnen meten. Met behulp van 
40036 Dycke, Kirsten.indd   132 11-04-16   11:02
133
8
Nederlandse samenvatting
transcriptoomanalyse is in dit proefschrift de basis gelegd voor de identificatie van 
deze biomarkers die onafhankelijk van het tijdstip van de dag gemeten kunnen 
worden. Bovendien kunnen diermodellen op korte termijn waardevolle informatie 
opleveren over de werkzaamheid van interventies bij mensen. Daarnaast hebben 
we laten zien dat het voor ziektegerelateerde biomarkers belangrijk is om rekening 
te houden met de dagvariatie bij het opzetten van humane studies. Ten slotte 
hebben we metabole flexibiliteit geïdentificeerd als eerste aanknopingspunt voor 
de benodigde interventies.
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hebt laten gaan in deze transcriptomics zee van data.
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Abstract
Application of omics-based technologies is a widely used approach in research 
aiming to improve testing strategies for human health risk assessment. In most 
of these studies, however, temporal variations in gene expression caused by the 
circadian clock are a commonly neglected pitfall. In the present study, we investigated 
the impact of the circadian clock on the response of the hepatic transcriptome 
after exposure of mice to the chemotherapeutic agent cyclophosphamide (CP). 
Analysis of the data without considering clock progression revealed common 
responses in terms of regulated pathways between light and dark phase exposure, 
including DNA damage, oxidative stress, and a general immune response. The 
overall response however was stronger in mice exposed during the day. Use of 
time-matched controls, thereby eliminating non-CP responsive circadian clock 
controlled genes, showed that this difference in response was actually even more 
pronounced: CP-related responses were only identified in mice exposed during 
the day. Only minor differences were found in acute toxicity pathways, namely 
lymphocyte counts and kidney weights, indicating that gene expression is subject 
to time of day effects. This study is the first to highlight the impact of the circadian 
clock on the identification of toxic responses by omics approaches.
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Introduction 
Human health risk assessment still requires the use of many laboratory animals 
to identify hazard and estimate risk of adverse health effects induced by 
environmental and pharmaceutical chemicals. Toxicogenomics approaches are 
applied to develop and validate risk profiles of biomarkers, identified by profiling 
the changes in transcript, protein and/or metabolite levels in in vivo exposed 
animals. The combined use of ‘omics’ technology and bioinformatics tools across 
platforms and species further supports the identification of common patterns in 
the toxic response, as well as the establishment of mechanism-based predictive 
biomarker sets. However, a commonly neglected pitfall of this approach is that 
temporal or daily variations in gene expression, as well as protein and metabolite 
levels, and as a consequence the time of day of exposure, may affect the outcome 
of a toxicogenomics experiment. 
To anticipate the day-night cycle, dictated by the Earth’s 24-hour rotation around 
its axis, most if not all life forms have developed a circadian clock (from the Latin 
circa diem, “about a day”) with a near 24-hour periodicity. This internal timekeeping 
system imposes day-night rhythms on behavior, physiology and metabolism: e.g. 
sleep-wake cycle, body temperature, blood pressure, energy metabolism and 
hormone levels. In this way, organisms adjust specific body functions to their 
special physiological needs during the 24-hour day (Lowrey and Takahashi 2011; 
Mohawk et al. 2012). In mammals, the circadian system consists of a master clock 
in the brain, and peripheral clocks in virtually all other cells and tissues. The master 
clock, comprised of the neurons of the suprachiasmatic nuclei (SCN), is sensitive to 
retinal light stimuli, allowing the clock to keep phase with the light-dark cycle. In 
turn, the SCN synchronize peripheral clocks through hormonal and neural factors 
(Balsalobre et al. 1998; Reppert and Weaver 2002; Weaver 1998; Welsh et al. 2010). 
Circadian rhythmicity is a cell-autonomous property. Rhythms are generated by a 
molecular oscillator, consisting of clock genes and proteins that are organized in 
positive and negative transcription translation feedback loops (TTFL) and cyclically 
switch each other on and off (Lee et al. 2001). Briefly, in the positive limb of the TTFL, 
a heterodimer of the basic loop-helix-loop/PAS (bHLH/PAS) domain containing 
transcription factors circadian locomotor output cycles caput (CLOCK) and aryl 
hydrocarbon receptor nuclear translocator-like (BMAL1) drives the transcription of 
the Period (Per1 and Per2) and Cryptochrome (Cry1 and Cry2) genes. In the negative 
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limb, the PER and CRY proteins shut down transcription of their own genes by 
forming a heterodimeric complex that translocates to the nucleus and represses 
CLOCK/BMAL1 driven transcription (Ko and Takahashi 2006; Lee et al. 2001; Reppert 
and Weaver 2001). This molecular clock is coupled to output processes via a series 
of clock-controlled genes, including transcription factors, cyclic expression of 
which further relays rhythmicity to a wider set of genes (Kumaki et al. 2008; Miller 
et al. 2007; Ueda et al. 2002; Yan et al. 2008). Indeed, various expression profiling 
studies have shown that, depending on the tissue, up to 10% of the transcriptome 
is under circadian control, with mRNA expression peaks distributed throughout 
the circadian cycle (Akhtar et al. 2002; Bozek et al. 2009; Panda et al. 2002; Storch 
et al. 2002). 
The liver plays a key role in most metabolic processes, especially in detoxification 
of xenobiotics. In this tissue, clock controlled transcription factors cause rhythmic 
expression of members of the cytochrome P450 (CYP) family and other phase I 
and phase II enzymes involved in this detoxification (Gachon et al. 2006). Adding 
to circadian control over xenobiotic metabolism (both activation and inactivation) 
is the diurnal variation in uptake and renal clearance of toxic substances (Levi and 
Schibler 2007). Circadian variation in the absorption, metabolism and excretion 
of toxic substances will ultimately determine the actual concentration to which 
the cells and tissues are exposed (Paschos et al. 2010). As such, the time of day 
of exposure to substances such as drugs, environmental chemicals and other 
xenobiotics may affect the severity of the toxic response, a phenomenon referred 
to as chronotoxicity.
To obtain insight into how the circadian clock affects the outcome of a 
transcriptomics experiment, we have performed an in vivo study in which mice 
were exposed to cyclophosphamide (CP) during the day or during the night. CP 
is a chemotherapeutic and immune suppressive agent that is widely used for 
treatment of several types of cancer, blood and bone marrow and tissue transplant 
rejections, and autoimmune disorders (Colvin 1999). As a prodrug, CP requires 
metabolic activation by cytochrome P450 enzymes (Hales 1982; Hill et al. 1972; 
Ludeman 1999). The human cytochrome P450 enzymes CYP2B6, CYP2C9, and 
CYP3A4/5 convert CP into the active metabolite 4-hydroxycyclophosphamide, 
which is in tautomeric equilibrium with aldophosphamide. A small proportion of 
aldophosphamide spontaneously decomposes to the genotoxic and carcinogenic 
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metabolite phosphoramide mustard and the toxic byproduct acrolein (Hales 1982; 
Kern and Kehrer 2002; King and Perry 2001). As shown here, analysis of the hepatic 
gene expression profiles of mice exposed to CP during the day or during the 
night revealed a remarkable time of day of exposure difference in the magnitude 
of the response. These results highlight the involvement of the circadian clock in 
genotoxic stress responses and indicate the importance to consider the circadian 
system when performing toxicological risk analyses studies. 
Methods
Animal experiments
Three-week-old male C57BL/6 mice were purchased from Harlan Laboratories 
(Horst, The Netherlands) and housed at the animal facilities of the National 
Institute for Public Health and the Environment (RIVM). Animals were kept under a 
regular 12-hr light: 12-hr dark cycle and food and water were provided ad libitum. 
All animal experiments were conducted in in accordance with national legislation 
and were approved by a local ethical committee on experimental animals.
For the microarray study, 8-week-old mice received a single i.p. injection of either 
300 mg/kg cyclophosphamide (CP, CAS 6055-19-2, Sigma-Aldrich) or the vehicle 
(PBS) at two different Zeitgeber times, ZT8 and ZT20 (ZT0 = lights on). Animals 
(n=4 per time point) were sacrificed by cervical dislocation at 0.5, 1, 2 and 4 hours 
after CP injection (T0.5, T1, T2 and T4), and at 0 and 4 hours after vehicle injection 
(C0 and C4). The left lobe of the liver was isolated and stored using RNAlater 
(Invitrogen, Grand Island, NY, USA) according to the manufacturer’s protocol. 
For the acute toxicity experiment, three dose groups were used: 30, 100 and 300 
mg/kg CP. Eight-week-old mice (n=5 per group) received a single i.p. injection of 
CP or the vehicle (PBS) at ZT8 or ZT20 and were sacrificed by orbital bleeding under 
Ketamine/Xylazine anesthesia at 24 hours and 72 hours after exposure. Blood was 
collected in both EDTA and gel collection tubes. Bone marrow was aspirated from 
femur bones. The left lobe of the liver and the kidneys were removed and collected 
in formalin. 
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Microarray analysis
RNA was extracted from all liver samples using the miRNeasy Mini Kit (Qiagen 
Benelux, Venlo, The Netherlands). RNA concentrations were measured using a 
NanoDrop ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, 
DE, USA), and RNA quality was assessed with an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Amstelveen, the Netherlands). 
RNA was hybridized to Affymetrix HT Mouse Genome 430 PM Array plates 
(Affymetrix Inc., Santa Clara, CA, USA) at the Microarray Department of the University 
of Amsterdam, the Netherlands. In short, labeled cRNA samples were prepared 
with the GeneChip 3” IVT express kit (Affymetrix) as described in the Affymetrix 
GeneChip HT 3” IVT Express Technical Manual (Affymetrix), using 200 ng of purified 
total RNA as template for the reaction. The array images were acquired using a 
GeneChip HT Array Plate Scanner (Affymetrix) and analyzed with Affymetrix HT 
software suite including expression console software (Affymetrix).
Data analysis
The raw data were subjected to a set of quality control checks. This quality check 
excluded the presence of significant hybridization and experimental blocking 
effects. All arrays passed quality control and were annotated according to de 
Leeuw et al. (de Leeuw et al. 2008) and expression values were calculated using the 
robust multi-array average (RMA) algorithm (Affy package, version 1.22.0; (Irizarry 
et al. 2003)), available from the Bioconductor project (http://www.bioconductor.
org) for the R statistical language (http://cran.r-project.org). After normalization, 
35,225 transcripts were used for Principal Component Analysis (PCA; produced in 
R, version 2.13.1), including non-annotated transcripts and without cut-off for fold 
change. All 35,225 transcripts were statistically analyzed for differential expression 
using a mixed linear model with coefficients for each experimental group (Smyth 
2004; Wolfinger et al. 2001). For each regime, a contrast analysis was applied to 
compare each exposure time point with the vehicle control time point C0, and 
to compare exposure time point T4 with the time-matched vehicle control C4. 
For hypothesis testing, a permutation-based Fs test was used (Cui et al. 2005). 
False discovery rate (FDR) correction per contrast was performed according to 
Storey and Tibshirani (Storey and Tibshirani 2003), with an FDR<0.05 considered 
as statistically significant. The gene expression results have been deposited in 
the National Center for Biotechnology Information Gene Expression Omnibus 
(Accession No. GSE46035).
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Enrichment of selected gene lists was analyzed with MetaCore Pathway Maps from 
GeneGo, Inc. (http://www.genego.com/). Gene expression data were imported 
into Metacore using their NCBI Entrez GeneID as identifier; therefore, only genes 
annotated with a GeneID in the current NCBI database were used for pathway 
enrichment analysis. Pathways were considered significantly enriched with an 
FDR<0.01. Gene Set Enrichment Analysis allowed us to identify significant up- or 
downregulation of enriched gene sets (P<0.05 and FDR<0.25) (Mootha et al. 2003; 
Subramanian et al. 2005). 
Histology, blood and bone marrow analysis
Paraffin-embedded, formalin fixed liver and kidney sections were stained 
with Hematoxylin and Eosin (H&E) for histopathological evaluation. Aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) levels were determined 
with an auto-analyzer (Cobas Fara, Roche Diagnostics, Woerden, the Netherlands), 
using dedicated kits from Roche Diagnostics. EDTA blood and bone marrow cells, 
aspirated from femur bones with impulse cytophotometer solution (composed 
as described previously in (Tonk et al. 2010)), were analyzed automatically using 
the ADVIA 2120 (Siemens, Deerfield, USA). Bone marrow cytospin slides (Shandon 
Cytospin 2, Thermo Fisher Scientific, Waltham, USA) were fixed with methanol, 
stained according to May Grunwald and Giemsa and analyzed according to OECD 
Test Guideline 474, Mammalian Erythrocyte Micronucleus Test (OECD). In short, 
2000 polychromatic erythrocytes (PCEs) were scored per animal for the incidence 
of micronucleated PCEs (MNPCEs). To determine myelotoxicity, 500 polychromatic 
and normochromatic cells (NCE) were scored (PCE/NCE ratio).
All parameter values are represented as means ± SD, where appropriate. Statistical 
analyses were performed using GraphPad Prism version 6.02 for Windows, 
(GraphPad Software, La Jolla, California, USA). Comparisons between groups were 
performed with one-way ANOVA or two-way ANOVA followed Dunnet’s test for 
dose groups and Sidak’s test for differences between ZTs. P-values smaller than 
0.05 were considered statistically significant.
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Results
Gene expression analysis - general impression
Male C57BL/6 mice, kept under a 12-hr light/12-hr dark cycle, were exposed to 
cyclophosphamide (CP, 300 mg/kg body weight i.p.) at two different times during 
the day, i.e. ZT8 and ZT20. Zeitgeber Time (ZT) is a standard experimental time 
based on the period of the Zeitgeber, which under aforementioned light regime 
equals a normal 24-hr day, and in which ZT0 represents “lights on” and ZT12 “lights 
off”. At 0.5, 1, 2 and 4 hours after CP treatment (T0.5, T1, T2 and T4), and 0 and 
4 hours after vehicle treatment (C0 and C4), animals were sacrificed and livers 
were collected for gene expression analysis. To obtain a general impression of the 
changes in transcription upon exposure to CP at different times of day, we first 
visualized the overall response using Principal Component Analysis (PCA) (Figure 
1). This analysis revealed two distinct clusters, reflecting exposure at the light (ZT8, 
left half panel) and dark (ZT20, right half panel) phase, with the response becoming 
stronger over time after exposure (C0, T0.5, T1, T2 and T4 top down). In addition, 
differences in gene expression between the various time points appeared to be 
more pronounced after exposure during the light phase (see Figure 1, left panel). 
From these results, especially those for C4-T4, we conclude that time of day of 
exposure has a significant impact on the overall response to CP exposure.
Analysis of differentially expressed genes and pathway enrichment
We subsequently analyzed the gene expression data following a commonly used 
toxicological approach, with ZT8-C0 and ZT20-C0 (time-zero) as the control time 
points. Differences in hepatic gene expression between CP-treated animals and 
the vehicle controls were calculated using a one-way ANOVA with an FDR<0.05. 
This analysis resulted in an increasing number of differentially expressed genes 
(DEGs) over time, with the highest number of DEGs observed 4 hours after 
exposure: 5,837 and 2,942 DEGs (including non-annotated genes) at ZT8-T4 and 
ZT20-T4, respectively (Figure 2). 
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Figure 1. Principal Component Analysis using data of all genes. This analysis revealed two distinct clusters, 
representing the differential response of the genome to cyclophosphamide exposure at different times of 
day, ZT8 (circles) and ZT20 (triangles). The response was stronger over time after exposure (C0 to T4, top 
down); gene expression differences between various time points were more pronounced upon light phase 
exposure (left half panel). Open and closed symbols represent vehicle control and exposed samples, 
respectively.
Figure 2. Differentially expressed genes time-zero analysis. The number of differentially expressed genes, 
including non-annotated genes (DEGs; FDR<0.05) in the liver of CP-treated animals compared to those of 
vehicle controls obtained at C0. The number of DEGs increases over time, both for animals exposed during 
the light (ZT8, open bars) and the dark phase (ZT20, dashed bars). However, the number of significantly 
regulated genes is two- to four-fold lower upon exposure at ZT20 compared to animals exposed at ZT8.
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Despite identical exposure, two to four times as many DEGs were found when 
animals were exposed at ZT8, as compared to exposure at ZT20. To investigate 
whether the observed differences in the number of significantly regulated genes 
also resulted in a different biological response, enrichment analyses of MetaCore 
Pathways was performed. Gene Set Enrichment Analysis (GSEA) was used to obtain 
an impression of up or down regulation of pathway groups. Since we observed 
the highest number of significantly expressed genes 4 hours after exposure, we 
focused on this time point. For these analyses, 4,089 and 2,084 DEGs (excluding 
non-annotated genes) were used as input for ZT8 and ZT20, respectively. CP 
exposure at ZT8 caused differential regulation of 125 pathways (Supplementary 
Table S1a), most of which are consistent with the known effects of CP: genotoxicity, 
oxidative stress, and immune modulation (Hussain et al. 2013; Rehman et al. 
2012; Tripathi and Jena 2008). We found induction of the ATM/ATR pathway and 
downregulation of pathways involved in cell cycle regulation, which are typically 
associated with a DNA damage response invoked by the alkylating properties 
of CP. Besides DNA damage, CP clearly induced oxidative stress as identified by 
the overrepresentation and upregulation of intracellular signaling cascades such 
as NF-ƙB, JAK/STAT, AKT/PI3K and MAPK pathways, all known to be activated 
by oxidative stress. In addition, cell adhesion and cytoskeleton pathways were 
enriched, probably in response to oxidative stress induced protein degradation. 
The liver is predominantly an organ of innate immunity, favoring a general defense 
response to stressors. Induction of several cytokine pathways, such as IL-1 and IL-6, 
is indicative of this general immune or stress response. This response is most likely 
coming from liver sinusoidal endothelial cells (LSEC) and Kupffer cells, which are 
known to be more sensitive to CP than hepatocytes (DeLeve 1996).
Exposure at ZT20 resulted in a far lower number of significantly responding 
pathways (i.e. 52 versus 125, see Supplementary Table S1b), which nonetheless 
share a strong overall similarity to those observed upon exposure at ZT8. 
Apparently, the response of the hepatic transcriptome is markedly weaker after 
CP treatment at ZT20. Interestingly, a DNA damage response, clearly visible at ZT8, 
was not significantly activated at ZT20 when using significantly regulated genes as 
input (Supplementary Table S1b). The observed differences in pathway regulation 
between the two time points may be due to the difference in number of genes 
used as input for the enrichment analyses. We therefore matched the number of 
input genes for ZT20 with ZT8, and used the top 4,089 genes (ranked according 
40036 Dycke, Kirsten.indd   166 11-04-16   11:02
Time of day effect of CP
167
A1
to FDR). This more balanced approach not only yielded an increased number of 
pathways (from 52 up to 188), but, more importantly, also revealed a pattern of 
responsive pathways that is similar to the one observed for ZT8 (Supplementary 
Table S1c and S1a, respectively). Overall, for both time points, the DNA damage, 
oxidative stress and immune response as described above could be identified 
using this approach. Taken together, these pathway analyses suggest that the 
response to CP exposure at ZT20 is comparable to the response observed at ZT8, 
but that the effects in terms of gene expression changes are much stronger at ZT8.
Time-matched analysis of differentially expressed genes and pathway 
enrichment
As evident from the PCA plot (Figure 1), the factor time of day of exposure resulted 
in a distinct expression profile, since the profiles of the control group at time point 
t=0 hours (C0) were markedly different from those at time point t=4 hours (C4), 
both for ZT8 and ZT20. This indicates that also in non-exposed animals gene 
expression patterns change over time, which is likely attributed to circadian clock 
progression. Accordingly, the commonly time-zero analysis (as presented in the 
previous section) identifies a mixture of (i) circadian clock controlled genes, (ii) 
CP responsive genes, and (iii) expression of circadian genes influenced by CP 
exposure. To take into account the circadian regulation of gene expression, we 
repeated the aforementioned analyses with time-matched controls, 4 hours after 
exposure (C4). As expected, this time-matched analysis resulted in a lower number 
of DEGs for both ZT8 and ZT20, due to exclusion of genes that are under control 
of the circadian clock and do not respond to CP. We cross-referenced DEGs for 
time-zero analysis and time-matched analysis with clock controlled genes from 5 
different literature data sets (Akhtar et al. 2002; Hughes et al. 2010; Miller et al. 2007; 
Panda et al. 2002; Ueda et al. 2002). A loss of circadian regulated genes using the 
time-matched analysis was observed. Remaining differentially expressed genes 
are a mixture of CP responsive genes and circadian genes affected by CP exposure 
The number of DEGS, however, remained higher at ZT8 than at ZT20, i.e. 2,015 
versus 179 DEGs (including non-annotated genes) (Supplementary Figure S1). 
To illustrate the effect of time-matched analysis in comparison to the time-
zero analysis, we examined the cytochrome P450 genes involved in the 
biotransformation of CP (Cyp2b10, Cyp2c29, and Cyp3a13; the mouse homologues 
of human CYP2B6, CYP2C9 and CYP3A4/5, respectively). Although, these genes 
40036 Dycke, Kirsten.indd   167 11-04-16   11:02
Appendix 1
168
 
Figure 3. Cytochrome P450 gene expression upon CP exposure. Expression of cytochrome P450 genes 
encoding enzymes involved in the metabolism of CP (Cyp2b10, Cyp2c29, and Cyp3a13; the mouse 
homologues of CYP2B6, CYP2C9 and CYP3A4/5, respectively) A. Fold Ratio (FR) of liver gene expression in CP-
treated animals compared to that of vehicle control animals obtained at C0. All genes showed a time-
dependent response to CP treatment from 0.5 until 4 hours after exposure. However, the magnitude of the 
response differed between light phase (ZT8) and dark phase exposure (ZT20). B. FR of liver gene expression 
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of CP-treated animals 4 hours after exposure compared to time-matched vehicle controls obtained at C4. 
Only a marginal difference in Cyp2c29 gene expression induction seemed to be caused by time of day of 
exposure. Cyp2b10 and Cyp3a13 show no difference in gene expression between circadian phases upon CP 
exposure.
were significantly induced at both ZT8 and ZT20 when using time-zero controls, 
fold ratios (induction) clearly differed between ZT8 and ZT20 exposure (Figure 3A). 
However, time-matched analysis of the expression levels of these CP metabolizing 
cytochrome P450 genes revealed that induction levels were comparable at both 
circadian phases (Figure 3B). Other examples of genes for which a time-matched 
analysis affects fold ratio differences between ZT8 and ZT20 exposed animals, in 
comparison to time-zero analyses are shown in Supplementary Figure S2.
Analyses directed towards functional enrichment showed 79 significantly 
responsive pathways for treatment at ZT8 (1,353 annotated genes, FDR<0.01 for 
significant pathways; Supplementary Table S2a), of which 51 overlapped with 
those found at this treatment time in the previous C0 control based pathway 
analysis. The observed 79 pathways included pathways involved in DNA damage 
response, as well as oxidative stress related pathways such as NF-ƙB and MAPK 
signaling. However, cell adhesion and cytoskeleton remodeling pathways 
associated with oxidative stress induced protein damage were not as pronounced 
as compared to the analysis using C0 as a control. On the other hand, immune 
related pathways showed a comparable induction as previously found. We did not 
find any functional enrichment at ZT20, owing to the low number of input genes, 
i.e. 112 annotated genes. Use of an equal number (top 1,353; ranked according 
to FDR) of input genes resulted in only eight significantly enriched pathways 
that, not surprisingly, only marginally reflect a response typical for CP exposure 
(Supplementary Table S2c).
Thus, the use of time-matched controls uncovered marked differences in the 
transcriptomic response of the liver when exposed at ZT20 and ZT8. Exposure at 
ZT8 induced an unambiguous CP response, whereas the known CP effects could 
hardly be detected after exposure at ZT20.
Time-zero versus time-matched analysis of pathway enrichment
The pathway analyses described in the previous sections, using either time-zero 
(C0) or time-matched (C4) controls, were performed with a different number of 
input genes, which hampers a direct comparison of their effect. We therefore re-
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analyzed enrichment of responsive biological pathways for the time-zero data set, 
using the same number of input genes as used for the time-matched analysis. 
Using the top 1,353 annotated genes, we still noticed a strong CP mediated toxic 
response after treatment at ZT8, as evident from the enrichment in DNA damage, 
oxidative stress and immune responsive pathways, while such response now 
appeared virtually absent when mice were treated at ZT20 (Supplementary Table 
S3a and S3b, respectively). A comparison of the number of significantly enriched 
MetaCore Pathways Maps, grouped per biological theme (Table 1) reveals that a 
reduced number of input genes for the time zero analysis results in a differential 
response at ZT8 and ZT20 that matches well with that observed when time-
matched controls are used. Taken together, our study, especially our time-matched 
analysis, has shown that although CP exposure induces cytochrome P450 gene 
expression equally at ZT8 and ZT20, a robust transcriptional response of the liver 
is only visible at ZT8.
Table 1. Summary of MetaCore Pathway Maps enrichment 
 C0 controls C4 controls
ZT8 ZT20 ZT8 ZT20
Oxidative stress response 36 6 35 2
Immune response 17 1 20 0
DNA damage response 14 0 14 4
Other 2 0 0 2
Number of significantly enriched MetaCore Pathways Maps, grouped per biological 
theme. Top 1,353 genes (ranked based on FDR) were used as input for this analysis. 
Unless stated otherwise, pathways were grouped based on the main MetaCore 
Pathway biological function groups (Supplementary Tables S1b and S1c). 
Acute toxicity effects
To correlate the observed changes in gene expression to more traditional 
toxicological endpoints, we conducted an acute toxicity experiment with a similar 
study design as used for the transcriptomics study. Animals were exposed to a 
single dose of 0, 30, 100 or 300 mg/kg CP at ZT8 or ZT20 and sacrificed 24 and 72 
hours after treatment. Body and organ weights were collected, and white blood 
cell (WBC) counts and micronuclei formation were determined. In addition, we 
performed a histopathological analysis of the liver and kidneys. Adverse effects of 
CP became apparent by body weight loss at the highest doses of CP, irrespective 
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of whether animals were treated at ZT8 or ZT20 (Supplementary Figure S3). We 
also observed a slight, dose dependent decrease in kidney weight at 72 hours 
after exposure in the ZT8 group, whereas no such effect was seen in the ZT20 
group (Supplementary Figure S4). Histopathology of the kidney, however, did not 
reveal any abnormalities in both groups. Likewise, we did not find any effect of 
CP exposure on the liver for all parameters examined. Liver weight loss was not 
observed (Supplementary Figure S5), and analysis of histopathology and serum 
levels of the toxicity serum marker enzymes ALT and AST did not reveal any 
abnormalities (data not shown). 
However, CP exposure at ZT8 and at ZT20 resulted in a dose dependent decrease 
in the overall number of white blood cells (Supplementary Table S4). This is largely 
accounted for by a loss of lymphocytes, which showed a very similar response 
(Figure 4). Exposure to a low dose of CP at ZT8 caused a significantly stronger 
reduction in the number of lymphocytes after 24 hours than exposure at ZT20. 
This effect however was no longer observed 72 hours after exposure. In bone 
marrow, CP exposure resulted in a dose dependent induction of micronucleated 
polychromatic erythrocytes (MNPCEs), a well-accepted parameter for genotoxicity, 
except for the highest dose group (Supplementary Figure S6). Lack of micronuclei 
formation at this dose is most likely due to myelotoxicity as indicated by the 
decreased PCE/NCE ratio (Supplementary Figure S6). Despite the clear effect of 
CP exposure on micronuclei formation, we did not find a difference in micronuclei 
induction between the two ZT groups. 
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Figure 4. Lymphocyte counts in peripheral blood of CP exposed mice. Lymphocyte counts were measured 
24 and 72 hours after exposure. Counts are depicted relative to vehicle controls per circadian phase, values 
represent mean ± sd. Exposure to 30 mg/kg CP at ZT8 significantly more reduced the number of lymphocytes 
at 24 hours than in the ZT20 exposed animal (Sidak's multiple comparisons test, P<0.05). 
Discussion
In toxicogenomic studies time of day of exposure of an animal to a (geno)toxic 
chemical is usually not taken into account. However, it has become evidently clear 
that the time of day of exposure can markedly influence the magnitude of the 
biological response, which is referred to as chronotoxicity (Levi et al. 2010; Levi 
and Schibler 2007), and which can be expected to translate into pronounced 
differences in the outcome of transcriptomics experiments (Destici et al. 2009). 
Likewise, with 10% of the active genes in a tissue being controlled by the clock, 
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one can envisage that the choice of the control time point (i.e. a time-zero control, 
taken at the start of exposure, or a time-matched control, taken when the animal 
is sacrificed) can be of influence. In the current study, we addressed the impact of 
the circadian clock on toxicogenomics experiments by exposing mice to a single 
dose of cyclophosphamide (CP) at defined time-points during the day (ZT8) and 
night (ZT20) and analyzing the response of the liver transcriptome. 
Initially, following a commonly used toxicological approach that uses the zero 
time points as a control, we observed a more than two-fold stronger response of 
the liver transcriptome at ZT8 compared to ZT20, as evident from the number of 
significantly differentially expressed genes (5,837 versus 2,942 DEGs). Subsequent 
pathway analysis with the top 4,098 annotated genes revealed common CP 
toxicity associated responses (i.e. DNA damage response, oxidative stress and 
immune related pathways (Hussain et al. 2013; Rehman et al. 2012; Tripathi and 
Jena 2008)), independent of the time of exposure. As expected, when repeating 
the analysis using time-matched controls, we observed an overall reduction of the 
number of differentially expressed genes at both ZT8 (from 5,837 to 2,015 DEGs) 
and ZT20 (from 2,942 to 179 DEGs), partially because we filtered out the clock-
controlled, CP non-responsive DEGs. Strikingly, this approach uncovered a massive 
impact of time of day effect of CP exposure on the hepatic transcriptome, being 
10-fold more responsive at ZT8 than at ZT20 (2,015 versus 179 DEGs). Moreover, 
after subjecting the top 1,353 annotated genes to pathway enrichment analysis, 
the DNA damage, immune and oxidative stress responses, remained clearly 
visible at ZT8, but were markedly less intense (DNA damage response), or virtually 
absent (immune and oxidative stress response) at ZT20. Apparently, when time-
matched controls are omitted, circadian clock progression during the experiment 
can partially blur the outcome of these experiments when DEGs are applied for 
functional analysis. However, the identified responsive pathways using an equal 
number of input genes as shown in Table 1 clearly show that the difference in liver 
responsiveness to CP can be identified using C0 and C4 controls. 
Our transcriptomics data point towards an increased responsiveness of the liver 
to CP exclusively during the light phase. Upon exposure at ZT8, we observed a 
marked induction of CP toxicity related pathways, whereas virtually no such 
pathways were found for animals exposed at ZT20. Thus, the challenging question 
arises which (clock-controlled) mechanisms are underlying this day and night 
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difference in CP sensitivity. We have shown that CP exposure at ZT8 or ZT20 results 
in a comparable upregulation of Cyp2b10, Cyp3a13 and Cyp2c29 expression, which 
implies that the rate of CP metabolization does not depend on the time of drug 
administration. Indeed, a pharmacokinetics study of Gorbacheva and coworkers 
has shown that the formation and clearance of CP metabolites does not show 
time of day dependency [38]. Accordingly, the presence and absence of a CP-
mediated toxic response at ZT8 and ZT20, respectively, is unlikely to originate from 
differences in the induction of DNA damage and rather relates to a differential 
magnitude of downstream events such as DNA damage signaling, DNA repair and 
apoptosis.
It has been suggested that all aspects of the cellular response to DNA damage are 
controlled or influenced by the circadian clock (Sancar et al. 2010). The CLOCK/
BMAL1 complex positively regulates the expression of the p21 gene, which plays 
a critical role in the G1/S checkpoint (Grechez-Cassiau et al. 2008) as well as the 
p53 gene, involved in DNA damage initiated or intrinsic apoptosis pathways 
(Mullenders et al. 2009). Both p21 and p53 show low expression at the light dark 
transition in the Mouse1.OST dataset of the CircaDB database (http://circadb.org) 
(Pizarro et al. 2013). As Bmal1 gene expression is also at its lowest around ZT12, it 
is tempting to speculate that this implies low expression of CLOCK/BMAL1 target 
genes at ZT8, which in turn results in a greater dynamic range for the CP response. 
This would fit with the observation that circadian clock deficient Cry1/Cry2 double 
knockout mice (constitutive high expression of E-box genes) are more tolerant to 
CP, while Clock mutant and Bmal1 knockout mice (constitutive low expression of 
E-box genes) appear to be more sensitive (Gorbacheva et al. 2005). 
Various animal studies have demonstrated that the time of administration can 
cause changes in the biological outcome upon exposure to CP and some other 
chemotherapeutic agents (Blumenthal et al. 2001; Gorbacheva et al. 2005; Granda 
et al. 2001; Ohdo 2010). Compounds like celocoxib, doxorubicin and docetaxel were 
best tolerated during the light phase, around ZT7 (Blumenthal et al. 2001; Granda 
et al. 2001). Also for CP, wild type mice seemed to be more tolerant when exposed 
at the end of the light phase (i.e. ZT10-ZT14) than when exposed at the end of the 
dark phase (i.e. ZT18-ZT2), as demonstrated by a higher mortality rate (Gorbacheva 
et al. 2005). Remarkably, our transcriptomics data contrast these survival data in 
that the liver appears more sensitive to CP during the light phase. Upon exposure 
at ZT8, we observed activation of CP toxicity related pathways, whereas virtually no 
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such pathways were induced in the liver of animals exposed during the dark phase 
(ZT20). This increase in sensitivity is supported by the slightly lower lymphocyte 
counts in ZT8 exposed animals as compared to ZT20 exposed animals. In contrast, 
the increased responsiveness of hepatic gene expression could be an enhanced 
adaptive response to CP induced toxicity. As a result, ZT8 exposed animals are 
better primed to CP exposure. Using gene-expression, we cannot differentiate 
between increased sensitivity or enhanced adaptive response. Although we used 
the same mouse strain, a major difference between our study and the study by 
Gorbacheva and co-workers is the number of doses used. We employed a single 
dose, whereas studies by Gorbacheva et al. were done using multiple doses of CP. 
In addition, the time points used for the resting and the active phase were slightly 
different: we used ZT8/ZT20 instead of ZT10-14/ZT22-2 as used by Gorbacheva, 
respectively.
Despite the substantial changes in hepatic gene expression, we did not observe 
pathological changes in the liver of CP exposed mice. CP exposure has been 
reported to change the ultrastructural organization of the hepatocytes and SECs 
(Lushnikova et al. 2011). Probably, a single dose is not able to induce pathological 
changes or, alternatively, these changes only may become apparent at later 
time points. C57Bl6 mice have been reported to be less sensitive to CP-induced 
hepatoxicity than other mouse strains (Anton 1993). Other parameters, however, 
such as body weight, kidneys weights, white blood cell counts (WBC) and 
micronuclei induction were affected by CP exposure. CP is well-known for its toxic 
effects, including immunosuppression and DNA damage induction (Emadi et al. 
2009), as also uncovered by our transcriptomics study. For example, CP has been 
reported to induce toxicity to B lymphocytes (Colvin 1999). Although in our study 
lymphocytes were not differentiated, the decrease in WBC could be contributed 
to the decrease in all lymphocytes. Overall, ZT8 exposed mice appeared to be 
somewhat more sensitive than ZT20 animals. These findings indicate that gene 
expression, in comparison to more traditional toxicity parameters, is more sensitive 
to time of day effects. Possibly, the observed differences in transcription do become 
apparent in apical end points at later time points.
In conclusion, this study highlights the importance of time of day in toxicity 
testing, especially in toxicogenomics studies. To our knowledge, exposures in in 
vivo rodent studies occur mainly during the day, which is comparable with ZT8 
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exposure in our study. For risk-assessment purposes, it is of the utmost importance 
to evaluate the worst-case scenario when estimating the risk of adverse health 
effects induced by environmental chemicals. For assessment of CP toxicity in mice, 
this seems to be exposure during the day. Whether ZT8 is the most sensitive time 
point, and whether this sensitivity to toxic effects of chemicals is higher in mice 
during the light phase in general, warrants further investigation. From a regulatory 
point of view, it would also be worthwhile to examine possible effects of the 
circadian clock on the outcome of in vitro toxicity tests. Furthermore, circadian 
sensitivity to pharmaceuticals might also be beneficial when used in a clinical 
setting, to minimize adverse effects and maximize efficacy, as has been shown for 
certain anti-cancer drugs (Levi et al. 2011). Thus, considering the circadian clock in 
toxicity testing might eventually lead to improved risk assessment and a more safe 
use of chemical substances, as well as to improved medicine use. 
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Figure S1. For the cross-sectional study (a) the differences in body weight increase between the groups was 
not significant (RM-ANOVA, group: F(1, 40) = 2.255, p=0.1410; time: F(17, 680) = 53.74, p<0.0001; interaction: 
F(17, 680) = 1.046, p=0.4049). The body weight gain is expressed relative to the body weights of animals at 
the start of the experiment (mean + SEM). (b) Food intake was slightly, but significantly (Two-way ANOVA, 
group: F(7, 108) = 0.4663, p<0.0001), lower in the animals kept under LD-inversion conditions (open bars) 
compared to the LD controls (closed bars) (*Sidak’s posttest p<0.05).
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Figure S2. Left and right panels show sleep timing for LD controls at different days of the week and animals 
exposed to LD-inversions at different days after an LD-inversion, for light and dark phase, respectively. Day 0 
corresponds to the day the light schedule inverses and day 1-6 indicate the number of days after the 
inversion. The timing of sleep continuously changes due to the alternating light schedule. Sleep in light 
instantly decreases at the day of the shift and subsequently increases the following days. Sleep in dark shows 
an inverse pattern. For separate analyses of the recorded weeks, see Figure S3a and Figure S3b.
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Figure S4. Hypotheses linking shift work with cancer (adapted from Fritschi et al., 2011). The present study 
underlines the importance of internal desynchronisation, sleep disruption and timing of food intake in the 
relationship between shift work and adverse health effects, especially breast cancer and obesity. Melatonin 
suppression and decreased vitamin D by less sunshine exposure were excluded in our model. 
Table S1. Pathology data
Tumor spectra
LD LD-inversions
Total number of mice analyzed 20 21
Tumor-bearing mice 20 21
Mammary gland tumor-bearing mice 16 16
Mammary gland tumor# 18 17
Carcinoma 5 1
Fibrosarcoma/Carcinosarcoma 12 15
Intraepithelial neoplasia 1 1
Mammary gland hyperplasia - 2
Lymphosarcoma 3 5
Other tumors 5 7
#Total number of mammary gland tumors per group, multiple tumors were found in some animals.
Supplemental data Chapter 3
The supplemental data of chapter 3 comprise three tables that are too extensive 
to be added in print. These tables are publically available via: http://onlinelibrary.
wiley.com/doi/10.1002/pmic.201100497/abstract
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Supporting Information Figure S1. Schematic overview of the experimental set up and time of sample 
collection. White areas indicate lights on, grey areas indicate lights off.
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Supporting Information Figure S2. Venn-diagram of selected hepatic gene expression biomarkers using 
the three classifier algorithms. The consensus gene set consists of the 15 genes overlapping between the 
three algorithms.
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Supporting Information Table S1. Results of prediction of the three classifier algorithms, using the 
consensus gene set (A-C). A summary of the prediction accuracy and other prediction parameters is shown 
in (D). 
A. SVM
Non-CRD CRD
Experiment Non-CRD 23 1 24
CRD 0 24 24
23 25
B. PAM-R
Non-CRD CRD
Experiment Non-CRD 21 3 24
CRD 0 24 24
21 27
C. RF
Non-CRD CRD
Experiment Non-CRD 21 3 24
CRD 2 22 24
23 25
D. SVM PAM-R RF
Accuracy 97.9% 93.6% 89.6%
Sensitivity 100% 100% 91.7%
Specificity 95.8% 87.5% 87.5%
Positive predictive value 96.0% 88.9% 88.0%
Negative predictive value 100% 100% 91.3%
Supporting Information Table S2. Ability of the consensus gene set to correctly classify phase-shifted 
animals as CRD after one shift, six shifts or five days recovery using the three classifier algorithms.
Sensitivity
SVM PAM-R RF
1 shift 33.3% 29.2% 29.2%
6 shifts 87.5% 91.7% 83.3%
5 days recovery 83.3% 87.5% 75.0%
Supporting Information Table S3. Sequential approach gene selection.
Supplemental Table S3 is too extensive to be added in print. This table is publically 
available via: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436131/
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Supplementary Table S1. Participant characteristics. Age is provided in years (y), weight in kilograms (kg), 
waist circumference in centimeters (cm), total sleep duration between the first sampling time at 08:00 AM 
and the last sampling time at 04:00 AM in hours (hr), sleep timing of sleep episodes between the first 
sampling time at 08:00 AM and the last sampling time at 04:00 AM provided in clock time (CT).
Participant Gender Age (y) Weight 
(kg)
Waist 
circumference 
(cm)
Total sleep 
duration (hr) 
between  
08:00 and 04:00
Sleep timing (CT) 
between 08:00 and 
04:00
F1 f 22 85 80 1.25 02:00-03:15
F2 f 22 52 68 5.42 13:30-14:30, 22:00-23:30, 
00:45-3:40
F3 f 22 50 83 3.00 00:15-03:15
F4 f 22 49 69 3.00 00:15-03:15
F5 f 22 48 67 3.00 00:15-03:15
F6 f 22 50 69 3.00 00:15-03:15
F7 f 21 59 75 6.50 09:00-10:00, 17:00-19:00, 
00:15-03:45
F8 f 21 55 77 4.75 16:15-18:00, 00:15-03:15
F9 f 21 82 93 0.00 none
F10 f 22 55 74 2.50 00:30-03:00
M1 m 41 105 123 4.00 14:00:15:30, 00:30-03:00
M2 m 24 100 110 3.00 00:30-03:30
M3 m 23 72 86 2.00 01:00-03:00
M4 m 21 70 83 5.00 20:30-23:30, 01:00-03:00
M5 m 21 88 85 3.00 00:15-03:15
M6 m 23 79 79 3.33 00:30-03:50
M7 m 21 75 90 3.67 00:10-03:50
Females
Mean 21.70 58.50 75.50 3.24
SD 0.48 13.61 8.17 1.91
Males
Mean 24.86 84.14 93.71 3.43
SD 7.22 13.90 16.35 0.94
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Supplementary Table S2. Overview of methods used to determine parameters in plasma and serum. The 
intra assay variation (CV) was determined with three quality control samples (N=8) for the markers as 
determined on the auto-analyzer and with two quality control samples (N=5) for markers as measured on 
the immune-analyzer. The CVs of markers measured with the Luminex technique were obtained from the 
manufacturer.
Technique CV Source
ACTH Luminex (Millipore) 10.8 Plasma
CORT Immune-analyzer (Access-2, Beckman-Coulter) 6.2  Serum
DHEAS Immune-analyzer (Access-2, Beckman-Coulter) 3.9 Serum
E2 Immune-analyzer (Access-2, Beckman-Coulter) 6.3 Serum
FSH Luminex (Millipore) 7.2 Plasma
hGH Immune-analyzer (Access-2, Beckman-Coulter) 2.3 Serum
LH Luminex (Millipore) 6.3 Plasma
PRL Immune-analyzer (Access-2, Beckman-Coulter) 1.8  Serum
PRG Immune-analyzer (Access-2, Beckman-Coulter) 10.8 Serum
TEST Immune-analyzer (Access-2, Beckman-Coulter) 1.4 Serum
TotT3 Immune-analyzer (Access-2, Beckman-Coulter) 4.2 Serum
TSH Immune-analyzer (Access-2, Beckman-Coulter) 1.4 Serum
FFA Auto-analyzer (Unicel DxC 800, Beckman-Coulter) 4.4 Plasma
HDL Auto-analyzer (Unicel DxC 800, Beckman-Coulter) 4.0 Plasma
LDL Auto-analyzer (Unicel DxC 800, Beckman-Coulter) 7.2 Plasma
TG Auto-analyzer (Unicel DxC 800, Beckman-Coulter) 4.3 Plasma
CHOL Auto-analyzer (Unicel DxC 800, Beckman-Coulter) 4.5 Plasma
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Supplementary Table S3. Overview of hormonal parameters in serum or plasma for A. CircWave analysis of 
circadian rhythms; B. Repeated-Measures ANOVA to determine daily variation. Amplitude is presented as the 
% of the median. Ct = Clock time. 
A. Circwave analysis
males females
Markers p-value peak (CT) amplitude p-value peak (CT) amplitude
ACTH 0.219 17:54 6.12% 0.714 17:22 3.71%
CORT 0.000 07:47 129.11% 0.000 07:29 161.63%
DHEAS 0.861 20:13 21.89% 0.571 18:23 21.36%
E2 0.306 06:51 24.66% 0.685 05:52 25.11%
FSH 0.964 02:03 40.47% 0.741 18:41 31.20%
hGH 0.895 04:13 581.23% 0.953 11:31 397.11%
LH 0.391 00:36 59.22% 0.968 07:15 45.25%
PRL 0.194 04:55 49.11% 0.081 06:20 97.09%
PRG 0.003 07:52 117.78% 0.870 06:17 44.70%
TEST 0.055 07:33 38.38% 0.282 07:38 22.75%
TotT3 0.025 06:18 10.14% 0.041 07:04 8.08%
TSH 0.001 01:54 75.89% 0.006 03:22 74.26%
B. RM-ANOVA all time points
males females
Markers p-value F-value p-value F-value
ACTH 0.288 F (2.277, 13.66) = 1.375 0.215 F (3.037, 27.33) = 1.775
CORT 0.003 F (2.611, 15.67) = 7.614 0.000 F (3.466, 31.19) = 20.56
DHEAS 0.045 F (2.389, 14.33) = 3.694 0.002 F (2.943, 26.49) = 6.530
E2 0.438 F (2.760, 16.56) = 0.938 0.154 F (3.873, 34.85) = 1.792
FSH 0.517 F (1.990, 11.94) = 0.695 0.512 F (2.079, 18.71) = 0.687
hGH 0.184 F (1.465, 8.792) = 2.091 0.459 F (2.243, 20.18) = 0.838
LH 0.198 F (2.794, 16.76) = 1.746 0.061 F (3.491, 31.42) = 2.617
PRL 0.014 F (2.715, 16.29) = 4.984 0.118 F (1.865, 16.79) = 2.461
PRG 0.020 F (2.310, 13.86) = 4.974 0.272 F (2.204, 19.84) = 1.395
TEST 0.021 F (2.945, 17.67) = 4.221 0.023 F (2.760, 24.84) = 3.922
TotT3 0.032 F (2.461, 14.77) = 4.078 0.078 F (2.896, 26.06) = 2.570
TSH 0.037 F (1.266, 7.596) = 5.991 0.008 F (1.700, 15.30) = 7.305
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Supplementary Table S4. Overview of lipid parameters in serum or plasma for A. CircWave analysis of 
circadian rhythms; B. Repeated-Measures ANOVA to determine daily variation. Amplitude is presented as the 
% of the median. Ct = Clock time.
A. Circwave analysis
males females
Markers p-value peak (CT) amplitude p-value peak (CT) amplitude
FFA 0.012 08:31 74.91% 0.36 06:56 80.70%
HDL 0.695 07:38 9.20% 0.97 07:30 3.86%
LDL 0.818 08:07 12.02% 0.96 08:46 8.35%
TG 0.105 13:46 70.36% 0.05 14:13 50.33%
CHOL 0.645 08:47 11.44% 0.83 08:57 8.17%
B. RM-ANOVA all time points
males females
Markers p-value F-value p-value F-value
FFA 0.069 F (2.442, 14.65) = 3.078 0.221 F (2.638, 23.75) = 1.589
HDL 0.110 F (2.708, 16.25) = 2.399 0.213 F (2.475, 22.28) = 1.641
LDL 0.002 F (2.875, 17.25) = 7.746 0.006 F (2.660, 23.94) = 5.670
TG 0.048 F (1.943, 11.66) = 4.012 0.063 F (2.846, 25.62) = 2.798
CHOL 0.003 F (2.381, 14.29) = 8.618 0.003 F (2.938, 26.44) = 6.020
Supplementary Table S5. CircWave analysis of circadian rhythms classical circadian markers in serum 
(CORT) or PBMCs (PER1, BMAL1). Amplitude is presented as the % of the median. Ct = Clock time.
Circwave analysis
males females
Markers p-value peak (CT) amplitude p-value peak (CT) amplitude
CORT 0.000 07:47 129.11% 0.000 07:29 161.63%
PER1 0.002 08:07 80.15 %
BMAL1 0.035 14:12 35.55 %
Supporting information S6. Raw data files of data presented in this study.
Supporting information S6 is too extensive to be added in print. This table is 
publically available via: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540433/
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Supplemental data Chapter 6
Supplemental Table S1. Genes oscillating under both LD and CRD conditions
Symbol
Gm13889
Ypel2
Chka
Nedd4l
Asap2
Dbp
Dnmt3b
Mif4gd
1110067D22Rik
Arntl
Clpx
Rorc
Per3
St5
A530001N23Rik
Fgfr4
Wdr91
Larp1
Dnajb11
Gramd4
Slc45a3
Tenc1
Hsd17b7
Nr1d2
D7Wsu130e
Prkd3
Gm129
9830001H06Rik
Pdcd2l
Stx2
Lingo4
Dynll2
Hist1h4i
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Supplemental Table S2. Significantly enriched processes based on 561 genes that lost significant circadian 
rhythmicity after CRD exposure. 
Processes Group
entrainment of circadian clock by photoperiod Circadian rhythm
entrainment of circadian clock Circadian rhythm
photoperiodism Circadian rhythm
circadian regulation of gene expression Circadian rhythm
regulation of circadian rhythm Circadian rhythm
circadian rhythm Circadian rhythm
rhythmic process Circadian rhythm
epithelial cell proliferation involved in mammary gland duct elongation Hormonal regulation
Sertoli cell proliferation Hormonal regulation
mammary gland branching involved in pregnancy Hormonal regulation
branch elongation involved in mammary gland duct branching Hormonal regulation
negative regulation of gonadotropin secretion Hormonal regulation
vagina development Hormonal regulation
branching involved in prostate gland morphogenesis Hormonal regulation
cellular response to follicle-stimulating hormone stimulus Hormonal regulation
Sertoli cell development Hormonal regulation
response to follicle-stimulating hormone Hormonal regulation
androgen metabolic process Hormonal regulation
cellular response to estradiol stimulus Hormonal regulation
Sertoli cell differentiation Hormonal regulation
cellular response to gonadotropin stimulus Hormonal regulation
cellular hormone metabolic process Hormonal regulation
regulation of endocrine process Hormonal regulation
hormone-mediated signaling pathway Hormonal regulation
response to testosterone Hormonal regulation
negative regulation of peptide hormone secretion Hormonal regulation
ovarian follicle development Hormonal regulation
ovulation cycle process Hormonal regulation
negative regulation of hormone secretion Hormonal regulation
ovulation cycle Hormonal regulation
female gonad development Hormonal regulation
hormone metabolic process Hormonal regulation
response to estradiol Hormonal regulation
female sex differentiation Hormonal regulation
development of primary female sexual characteristics Hormonal regulation
regulation of peptide hormone secretion Hormonal regulation
regulation of hormone levels Hormonal regulation
male sex differentiation Hormonal regulation
steroid metabolic process Hormonal regulation
cellular response to hormone stimulus Hormonal regulation
cellular response to peptide hormone stimulus Hormonal regulation
regulation of hormone secretion Hormonal regulation
response to estrogen Hormonal regulation
response to peptide hormone Hormonal regulation
response to steroid hormone Hormonal regulation
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Processes Group
negative regulation of mitosis Cell cycle
negative regulation of nuclear division Cell cycle
DNA damage response, signal transduction by p53 class mediator Cell cycle
transforming growth factor beta receptor signaling pathway Cell cycle
signal transduction in response to DNA damage Cell cycle
regulation of mitosis Cell cycle
cellular response to transforming growth factor beta stimulus Cell cycle
regulation of nuclear division Cell cycle
response to transforming growth factor beta Cell cycle
negative regulation of cell cycle process Cell cycle
regulation of cell division Cell cycle
negative regulation of cell cycle Cell cycle
regulation of mitotic cell cycle Cell cycle
regulation of cell cycle process Cell cycle
mitotic cell cycle process Cell cycle
mitotic cell cycle Cell cycle
negative regulation of cell proliferation Cell cycle
lipid storage Glucose and lipid metabolism
positive regulation of phospholipase activity Glucose and lipid metabolism
regulation of glucose import Glucose and lipid metabolism
positive regulation of glucose import Glucose and lipid metabolism
regulation of glycogen metabolic process Glucose and lipid metabolism
positive regulation of lipase activity Glucose and lipid metabolism
regulation of phospholipase activity Glucose and lipid metabolism
positive regulation of glucose transport Glucose and lipid metabolism
negative regulation of insulin secretion Glucose and lipid metabolism
regulation of glucose transport Glucose and lipid metabolism
regulation of lipase activity Glucose and lipid metabolism
monosaccharide metabolic process Glucose and lipid metabolism
regulation of insulin secretion Glucose and lipid metabolism
glucose metabolic process Glucose and lipid metabolism
hexose metabolic process Glucose and lipid metabolism
regulation of lipid metabolic process Glucose and lipid metabolism
lipid biosynthetic process Glucose and lipid metabolism
coumarin metabolic process Resp. to exogenous compound
phenylpropanoid metabolic process Resp. to exogenous compound
flavonoid glucuronidation Resp. to exogenous compound
flavonoid biosynthetic process Resp. to exogenous compound
flavonoid metabolic process Resp. to exogenous compound
cellular glucuronidation Resp. to exogenous compound
glucuronate metabolic process Resp. to exogenous compound
uronic acid metabolic process Resp. to exogenous compound
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Processes Group
quinone metabolic process Resp. to exogenous compound
catechol-containing compound biosynthetic process Resp. to exogenous compound
catecholamine biosynthetic process Resp. to exogenous compound
secondary metabolic process Resp. to exogenous compound
response to dexamethasone Resp. to exogenous compound
water-soluble vitamin metabolic process Resp. to exogenous compound
xenobiotic metabolic process Resp. to exogenous compound
cellular response to xenobiotic stimulus Resp. to exogenous compound
vitamin metabolic process Resp. to exogenous compound
response to xenobiotic stimulus Resp. to exogenous compound
isoprenoid metabolic process Resp. to exogenous compound
response to purine-containing compound Resp. to exogenous compound
organic hydroxy compound biosynthetic process Resp. to exogenous compound
response to ethanol Resp. to exogenous compound
monocarboxylic acid metabolic process Resp. to exogenous compound
response to alcohol Resp. to exogenous compound
response to nutrient Resp. to exogenous compound
response to drug Resp. to exogenous compound
cellular response to nitrogen compound Resp. to exogenous compound
ephrin receptor signaling pathway Various signaling pathways
positive regulation of epidermal growth factor receptor signaling 
pathway
Various signaling pathways
positive regulation of ERBB signaling pathway Various signaling pathways
ERK1 and ERK2 cascade Various signaling pathways
cellular response to growth hormone stimulus Various signaling pathways
cellular response to cAMP Various signaling pathways
response to cAMP Various signaling pathways
response to organophosphorus Various signaling pathways
transmembrane receptor protein serine/threonine kinase signaling 
pathway
Various signaling pathways
regulation of stress-activated MAPK cascade Various signaling pathways
regulation of stress-activated protein kinase signaling cascade Various signaling pathways
activation of MAPK activity Various signaling pathways
regulation of ERK1 and ERK2 cascade Various signaling pathways
regulation of JNK cascade Various signaling pathways
cellular response to fibroblast growth factor stimulus Various signaling pathways
neurotrophin TRK receptor signaling pathway Various signaling pathways
response to glucocorticoid Various signaling pathways
response to fibroblast growth factor Various signaling pathways
MAPK cascade Various signaling pathways
neurotrophin signaling pathway Various signaling pathways
response to corticosteroid Various signaling pathways
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Processes Group
cellular response to peptide Various signaling pathways
response to hypoxia Various signaling pathways
response to decreased oxygen levels Various signaling pathways
transmembrane receptor protein tyrosine kinase signaling pathway Various signaling pathways
response to oxygen levels Various signaling pathways
response to metal ion Various signaling pathways
positive regulation of MAPK cascade Various signaling pathways
cellular response to organonitrogen compound Various signaling pathways
cellular response to growth factor stimulus Various signaling pathways
response to peptide Various signaling pathways
regulation of MAPK cascade Various signaling pathways
response to growth factor Various signaling pathways
response to extracellular stimulus Various signaling pathways
positive regulation of intracellular signal transduction Various signaling pathways
iron ion transmembrane transport Other
positive regulation of myelination Other
CDP-diacylglycerol biosynthetic process Other
regulation of oligodendrocyte progenitor proliferation Other
CDP-diacylglycerol metabolic process Other
positive regulation of neurological system process Other
regulation of transmission of nerve impulse Other
negative regulation of heart rate Other
positive regulation of bone remodeling Other
positive regulation of bone resorption Other
regulation of smooth muscle cell apoptotic process Other
response to lead ion Other
regulation of calcium ion import Other
negative regulation of smooth muscle cell proliferation Other
positive regulation of phospholipase C activity Other
regulation of phospholipase C activity Other
negative regulation of muscle cell apoptotic process Other
negative regulation of heart contraction Other
positive regulation of heart contraction Other
regulation of muscle cell apoptotic process Other
osteoclast differentiation Other
transferrin transport Other
positive regulation of multicellular organism growth Other
positive regulation of fibroblast proliferation Other
regulation of bone resorption Other
ferric iron transport Other
trivalent inorganic cation transport Other
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Processes Group
cellular aldehyde metabolic process Other
regulation of smooth muscle cell proliferation Other
regulation of phosphatidylinositol 3-kinase activity Other
activation of phospholipase C activity Other
regulation of bone remodeling Other
protein targeting to mitochondrion Other
cellular ketone metabolic process Other
establishment of protein localization to mitochondrion Other
iron ion transport Other
pigment metabolic process Other
positive regulation of blood pressure Other
negative regulation of peptide secretion Other
protein localization to mitochondrion Other
regulation of neurological system process Other
regulation of fibroblast proliferation Other
actin filament organization Other
nucleoside monophosphate biosynthetic process Other
coenzyme biosynthetic process Other
regulation of cellular amine metabolic process Other
regulation of heart rate Other
transition metal ion transport Other
mitochondrial transport Other
cofactor biosynthetic process Other
tissue remodeling Other
exocytosis Other
actin cytoskeleton organization Other
actin filament-based process Other
cofactor metabolic process Other
cell-cell junction organization Other
regulation of peptide secretion Other
regulation of peptide transport Other
phospholipid biosynthetic process Other
coenzyme metabolic process Other
activation of protein kinase activity Other
positive regulation of ion transport Other
organophosphate biosynthetic process Other
regulation of neuron apoptotic process Other
regulation of blood pressure Other
regulation of actin cytoskeleton organization Other
regulation of actin filament-based process Other
regulation of homeostatic process Other
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regulation of neuron death Other
phospholipid metabolic process Other
positive regulation of kinase activity Other
positive regulation of transferase activity Other
positive regulation of protein kinase activity Other
secretion by cell Other
regulation of cytoskeleton organization Other
small molecule biosynthetic process Other
organonitrogen compound biosynthetic process Other
cellular metal ion homeostasis Other
secretion Other
metal ion homeostasis Other
cellular cation homeostasis Other
positive regulation of protein phosphorylation Other
cation homeostasis Other
cellular ion homeostasis Other
regulation of protein serine/threonine kinase activity Other
regulation of organelle organization Other
negative regulation of cellular component organization Other
regulation of kinase activity Other
ion homeostasis Other
regulation of protein kinase activity Other
positive regulation of multicellular organismal process Other
positive regulation of monocyte chemotaxis Other
response to interleukin-15 Other
acute-phase response Other
acute inflammatory response Other
platelet degranulation Other
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Supplementary Table S3. Top 20 genes with largest decrease in amplitude.
Symbol Diff. amplitude
Upp2 -0.5235
Sybu -0.4985
Atxn7l1 -0.4623
Pdk4 -0.4521
Slc16a5 -0.4486
Ccrn4l -0.4224
Nr1d1 -0.4044
Etnk2 -0.3957
Igfbp1 -0.388
Stbd1 -0.3809
Wfdc2 -0.3807
Serpina6 -0.3761
Aqp4 -0.3759
B130006D01Rik -0.3631
Olfr1134 -0.362
Ppard -0.3608
Cyp2s1 -0.3605
Wdr81 -0.3541
Mcm10 -0.3462
Itsn1 -0.3454
 
Supplementary Table S4. Genes differentially expressed in the CRD group compared to LD controls.
Symbol p-value FC
Nespas 2.96E-06 -0.1539
Gm128 6.37E-05 -0.3601
Rfx7 9.32E-05 0.1652
Defa-rs1 0.000136 0.1718
Adamts5 0.000168 -0.1777
Rhox4e 0.000192 -0.1678
Sprr1a 0.000235 -0.2050
Gm1123 0.000316 -0.1293
Mpped2 0.00036 0.1585
9630013A20Rik 0.00043 0.1606
Gm10295 0.00052 -0.1364
LOC100503435 0.000674 0.1059
1190028D05Rik 0.000778 0.1334
Olfr1248 0.000815 0.1640
Mixl1 0.000868 -0.1246
Glt25d2 0.000912 -0.2461
Gm10773 0.000912 0.1299
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Supplemental Table S5. Overrepresentation of up or down regulated genes in GO processes or the C2 
gene sets.
Upregulated
REACTOME_MEIOSIS Cell cycle
REACTOME_ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS DNA damage
KEGG_MISMATCH_REPAIR DNA damage
REACTOME_G2_M_CHECKPOINTS DNA damage
PID_FANCONI_PATHWAY DNA damage
REACTOME_DNA_STRAND_ELONGATION DNA replication
KEGG_DNA_REPLICATION DNA replication
REACTOME_EXTENSION_OF_TELOMERES DNA replication
REACTOME_LAGGING_STRAND_SYNTHESIS DNA replication
DNA_DEPENDENT_ATPASE_ACTIVITY DNA replication
REACTOME_MEIOTIC_RECOMBINATION DNA replication
REACTOME_TELOMERE_MAINTENANCE DNA replication
REACTOME_ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX DNA replication
REACTOME_CHROMOSOME_MAINTENANCE DNA replication
REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION Immune
REACTOME_INFLUENZA_LIFE_CYCLE Immune
GLUTATHIONE_TRANSFERASE_ACTIVITY Metabolism
REACTOME_PHASE_II_CONJUGATION Metabolism
REACTOME_GLUTATHIONE_CONJUGATION Metabolism
KEGG_GLUTATHIONE_METABOLISM Metabolism
REACTOME_CHOLESTEROL_BIOSYNTHESIS Metabolism
REACTOME_METABOLISM_OF_PROTEINS Metabolism
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_
JUNCTION_COMPLEX
Transcription
REACTOME_METABOLISM_OF_RNA Transcription
REACTOME_METABOLISM_OF_MRNA Transcription
REACTOME_CLEAVAGE_OF_GROWING_TRANSCRIPT_IN_THE_TERMINATION_
REGION_
Transcription
KEGG_RIBOSOME Translation
REACTOME_SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_
MEMBRANE
Translation
REACTOME_PEPTIDE_CHAIN_ELONGATION Translation
STRUCTURAL_CONSTITUENT_OF_RIBOSOME Translation
REACTOME_TRANSLATION Translation
REACTOME_3_UTR_MEDIATED_TRANSLATIONAL_REGULATION Translation
TRANSFERASE_ACTIVITY_TRANSFERRING_ALKYL_OR_ARYLOTHER_THAN_
METHYLGROUPS
Various
KEGG_ALZHEIMERS_DISEASE Various
STRUCTURAL_MOLECULE_ACTIVITY Various
REGULATION_OF_MUSCLE_CONTRACTION Various
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Downregulated
REACTOME_APOPTOSIS Cell cycle
REACTOME_REGULATION_OF_MITOTIC_CELL_CYCLE Cell cycle
REACTOME_SCF_BETA_TRCP_MEDIATED_DEGRADATION_OF_EMI1 Cell cycle
REACTOME_AUTODEGRADATION_OF_THE_E3_UBIQUITIN_LIGASE_COP1 Cell cycle
REACTOME_APC_C_CDC20_MEDIATED_DEGRADATION_OF_MITOTIC_PROTEINS Cell cycle
REACTOME_ADAPTIVE_IMMUNE_SYSTEM Immune
REACTOME_INTERFERON_GAMMA_SIGNALING Immune
REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM Immune
REACTOME_INTERFERON_SIGNALING Immune
REACTOME_INTERFERON_ALPHA_BETA_SIGNALING Immune
REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR Immune
KEGG_ACUTE_MYELOID_LEUKEMIA Immune
REACTOME_ACTIVATION_OF_NF_KAPPAB_IN_B_CELLS Immune
KEGG_CHEMOKINE_SIGNALING_PATHWAY Immune
KEGG_PRIMARY_IMMUNODEFICIENCY Immune
REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_LEADING_TO_
GENERATION_OF_SECOND_MESSENGERS
Immune
REACTOME_CROSS_PRESENTATION_OF_SOLUBLE_EXOGENOUS_ANTIGENS_
ENDOSOMES
Immune
BIOCARTA_IL2_PATHWAY Immune
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_
AND_A_NON_LYMPHOID_CELL
Immune
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY Immune
REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION Immune
REACTOME_IL_2_SIGNALING Immune
PID_TCR_PATHWAY Immune
DEFENSE_RESPONSE Immune
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY Immune
BIOCARTA_NFAT_PATHWAY Immune
REACTOME_DOWNSTREAM_SIGNALING_EVENTS_OF_B_CELL_RECEPTOR_BCR Immune
REACTOME_ER_PHAGOSOME_PATHWAY Immune
REACTOME_INTEGRIN_ALPHAIIB_BETA3_SIGNALING Immune
PID_IL4_2PATHWAY Immune
REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_
DEGRADATION
Immune
PID_INTEGRIN_A4B1_PATHWAY Immune
REACTOME_CYTOCHROME_P450_ARRANGED_BY_SUBSTRATE_TYPE Metabolism
PROTEIN_CATABOLIC_PROCESS Metabolism
CELLULAR_PROTEIN_CATABOLIC_PROCESS Metabolism
MONOOXYGENASE_ACTIVITY Metabolism
BIOPOLYMER_CATABOLIC_PROCESS Metabolism
REACTOME_SYNTHESIS_OF_BILE_ACIDS_AND_BILE_SALTS Metabolism
PID_ERBB1_INTERNALIZATION_PATHWAY Proliferation
PID_MET_PATHWAY Proliferation
PID_PDGFRBPATHWAY Proliferation
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Downregulated Continued
TRANSMEMBRANE_RECEPTOR_PROTEIN_SERINE_THREONINE_KINASE_
SIGNALING_PATHWAY
Proliferation
REACTOME_SIGNALING_BY_WNT Proliferation
REACTOME_SIGNALING_BY_SCF_KIT Proliferation
PID_AURORA_A_PATHWAY Proliferation
KEGG_ERBB_SIGNALING_PATHWAY Proliferation
PID_ECADHERIN_KERATINOCYTE_PATHWAY Proliferation
KEGG_PROTEASOME Proteasome
PID_PI3KCIPATHWAY Proteasome
REACTOME_REGULATION_OF_ORNITHINE_DECARBOXYLASE_ODC Proteasome
AMINE_TRANSPORT Transport
AMINO_ACID_TRANSPORT Transport
INTRACELLULAR_TRANSPORT Transport
CYTOPLASMIC_VESICLE_PART Transport
CYTOPLASMIC_VESICLE_MEMBRANE Transport
AMINE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY Transport
RNA_BINDING Various
PID_TCPTP_PATHWAY Various
MITOCHONDRION Various
MEMBRANE_FRACTION Various
CYTOSKELETON Various
ENZYME_LINKED_RECEPTOR_PROTEIN_SIGNALING_PATHWAY Various
PROTEIN_TRANSPORT Transport
BIOCARTA_TPO_PATHWAY Various
POST_TRANSLATIONAL_PROTEIN_MODIFICATION Various
REACTOME_METABOLISM_OF_AMINO_ACIDS_AND_DERIVATIVES Various
REACTOME_SIGNAL_TRANSDUCTION_BY_L1 Various
PHOSPHORYLATION Various
KEGG_FOCAL_ADHESION Various
MITOCHONDRIAL_PART Various
ACTIN_POLYMERIZATION_AND_OR_DEPOLYMERIZATION Various
REGULATION_OF_PROTEIN_METABOLIC_PROCESS Various
CELL_FRACTION Various
MICROTUBULE Various
PROTEIN_TARGETING Various
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